

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/495, 14/51, 14/575, C12N 15/12		A1	(11) International Publication Number: WO 96/40771
			(43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09293			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(22) International Filing Date: 6 June 1996 (06.06.96)			
(30) Priority Data: 08/478,097 7 June 1995 (07.06.95) US			
(71) Applicant: CREATIVE BIOMOLECULES, INC. [US/US]; 45 South Street, Hopkinton, MA 01748 (US).			
(72) Inventors: KECK, Peter, C.; 50 Dolan Road, Millbury, MA 01527 (US). SMART, John, E.; 50 Meadow Brook Road, Weston, MA 02193 (US).			
(74) Agent: GREENHALGH, Duncan, A.; Testa, Hurwitz & Thibault L.L.P., High Street Tower, 125 High Street, Boston, MA 02110 (US).			
(54) Title: SINGLE CHAIN ANALOGS OF THE TGF- β SUPERFAMILY (MORPHONS)			
(57) Abstract Disclosed is a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF- β superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complementary to the ligand binding surface of a receptor that binds a TGF- β superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF- β superfamily.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

Single Chain Analogs of the TGF- β Superfamily (Morphons)

Background of the Invention

This invention relates to the design and production of single-chain biosynthetic constructs herein called "morphons" which mimic the activities of one or more members of the TGF- β superfamily.

The TGF- β superfamily includes five distinct forms of TGF- β (Sporn and Roberts (1990) in Peptide Growth Factors and Their Receptors, Sporn and Roberts, eds., Springer-Verlag: Berlin pp. 419-472), as well as the differentiation factors vg-1 (Weeks and Melton (1987) Cell 51: 861-867), DPP-C polypeptide (Padgett *et al.* (1987) Nature 325: 81-84), the hormones activin and inhibin (Mason *et al.* (1985) Nature 318: 659-663; Mason *et al.* (1987) Growth Factors 1: 77-88), the Mullerian-inhibiting substance, MIS (Cate *et al.* (1986) Cell 45: 685-698), osteogenic and morphogenic proteins OP-1 (PCT/US90/05903), OP-2 (PCT/US91/07654), OP-3 (PCT/WO94/10202), the BMPs, (see U.S. Patent Nos. 4,877,864; 5,141,905; 5,013,649; 5,116,738; 5,108,922; 5,106,748; and 5,155,058), the developmentally regulated protein VGR-1 (Lyons *et al.* (1989) Proc. Natl. Acad. Sci. USA 86: 4554-4558) and the growth/differentiation factors GDF-1, GDF-3, GDF-9 and dorsalin-1 (McPherron *et al.* (1993) J. Biol. Chem. 268: 3444-4449; Basler *et al.* (1993) Cell 73: 687-702).

The proteins of the TGF- β superfamily are disulfide-linked homo- or heterodimers that are expressed as large precursor polypeptide chains containing a hydrophobic signal sequence, a long and relatively poorly conserved N-terminal pro region of several hundred amino acids, a cleavage site, and a mature domain comprising an N-terminal region which varies among the family members and a more highly conserved C-terminal region. This C-terminal region, present in the processed mature proteins of all known family members, contains approximately 100 amino acids with a characteristic cysteine motif having a conserved six or seven cysteine skeleton. Although the position of the cleavage site between the mature and pro regions varies among the family members, the cysteine pattern of the C-terminus of all of the proteins is in the identical format, ending in the sequence Cys-X-Cys-X (Sporn and Roberts (1990), *supra*).

Recombinant TGF- β 1 has been cloned (Derynck *et al.* (1985) Nature 316: 701-705), and expressed in Chinese hamster ovary cells (Gentry *et al.* (1987) Mol. Cell. Biol. 7: 3418-3427). Additionally, recombinant human TGF- β 2 (deMartin *et al.* (1987) EMBO J. 6: 3673), as well as human and porcine TGF- β 3 (Derynck *et al.* (1988) EMBO J. 7: 3737-3743; Dijke *et al.* (1988)

- 2 -

Proc. Natl. Acad. Sci. USA 85: 4715), have been cloned. Expression levels of the mature TGF- β 1 protein in COS cells have been increased by substituting cysteine residues located in the pro region of the TGF- β 1 precursor with serine residues (Brunner *et al.* (1989) J. Biol. Chem. 264: 13660-13664).

5 A unifying feature of the biology of the proteins of the TGF- β superfamily is their ability to regulate developmental processes. These structurally related proteins have been identified as being involved in a variety of developmental events. For example, TGF- β and the polypeptides of the inhibin/activin group appear to play a role in the regulation of cell growth and differentiation. MIS causes regression of the Mullerian duct in development of the mammalian male embryo, and
10 dpp, the gene product of the Drosophila decapentaplegic complex, is required for appropriate dorsal-ventral specification. Similarly, Vg-1 is involved in mesoderm induction in Xenopus, and Vgr-1 has been identified in a variety of developing murine tissues. Regarding bone formation, many of the proteins in the TGF- β supergene family, namely OP-1 and a subset of the BMPs apparently play the major role. OP-1 (BMP-7) and other osteogenic proteins have been produced
15 using recombinant techniques (U.S. Patent No. 5,011,691 and PCT Application No. US 90/05903) and shown to be able to induce formation of true endochondral bone *in vivo*. BMP-2 has been recombinantly produced in monkey COS-1 cells and Chinese hamster ovary cells (Wang *et al.* (1990) Proc. Natl. Acad. Sci. USA 87: 2220-2224).

20 Recently the family of proteins taught as having osteogenic activity as judged by the Sampath and Reddi bone formation assay have been shown to be morphogenic, i.e., capable of inducing the developmental cascade of tissue morphogenesis in a mature mammal (See PCT Application No. US 92/01968). In particular, these proteins are capable of inducing the proliferation of uncommitted progenitor cells, and inducing the differentiation of these stimulated progenitor cells in a tissue-specific manner under appropriate environmental conditions. In
25 addition, the morphogens are capable of supporting the growth and maintenance of these differentiated cells. These morphogenic activities allow the proteins to initiate and maintain the developmental cascade of tissue morphogenesis in an appropriate, morphogenically permissive environment, stimulating stem cells to proliferate and differentiate in a tissue-specific manner, and inducing the progression of events that culminate in new tissue formation. These morphogenic
30 activities also allow the proteins to induce the "redifferentiation" of cells previously stimulated to stray from their differentiation path. Under appropriate environmental conditions it is anticipated that these morphogens also may stimulate the "redifferentiation" of committed cells.

The tertiary and quaternary structure of both TGF- β 2 and OP-1 have been determined. Although TGF- β 2 and OP-1 exhibit only about 35% amino acid identity in their respective amino
35 acid sequences the tertiary and quaternary structures of both molecules are strikingly similar.

- 3 -

Both TGF- β 2 and OP-1 are dimeric in nature and have a unique folding pattern involving six of the seven C-terminal cysteine residues, as illustrated in Figure 1A. Figure 1A shows that in each subunit four cysteines bond to generate an eight residue ring, and two additional two cysteine residues form a disulfide bond that passes through the ring to form a knot-like structure. With a numbering scheme beginning with the most N-terminal cysteine of the 7 conserved cysteine residues assigned number 1, the 2nd and 6th cysteine residues bond to close one side of the eight residue ring while the 3rd and 7th cysteine residues close the other side. The 1st and 5th conserved cysteine residues bond through the center of the ring to form the core of the knot. The 4th cysteine forms an interchain disulfide bond with the corresponding residue in the other subunit.

The TGF- β 2 and OP-1 monomer subunits comprise three major structural elements and an N-terminal region. The structural elements are made up of regions of contiguous polypeptide chain that possess over 50% secondary structure of the following types: (1) loop, (2) helix and (3) β -sheet. Furthermore, in these regions the N-terminal and C-terminal strands are not more than 7 Å apart. The residues between the 1st and 2nd conserved cysteines (Fig. 1A) form a structural region characterized by an anti-parallel β -sheet finger, referred to herein as the finger 1 region (F1). A ribbon trace of the finger 1 peptide backbone is shown in Fig. 1B. Similarly the residues between the 5th and 6th conserved cysteines in Fig. 1A also form an anti-parallel β -sheet finger, referred to herein as the finger 2 region (F2). A ribbon trace of the finger 2 peptide backbone is shown in Fig. 1D. A β -sheet finger is a single amino acid chain, comprising a β -strand that folds back on itself by means of a β -turn or some larger loop so that the entering and exiting strands form one or more anti-parallel β -sheet structures. The third major structural region, involving the residues between the 3rd and 4th conserved cysteines in Fig. 1A, is characterized by a three turn α -helix referred to herein as the heel region (H). A ribbon trace of the heel peptide backbone is shown in Fig. 1C.

The organization of the monomer structure is similar to that of a left hand where the knot region is located at the position equivalent to the palm, finger 1 is equivalent to the index and middle fingers, the α -helix is equivalent to the heel of the hand, and finger 2 is equivalent to the ring and small fingers. The N-terminal region (not well defined in the published structures) is predicted to be located at a position roughly equivalent to the thumb.

In the dimeric forms of both TGF- β 2 and OP-1, the subunits are oriented such that the heel region of one subunit contacts the finger regions of the other subunit with the knot regions of the connected subunits forming the core of the molecule. The 4th cysteine forms a disulfide bridge with its counterpart on the second chain thereby equivalently linking the chains at the center of the palms. The dimer thus formed is an ellipsoidal (cigar shaped) molecule when viewed from the top

- 4 -

looking down the two-fold axis of symmetry between the subunits (Fig. 2A). Viewed from the side, the molecule resembles a bent "cigar" since the two subunits are oriented at a slight angle relative to each other (Fig. 2B).

- U.S. Patent Nos.: 5,132,405; 5,091,513; and 5,258,498 and PCT Application No.
- 5 PCT/US88/01737 disclose how to make single-chain binding proteins which mimic the structure of an immunoglobulin Fv region by linking the C- and N-termini of light- and heavy chain variable region domains, and how to make multifunctional proteins by linking together separate protein domains which function either independently or in concert. U.S. Patent Nos.: 4,704,692; 4,881,175; 4,939,666; 4,946,778; and 5,260,203 disclose computer-based techniques for
- 10 selecting a peptide linker sequences for connecting separate protein chains to produce a single-chain protein.

Summary of the Invention

The invention provides a family of single-chain constructs of the TGF- β superfamily (hereinafter called "morphons") which mimic the physiological effects of one or more members of the superfamily. Specifically, the morphon constructs of the invention bind preferentially to a natural cell surface receptor that typically interacts with a TGF- β superfamily member, and the morphon, upon binding with the receptor initiates a cascade of events that would occur when the TGF- β superfamily member binds to the receptor.

The morphon constructs differ from the natural TGF- β superfamily members in that they are single-chain proteins which preferably are expressed from a single DNA in a host cell. The natural members of the TGF- β superfamily are dimeric structures wherein the monomer subunits are held together by non-covalent interactions or by one or more disulfide bonds. The TGF- β superfamily members are inactive as monomers. In contrast, the morphon constructs comprise a functional monomer subunit and, therefore, are believed to be more stable than the natural dimers, particularly under reducing conditions. In addition, the morphon constructs may have a molecular weight significantly lower than the natural dimers and thus are likely to diffuse faster and be cleared by the body faster than natural superfamily members.

The morphon constructs preferably are manufactured in accordance with the principles disclosed herein by assembly of nucleotides and/or joining DNA restriction fragments to produce synthetic DNAs. The DNAs are transfected into an appropriate protein expression vehicle, the encoded protein expressed, folded if necessary, and purified. Particular constructs can be tested for agonist activity in vitro. The tertiary structure of the candidate morphon constructs may be iteratively refined and binding modulated by site-directed or nucleotide sequence directed mutagenesis aided by the principles disclosed herein, computer-based protein structure modeling, and recently developed rational drug design techniques to improve or modulate specific properties of a molecule of interest. Known phage display or other nucleotide expression systems may be exploited to produce simultaneously a large number of candidate constructs. The pool of candidate constructs subsequently may be screened for binding specificity using, for example, a chromatography column comprising surface immobilized receptors, salt gradient elution to select for, and to concentrate high binding candidates, and in vitro assays to determine whether or not particular isolated candidates agonize the activity of the template superfamily member. Identification of a useful construct is followed by production of cell lines expressing commercially useful quantities of the construct for laboratory use and ultimately for producing therapeutically useful drugs. It is contemplated also that preferred single-chain constructs, once identified and characterized by the recombinant DNA methodologies described above, may be produced by standard peptide synthesis methodologies.

- 6 -

It has now been discovered how to design, make, test and use single-chain amino acid constructs comprising an amino acid sequence which, when properly folded, assume a tertiary structure defining a finger 1 region, a finger 2 region, and a heel region which together are complementary to the ligand binding interactive surface of a TGF- β superfamily member receptor.

5 The constructs, upon binding with the receptor agonize the activity of a TGF- β superfamily member. In one important subset of embodiments, the constructs agonize initiation of cellular differentiation and tissue morphogenesis, e.g., initiate cell transformation leading to new tissue formation, such as, bone formation. The constructs comprise an amino acid sequence sufficiently duplicative of the amino acid sequence of a TGF- β superfamily member such that it preferentially
10 binds the cognate receptor for that member.

All of the morphon constructs of the invention comprise regions of amino acid sequences defining the three regions required for utility, namely, finger 1, finger 2, and heel regions, and additional linker sequences which join these regions, maintain them in their proper conformation individually, and maintain their relative positions and orientations in space. Sequences for the
15 finger and heel regions may be copied from the respective finger and heel region sequences of any known TGF- β superfamily member identified herein. Alternatively, the finger and heel regions may be selected from the amino acid sequence of a new member of this superfamily discovered hereafter using the principles disclosed hereinbelow.

The finger, heel, and linker sequences also may be altered by amino acid substitution, for
20 example by exploiting substitute amino acid residues selected in accordance with the principles disclosed in Smith *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87: 118-122, the disclosure of which is incorporated herein by reference. Smith *et al.* disclose an amino acid class hierarchy, similar to the amino acid hierarchy table set forth in Figure 10, which may be used to rationally substitute one amino acid for another while minimizing gross conformational distortions of the type which
25 otherwise may inactivate the protein. In any event, it is contemplated that many synthetic finger 1, finger 2, and heel region sequences, having only 70% homology with natural regions, preferably 80%, and most preferably at least 90%, may be used to produce active morphon constructs. It is contemplated also, as disclosed herein, that the size of the constructs may be reduced significantly by truncating the natural finger and heel regions of the template TGF- β
30 superfamily member, while compensating for dimensional changes using linkers as disclosed below.

The linker sequences, as described herein, join and maintain the spatial relationship of the finger and heel regions within a monomeric subunit. The linker sequences typically comprising about 3-13 amino acids serve to maintain, for example, the cysteine structural motif, namely, the
35 cysteine pattern and knot structure (cysteines 1, 2, 3, 5, 6, and 7, and their respective spatial and

- 7 -

bonding relationship) which characterize, and are believed to be essential for maintaining the tertiary structure of the members of the superfamily. Principles and methods for selecting appropriate polypeptide linker sequences are disclosed hereinbelow.

More specifically, the invention provides a functional morphon construct that is constituted by a finger 1, a finger 2, and a heel region, joined together by peptide linkers having, e.g., 3-13 amino acids, and optionally including an N-terminal sequence upstream of the first cysteine beginning the sequence of the finger 1 region. In the single-chain morphon constructs of the invention, the finger 1, finger 2 and heel regions together define a structure complementary to the ligand binding surface of a TGF- β superfamily member receptor structure and are sufficiently duplicative of a sequence of a member of the TGF- β superfamily such that the construct preferentially binds the receptor. Where the finger 1 region is designated F1, the finger 2 designated F2, and the heel designated H, the constructs of this type can take the form of one of the constructs set forth below, and include:

F1-linker-F2-linker-H;
F1-linker-H-linker-F2;
F2-linker-F1-linker-H;
F2-linker-H-linker-F1;
H-linker-F1-linker-F2; and
H-linker-F2-linker-F1.

Generic and specific sequences of amino acids which constitute the finger 1, finger 2, heel regions, and N-terminal sequences are disclosed hereinbelow.

The invention further comprises DNAs encoding the morphon constructs of the invention, cell lines transformed with the DNAs, and methods of making the morphons by culturing transformed cells to produce them followed by purification.

The invention may be understood further, and various of its objects and features better appreciated by referring to the drawings, description, sequence listing, and claims which follow.

- 8 -

Brief Description of the Drawings

Figure 1A is a simplified line drawing useful in describing the structure of a monomeric subunit of a TGF- β superfamily member. See the Background of the Invention, *supra*, for explanation. Figures 1B, 1C, and 1D are monovision ribbon tracings of the respective peptide
5 backbones of typical secondary structures of the finger 1, heel, and finger 2 regions.

Figures 2A and 2B are stereo peptide backbone ribbon trace drawings illustrating the generic three-dimensional shape of TGF- β superfamily member protein dimer: A) from the "top" (down the two-fold axis of symmetry between the subunits) with the axes of the helical heel regions generally normal to the paper and the axes of each of the finger 1 and finger 2 regions generally
10 vertical, and B) from the "side" with the two-fold axis between the subunits in the plane of the paper, with the axes of the heels generally horizontal, and the axes of the fingers generally vertical. The reader is encouraged to view the stereo alpha carbon trace drawings in wall eyed stereo to understand better the spatial relationships in the morphon design.

Figures 3A and 3B are respective schematic representations of a natural member of the TGF- β superfamily and a morphon construct of the invention.
15

Figures 4A and 4B are stereo peptide backbone ribbon trace drawings of a half molecule or morphon construct viewed from the top (same convention as used in Figure 2) and side, respectively.

Figures 5A, 5B, and 5C are single letter code listings of amino acid sequences, arranged to
20 indicate alignments and homologies of the finger 1, heel, and finger 2 regions, respectively, of the currently known members of the TGF- β superfamily. Shown are the respective amino acids comprising each region of human TGF- β 1 through TGF- β 5 (the TGF- β subgroup), the Vg/dpp subgroup consisting of dpp, Vg-1, Vgr-1, 60A (see copending U.S.S.N. 08/271,556), BMP-2A (also known in the literature as BMP-2), dorsalin, BMP-2B (also known in the literature as BMP-
25 4), BMP-3, BMP-5, BMP-6, OP-1 (also known in the literature as BMP-7), OP-2 (see PCT/US91/07635 and U.S. Patent No. 5,266,683) and OP-3 (U.S.S.N 07/971,091), the GDF subgroup consisting of GDF-1, GDF-3, and GDF-9, the Inhibin subgroup consisting of Inhibin α , Inhibin β A, and Inhibin β B. The dashes (-) indicate a peptide bond between adjacent amino acids. A consensus sequence pattern for each subgroup is shown at the bottom of each subgroup.

Figure 6 is a single letter code listing of amino acid sequences, identified in capital letter in
30 standard single letter amino acid code, and in lower case letters to identify groups of amino acids useful in that location, wherein the lower case letters stand for the amino acids indicated in accordance with the pattern definition key table set forth in Figure 10. Figure 6 identifies

- 9 -

preferred pattern sequences for constituting the finger 1, heel, and finger 2 regions of biosynthetic constructs of the invention. The dashes (-) indicate a peptide bond between adjacent amino acids.

Figures 7A, 7B, and 7C are single letter code listings of large, medium, and small peptides, respectively, comprising 24 (large), 20 (medium) or 12 (small) amino acids embodying truncated versions of finger 1 regions useful in constructing morphon constructs of the invention. Also disclosed in Figures 7A, 7B, and 7C are sequence patterns identifying specific amino acid residues (upper case letters in accordance with the standard single letter amino acid code) or groups of amino acid residues (lower case letters in accordance with the principles described in Figure 10) that are useful at particular locations in the finger 1 region or the truncated versions thereof.

Figures 7D, 7E, 7F, and 7G are stereo peptide backbone ribbon trace drawings defining the whole TGF- β 2 finger 1 region, and the large, medium, and small finger 1 peptide sequences, respectively. The stereo ribbon trace drawings of Figs. 7E, 7F, and 7G correspond to the TGF- β 2 peptide sequences set forth in Figs. 7A, 7B, and 7C, respectively.

Figures 8A, 8B, and 8C are single letter code listings of large, medium, and small peptides comprising amino acid sequences embodying truncated versions of heel regions useful in constructing morphon constructs of the invention. The "large" sequence comprises as few as 14 amino acids (e.g., for Inhibin α) and up to 18 (e.g., for Inhibin β A). The "medium" peptide comprises between 11 and 15 amino acids, and the "small" peptide between 6 and 9 amino acids. Pattern sequences are given for each subgroup identifying specific amino acid residues (upper case letters in accordance with the standard single letter amino acid code) or groups of amino acid residues (lower case letters in accordance with the principles described in Figure 10) that are useful at particular locations in the heel region or the truncated versions thereof.

Figures 8D, 8E, 8F, and 8G are stereo peptide backbone ribbon trace drawings defining the whole TGF- β 2 heel region, and the large, medium, and small heel peptide sequences, respectively. The stereo ribbon trace drawings of Figs. 8E, 8F, and 8G correspond to the TGF- β 2 peptide sequences set forth in Figs. 8A, 8B, and 8C, respectively.

Figures 9A, 9B and 9C are single letter code listings of large, medium, and small peptides, respectively, embodying truncated versions of some finger 2 regions useful in constructing morphons of the invention. The "large" sequence comprises as few as 16 amino acids (e.g., for the members of the TGF- β subgroup) and up to 18 amino acids (e.g., for Dorsalin). The "medium" peptide comprises between 12 and 14 amino acids, and the "small" peptide between 8 and 12 amino acids. Also disclosed are pattern sequences identifying specific amino acid residues (upper case letters in accordance with the standard single letter amino acid code) or groups of

- 10 -

amino acid residues (lower case letters in accordance with the principles described in Figure 10) that are useful at particular locations in the finger 2 region or the truncated versions thereof.

Figures 9D, 9E, 9F, and 9G are stereo peptide backbone ribbon trace drawings defining the whole TGF- β 2 finger 2 region, and the large, medium, and small finger 2 peptide sequences, respectively. The stereo ribbon trace drawings of Figs. 9E, 9F, and 9G correspond to the peptide sequences set forth in Figs. 9A, 9B, and 9C, respectively.

Figure 10 is a pattern definition table prepared in accordance with the teaching of Smith and Smith (1990) Proc. Natl. Acad. Sci. USA 87:118-122.

Figure 11 is a single letter code listing of aligned amino acid sequences corresponding to a natural OP-1 monomer (denoted OP-1/BMP-7) and an OP-1 morphon (denoted M-OP1). For convenience, the natural OP-1 and OP-1 morphon sequences are shown as separate finger 1, heel, and finger 2 regions. The additional linkers connecting these three domains in the OP-1 morphon are denoted as linker 1 and linker 2.

Further particulars concerning the drawings are disclosed in the following description which discloses details of the structure of single chain morphogens and morphons, how to make them, how to test their activity, how to use them, and provides exemplary constructs.

- 11 -

Detailed Description of the Invention

The instant invention provides a family of single-chain morphon constructs based upon members of the TGF- β superfamily that bind preferentially, either in vivo or in vitro, to a natural cell surface receptor complementary to a TGF- β superfamily member. The single-chain morphon constructs upon binding to the receptor agonize or mimic the activity of the TGF- β superfamily member.

The invention disclosed herein is based on a combination of insights extrapolated from data in the literature and data generated by the inventors and their coworkers. The inventors studied the homologies between structures and sequences of currently known members of the TGF- β superfamily, made observations and comparisons of the activity and structural properties of truncated and mutated analogs of certain members of the superfamily, and developed in-depth knowledge of how to design, make, and use peptide linkers to produce biologically active single-chain proteins by linking naturally separate protein domains.

Structural Features TGF- β 2 and OP-1.

The design of the single-chain biosynthetic constructs of the invention has been facilitated by modeling structures based upon the tertiary and quaternary structures of both TGF- β 2 and OP-1. Although the amino acid sequences of TGF- β 2 and OP-1 exhibit only about 36% amino acid sequence identity, when taken together with the fact that TGF- β 2 and OP-1 exhibit different physiological activities it is striking that both the tertiary and quaternary structures of these molecules are substantially the same.

Each of the subunits in either TGF β 2 or OP-1 have a characteristic folding pattern, illustrated schematically in fig. 1A, that involves six of the seven C-terminal cysteine residues. Briefly, four of the cysteine residues in each subunit form two disulfide bonds which together create an eight residue ring, while two additional cysteine residues form a disulfide bond that passes through the ring to form a knot-like structure. With a numbering scheme beginning with the most N-terminal cysteine of the 7 conserved cysteine residues assigned number 1, the 2nd and 6th cysteine residues are disulfide bonded to close one side of the eight residue ring while the 3rd and 7th cysteine residues are disulfide bonded to close the other side of the ring. The 1st and 5th conserved cysteine residues are disulfide bonded through the center of the ring to form the core of the knot. Amino acid sequence alignment patterns suggest this structural motif is conserved between members of the TGF- β superfamily. The 4th cysteine is semi-conserved and when present typically forms an interchain disulfide bond (ICDB) with the corresponding cysteine residue in the other subunit.

- 12 -

The structure of each subunit in TGF- β 2 and OP-1 comprise three major tertiary structural elements and an N-terminal region. The structural elements are made up of regions of contiguous polypeptide chain that possess over 50% secondary structure of the following types: (1) loop, (2) helix and (3) β -sheet. Another defining criterion for each structural region is that the entering (N-terminal) and exiting (C-terminal) peptide strands are fairly close together, being about 7 Å apart.

The amino acid sequence between the 1st and 2nd conserved cysteines, as shown in Fig. 1A, form a structural region characterized by an anti-parallel β -sheet finger referred to herein as the finger 1 region. Similarly the residues between the 5th and 6th conserved cysteines, as shown in Fig. 1A, also form an anti-parallel β -sheet finger, referred to herein as the finger 2 region. A β -sheet finger is a single amino acid chain, comprising a β -strand that folds back on itself by means of a β -turn or some larger loop so that the polypeptide chain entering and exiting the region form one or more anti-parallel β -sheet structures. The third major structural region, involving the residues between the 3rd and 5th conserved cysteines, as shown in Fig. 1A, is characterized by a three turn α -helix, referred to herein as the heel region. The organization of the monomer structure is similar to that of a left hand where the knot region is located at the position equivalent to the palm, the finger 1 region is equivalent to the index and middle fingers, the α -helix, or heel region, is equivalent to the heel of the hand, and the finger 2 region is equivalent to the ring and small fingers. The N-terminal region whose sequence is not conserved across the TGF- β superfamily is predicted to be located at a position roughly equivalent to the thumb.

Monovision ribbon tracings of the alpha carbon backbones of each of the three major independent structural elements of the TGF- β 2 monomer are illustrated in Figures 1B-1D. Specifically, an exemplary finger 1 region comprising the first anti-parallel β -sheet segment is shown in Fig. 1B, an exemplary heel region comprising the three turn α -helical segment is shown in Fig. 1C, and an exemplary finger 2 region comprising second and third anti-parallel β -sheet segments is shown in Fig. 1D.

Fig. 2 shows stereo ribbon trace drawings of the peptide backbone of the conformationally active TGF- β 2 dimer complex. The two monomer subunits in the dimer complex are oriented symmetrically such that the heel region of one subunit contacts the finger regions of the other subunit with the knot regions of the connected subunits forming the core of the molecule. The 4th cysteine forms an interchain disulfide bond with its counterpart on the second chain thereby equivalently linking the chains at the center of the palms. The dimer thus formed is an ellipsoidal (cigar shaped) molecule when viewed from the top looking down the two-fold axis of symmetry between the subunits (Fig. 2A). Viewed from the side, the molecule resembles a bent "cigar" since the two subunits are oriented at a slight angle relative to each other (Fig. 2B).

- 13 -

As shown in Fig. 2, each of the structural elements which together define the native monomer subunits of the dimer are labeled 22, 22', 23, 23', 24, 24', 25, 25', 26, and 26', wherein, elements 22, 23, 24, 25, and 26 are defined by one subunit and elements 22', 23', 24', 25', and 26' belong to the other subunit. Specifically, 22 and 22' denote N-terminal domains; 23 and 23' denote the finger 1 regions; 24 and 24' denote heel regions; 25 and 25' denote the finger 2 regions; and 26 and 26' denote disulfide bonds which connect the 1st and 5th conserved cysteines of each subunit to form the knot-like structure. From Fig. 2, it can be seen that the heel region from one subunit, e.g., 24, and the finger 1 and finger 2 regions, e.g., 23' and 25', respectively from the other subunit, interact with one another. These three elements co-operate with one other to define a structure interactive with, and complimentary to the ligand binding interactive surface of the cognate receptor.

Single-Chain Biosynthetic Constructs of the Invention (Morphons).

As mentioned above, the morphon constructs differ from the natural TGF- β superfamily members in that they are single-chain proteins expressed preferably from a single DNA in a host cell. Natural TGF- β superfamily members are dimeric molecules wherein the subunits are held together by non-polar interactions and/or one or more inter-chain disulfide bonds. The TGF- β superfamily members are only active in their dimeric conformation. In contrast, the morphons are active as a monomer subunit and comprise in the single subunit, two finger regions which normally would belong to one subunit of the natural dimer and a heel region which normally would belong to the other subunit of the natural dimer. It is, therefore, contemplated that the biosynthetic constructs of the invention may be more stable, particularly under reducing conditions, than the natural morphogen dimers. In addition, it is contemplated that the biosynthetic morphon constructs may have a molecular weight substantially lower than natural biologically active TGF- β superfamily members, and therefore may diffuse faster, and be cleared by the body faster than the natural superfamily members.

The differences between functionally active TGF- β superfamily members and morphons are shown schematically in Fig. 3. For example, Fig. 3A shows a dimeric TGF- β superfamily member wherein one subunit defining a finger 1 (33), finger 2 (35), heel region (34), and a knot region (36) is represented by the completely filled motif and the other subunit defining a finger 1 (33'), finger 2 (35'), a heel region (34'), and a knot region (36') is represented by the stippled motif. Figure 3B shows a morphon construct defining a finger 1 (33'), a finger 2 (35'), and a heel region (34), however, the finger 1 and finger 2 regions, as defined by the stippled motif, typically are derived from one subunit of a dimeric TGF- β superfamily member and the heel region, as defined by the completely filled motif, typically is derived from the other subunit of the TGF- β

- 14 -

superfamily member. In the morphon construct, the finger and heel regions are connected by two polypeptide linkers (38 and 39).

The morphon constructs of the invention comprise a finger 1 region, a heel region and a finger 2 region, joined together by polypeptide linkers comprising, for example, about 3-13 amino acids, and optionally including an N-terminal sequence upstream of the first cysteine beginning the sequence of the first finger region. Where the finger 1 region is designated F1, the finger 2 region is designated F2, and the heel region is designated H, the constructs of this type can take several forms and include, for example:

F1-linker-F2-linker-H;
F1-linker-H-linker-F2;
F2-linker-F1-linker-H;
F2-linker-H-linker-F1;
H-linker-F1-linker-F2; and
H-linker-F2-linker-F1.

Fig. 4 shows stereo ribbon trace drawings of the peptide backbone of an exemplary morphon construct, wherein Figs. 4A and 4B show top and side views of the morphon, respectively, using the same convention as described in Fig. 2. Each of the structural elements of the exemplary morphon are labeled 42, 43, 44, 45, 46, 47, 48, and 49. Label 42 denotes the N-terminal domain, label 43 denotes the finger 1 region, label 44 denotes the heel region, label 45 denotes the finger 2 region, labels 46 and 47 denote polypeptide linkers which link the finger and heel regions, and labeled 48 and 49 denote disulfide bonds. In this figure, the disulfide bond 48 links an N-terminal part of the finger 1 region to an N-terminal part of the finger 2 region and the disulfide bond 49 links a C-terminal part of the finger 1 region to a C-terminal part of the finger 2 region.

Without wishing to be bound by theory, it is contemplated that hydrophobic interactions between the finger and heel elements may stabilize the tertiary structure of each morphon. It is contemplated also that engineered disulfide bonds may likewise stabilize the folded structure of the morphon construct. It is understood that the skilled artisan need not determine *a priori* the precise locations of the disulfide bonds when designing the constructs because morphogen constructs having optimal stability and biological activity may be isolated using conventional screening methodologies, such as those discussed hereinbelow.

It is contemplated that the amino acid sequences defining the finger and heel regions may be copied from the respective finger and heel region sequences of any known member of the TGF- β superfamily. Furthermore, it is contemplated also that the size of the morphon constructs of the invention may be reduced significantly by truncating the natural finger and heel regions of the

- 15 -

template TGF- β superfamily member, while compensating for dimensional changes by using polypeptide linker sequences. Truncated forms of the morphon constructs are referred to herein as "mini morphons".

I. Selection of Finger and Heel Regions

5 As mentioned above, amino acid sequences defining finger and heel regions may be copied either from the respective finger and heel region sequences of any known TGF- β superfamily member, identified herein, or from amino acid sequences of a new superfamily member discovered hereafter.

10 Fig. 5 summarizes the amino acid sequences of currently identified TGF- β superfamily members aligned into finger 1 (Fig. 5A), heel (Fig. 5B) and finger 2 (Fig. 5C) regions. The sequences were aligned by a computer algorithm which in order to optimally align the sequences inserted gaps into regions of amino acid sequence known to define loop structures rather than regions of amino acid sequence known to have conserved amino acid sequence or secondary structure. For example, if possible, no gaps were introduced into amino acid sequences of finger
15 1 and finger 2 regions defined by β sheet or heel regions defined by α helix. The dashes (-) indicate a peptide bond between adjacent amino acids. A consensus sequence pattern for each subgroup is shown at the bottom of each subgroup.

After the amino acid sequences of each of the TGF- β superfamily members were aligned, the aligned sequences were used to produce amino acid sequence alignment patterns which identify
20 amino acid residues that may be substituted by another amino acid or group of amino acids without altering the overall tertiary structure of the morphon construct. The amino acids or groups of amino acids that may be useful at a particular position in the finger and heel regions were identified by a computer algorithm implementing the amino acid hierarchy pattern structure shown in Fig. 10.

25 Briefly, the algorithm performs four levels of analysis. In level I, the algorithm determines whether a particular amino acid residue occurs with a frequency greater than 75% at a specific position within the amino acid sequence. For example, if a glycine residue occurs 8 out of 10 times at a particular position in an amino acid sequence, then a glycine is designated at that position. If the position to be tested consists of all gaps then a gap character (-) is assigned to the
30 position, otherwise, if at least one gap exists then a "z" (standing for any residue or a gap) is assigned to the position. If, no amino acid occurs in 75% of the candidate sequences at a particular position the algorithm implements the Level II analysis.

- 16 -

Level II defines pattern sets a, b, d, l, k, o, n, i, and h, wherein l, k, and o share a common amino acid residue. The algorithm then determines whether 75% or more of the amino acid residues at a particular position in the amino acid sequence satisfy one of the aforementioned patterns. If so, then the pattern is assigned to that position. It is possible, however, that both
5 patterns l and k may be simultaneously satisfied because they share the same amino acid, specifically aspartic acid. If simultaneous assignment of l and k occurs then pattern m (Level III) is assigned to that position. Likewise, it is possible that both patterns k and o may be simultaneously assigned because they share the same amino acid, specifically glutamic acid. If simultaneous assignment of k and o occurs, then pattern q (Level III) is assigned to that position.
10 If neither a Level II pattern nor the Level III patterns, m and q, satisfy a particular position in the amino acid sequence then the algorithm implements a Level III analysis.

Level III defines pattern sets c, e, m, q, p, and j, wherein m, q, and p share a common amino residue. Pattern q, however, is not tested in the Level III analysis. It is possible that both
15 patterns m and p may be simultaneously satisfied because they share the same amino acid, specifically, glutamic acid. If simultaneous assignment of m and p occurs then pattern r (Level IV) is assigned to that position. If 75 % of the amino acids at a pre-selected position in the aligned amino acid sequences satisfy a Level III pattern, then the Level III pattern is assigned to that position. If a Level III pattern cannot be assigned to that position then the algorithm implements a Level IV analysis.

20 Level IV comprises two non-overlapping patterns f and r. If 75% of the amino acids at a particular position in the amino acid sequence satisfy a Level IV pattern then the pattern is assigned to the position. If no Level IV pattern is assigned the algorithm assigns an X representing any amino acid (Level V) to that position.

25 In Fig. 10, Level I lists in upper case letters in single amino acid code the 20 naturally occurring amino acids. Levels II-V define, in lower case letters, groups of amino acids based upon the amino acid hierarchy set forth in Smith *et al.*, *supra*. The amino acid sequences set forth in Figs. 5 through 9 were aligned using the aforementioned computer algorithms.

30 It is contemplated that if the artisan wishes to produce a morphon construct based upon currently identified members of the TGF- β superfamily, then the artisan may use the amino acid sequences shown in Fig. 5 to provide the finger 1, finger 2 and heel regions useful in the production of the morphon constructs of the invention. In the case of members of the TGF- β superfamily discovered hereafter, the amino acid sequence of the new member may be aligned, either manually or by means of a computer algorithm, with the sequences set forth in Fig. 5 to define heel and finger regions useful in the practice of the invention.

- 17 -

Table 1 below summarizes publications which describe the amino acid sequences of each TGF- β superfamily member that were used to produce the sequence alignment patterns set forth in Figs. 5-9.

Table 1.

5	TGF- β Superfamily Member	SEQ. ID. No.	Publication
	TGF- β 1	1	Derynck <u>et al.</u> (1987) <u>Nucl. Acids. Res.</u> <u>15</u> :3187
	TGF- β 2	2	Burt <u>et al.</u> (1991) <u>DNA Cell Biol.</u> <u>10</u> :723-734
10	TGF- β 3	3	Ten Dijke <u>et al.</u> (1988) <u>Proc. Natl. Acad. Sci. USA</u> <u>85</u> :4715-4719; Derynck <u>et al.</u> (1988) <u>EMBO J.</u> <u>7</u> :3737-3743.
	TGF- β 4	4	Burt <u>et al.</u> (1992) <u>Mol. Endocrinol.</u> <u>6</u> :989-922.
	TGF- β 5	5	Kondaiah <u>et al.</u> (1990) <u>J. Biol. Chem</u> <u>265</u> :1089-1093
15	dpp	6	Padgett <u>et al.</u> (1987) <u>Nature</u> <u>325</u> :81-84; Paganiban <u>et al.</u> (1990) <u>Mol. Cell Biol.</u> <u>10</u> :2669-2677.
	vg-1	7	Weeks <u>et al.</u> (1987) <u>Cell</u> <u>51</u> :861-867
	vgr-1	8	Lyons <u>et al.</u> (1989) <u>Proc. Natl. Acad. Sci. USA</u> <u>86</u> :4554-4558
	60A	9	Wharton <u>et al.</u> (1991) <u>Proc. Natl. Acad. Sci. USA</u> <u>88</u> :9214-9218; Doctor <u>et al.</u> (1992) <u>Dev. Biol.</u> <u>151</u> :491-505
20	BMP-2A	10	Wozney <u>et al.</u> (1988) <u>Science</u> <u>242</u> : 1528-1534
	BMP-3	11	Wozney <u>et al.</u> (1988) <u>Science</u> <u>242</u> : 1528-1534
	BMP-4	12	Wozney <u>et al.</u> (1988) <u>Science</u> <u>242</u> : 1528-1534
	BMP-5	13	Celeste <u>et al.</u> (1990) <u>Proc. Natl. Acad. Sci. USA</u> <u>87</u> : 9843-9847
	BMP-6	14	Celeste <u>et al.</u> (1990) <u>Proc. Natl. Acad. Sci. USA</u> <u>87</u> : 9843-9847
25	Dorsalin	15	Basler <u>et al.</u> (1993) <u>Cell</u> <u>73</u> :687-702
	OP-1	16	Celeste <u>et al.</u> (1990) <u>Proc. Natl. Acad. Sci. USA</u> <u>87</u> : 9843-9847; Ozkaynak <u>et al.</u> (1990) <u>EMBO J.</u> <u>9</u> :2085-2093
	OP-2	17	Ozkaynak <u>et al.</u> (1992) <u>J. Biol. Chem.</u> <u>267</u> : 25220-25227
	OP-3	18	Ozkaynak <u>et al.</u> PCT/WO94/10203 Seq. I.D. No. 1.

- 18 -

	GDF-1	19	Lee (1990) <u>Mol. Endocrinol.</u> 4: 1034-1040
	GDF-3	20	McPherron <u>et al.</u> (1993) <u>J. Biol. Chem.</u> 268:3444-3449
	GDF-9	21	McPherron <u>et al.</u> (1993) <u>J. Biol. Chem.</u> 268:3444-3449
5	Inhibin α	22	Mayo <u>et al.</u> (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:5849-5853; Stewart <u>et al.</u> (1986) <u>FEBS Lett</u> 206:329-334; Mason <u>et al.</u> (1986) <u>Biochem. Biophys. Res. Commun.</u> 135: 957-964
	Inhibin β A	23	Forage <u>et al.</u> (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:3091-3095; Chertov <u>et al.</u> (1990) <u>Biomed. Sci.</u> 1:499-506
10	Inhibin β B 964	24	Mason <u>et al.</u> (1986) <u>Biochem. Biophys. Res. Commun.</u> 135:957-

In particular, it is contemplated that amino acid sequences defining finger 1 regions useful in the practice of the instant invention may be copied directly from the amino acid sequence defining a finger 1 region for any TGF- β superfamily member identified herein. Useful intact finger 1 regions include, but are not limited to

15	TGF- β 1	SEQ. ID. No. 1, residues 2 through 29,
	TGF- β 2	SEQ. ID. No. 2, residues 2 through 29,
	TGF- β 3	SEQ. ID. No. 3, residues 2 through 29,
	TGF- β 4	SEQ. ID. No. 4, residues 2 through 29,
	TGF- β 5	SEQ. ID. No. 5, residues 2 through 29,
20	dpp	SEQ. ID. No. 6, residues 2 through 29,
	Vg-1	SEQ. ID. No. 7, residues 2 through 29,
	Vgr-1	SEQ. ID. No. 8, residues 2 through 29,
	60A	SEQ. ID. No. 9, residues 2 through 29,
	BMP-2A	SEQ. ID. No. 10, residues 2 through 29,
25	BMP-3	SEQ. ID. No. 11, residues 2 through 29,
	BMP-4	SEQ. ID. No. 12, residues 2 through 29,
	BMP-5	SEQ. ID. No. 13, residues 2 through 29,
	BMP-6	SEQ. ID. No. 14, residues 2 through 29,
	Dorsalin	SEQ. ID. No. 15, residues 2 through 29,
30	OP-1	SEQ. ID. No. 16, residues 2 through 29,
	OP-2	SEQ. ID. No. 17, residues 2 through 29,
	OP-3	SEQ. ID. No. 18, residues 2 through 29,
	GDF-1	SEQ. ID. No. 19, residues 2 through 29,
	GDF-3	SEQ. ID. No. 20, residues 2 through 29,

- 19 -

GDF-9	SEQ. ID. No. 21, residues 2 through 29,
Inhibin α	SEQ. ID. No. 22, residues 2 through 29,
Inhibin β A	SEQ. ID. No. 23, residues 2 through 29, and
Inhibin β B	SEQ. ID. No. 24, residues 2 through 29.

5 It is contemplated also that amino acid sequences defining heel regions useful in the practice of the instant invention may be copied directly from the amino acid sequence defining an intact heel region for any TGF- β superfamily member identified herein. Useful intact heel regions may include, but are not limited to

	TGF- β 1	SEQ. ID. No. 1, residues 35 through 62,
10	TGF- β 2	SEQ. ID. No. 2, residues 35 through 62,
	TGF- β 3	SEQ. ID. No. 3, residues 35 through 62,
	TGF- β 4	SEQ. ID. No. 4, residues 35 through 62,
	TGF- β 5	SEQ. ID. No. 5, residues 35 through 62,
	dpp	SEQ. ID. No. 6, residues 35 through 65,
15	Vg-1	SEQ. ID. No. 7, residues 35 through 65,
	Vgr-1	SEQ. ID. No. 8, residues 35 through 65,
	60A	SEQ. ID. No. 9, residues 35 through 65,
	BMP-2	SEQ. ID. No. 10, residues 35 through 64,
	BMP3	SEQ. ID. No. 11, residues 35 through 66,
20	BMP-4	SEQ. ID. No. 12, residues 35 through 64,
	BMP-5	SEQ. ID. No. 13, residues 35 through 65,
	BMP-6	SEQ. ID. No. 14, residues 35 through 65,
	Dorsalin	SEQ. ID. No. 15, residues 35 through 65,
	OP-1	SEQ. ID. No. 16, residues 35 through 65,
25	OP-2	SEQ. ID. No. 17, residues 35 through 65,
	OP-3	SEQ. ID. No. 18, residues 35 through 65,
	GDF-1	SEQ. ID. No. 19, residues 35 through 70,
	GDF-3	SEQ. ID. No. 20, residues 35 through 64,
	GDF-9	SEQ. ID. No. 21, residues 35 through 65,
30	Inhibin α	SEQ. ID. No. 22, residues 35 through 65,
	Inhibin β A	SEQ. ID. No. 23, residues 35 through 69, and
	Inhibin β B	SEQ. ID. No. 24, residues 35 through 68.

It is contemplated also that amino acid sequences defining finger 2 regions useful in the practice of the instant invention may be copied directly from the amino acid sequence defining an

- 20 -

intact finger 2 region for any TGF- β superfamily member identified herein. Useful intact finger 2 regions may include, but are not limited to

	TGF- β 1	SEQ. ID. No. 1, residues 65 through 94,
	TGF- β 2	SEQ. ID. No. 2, residues 65 through 94,
5	TGF- β 3	SEQ. ID. No. 3, residues 65 through 94,
	TGF- β 4	SEQ. ID. No. 4, residues 65 through 94,
	TGF- β 5	SEQ. ID. No. 5, residues 65 through 94,
	dpp	SEQ. ID. No. 6, residues 68 through 98,
	Vg-1	SEQ. ID. No. 7, residues 68 through 98,
10	Vgr-1	SEQ. ID. No. 8, residues 68 through 98,
	60A	SEQ. ID. No. 9, residues 68 through 98,
	BMP-2A	SEQ. ID. No. 10, residues 67 through 97,
	BMP-3	SEQ. ID. No. 11, residues 69 through 99,
	BMP-4	SEQ. ID. No. 12, residues 67 through 97,
15	BMP-5	SEQ. ID. No. 13, residues 68 through 98,
	BMP-6	SEQ. ID. No. 14, residues 68 through 98,
	Dorsalin	SEQ. ID. No. 15, residues 68 through 99,
	OP-1	SEQ. ID. No. 16, residues 68 through 98,
	OP-2	SEQ. ID. No. 17, residues 68 through 98,
20	OP-3	SEQ. ID. No. 18, residues 68 through 98,
	GDF-1	SEQ. ID. No. 19, residues 73 through 103,
	GDF-3	SEQ. ID. No. 20, residues 67 through 97,
	GDF-9	SEQ. ID. No. 21, residues 68 through 98,
	Inhibin α	SEQ. ID. No. 22, residues 68 through 101,
25	Inhibin β A	SEQ. ID. No. 23, residues 72 through 102, and
	Inhibin β B	SEQ. ID. No. 24, residues 71 through 101.

Furthermore, it is contemplated that the size of the constructs may be reduced significantly by truncating the natural finger and heel regions of the template TGF- β superfamily members, while compensating for dimensional change using linkers as disclosed hereinbelow. Preferred truncated polypeptide sequences that define the finger 1, heel and finger 2 domains are shown in Figs. 7, 8, and 9, respectively. The truncated polypeptides of the finger and heel regions are defined as: large peptides (typically about 25 amino acids in length); medium peptides (typically about 20 amino acids in length); or small peptides (typically about 16 amino acids in length). Each of the aforementioned large, medium, and small finger and heel region peptides preferably comprise an additional residue(s) i.e., either cys or ser-cys at the N-termini and either cys or cys-ser at the C-termini in order to introduce structure stabilizing disulfide bonds into the constructs.

- 21 -

Although, the additional N- and C-terminal serine residues may enhance the water solubility of the constructs, it is anticipated that polar amino acid residues other than serine may likewise be used to enhance solubility of the peptides.

Specifically, Fig. 7 shows preferred amino acid sequences, in a single letter code, for the
 5 finger 1 large peptide (Fig. 7A), the finger 1 medium peptide (Fig. 7B) and the finger 1 small peptide (Fig. 7C) for each member of the TGF- β superfamily. Consensus sequence patterns, described in detail below, for each subgroup are shown also at the bottom of each subgroup. In the patterns, upper case letters identify conserved amino acids in the standard single letter amino acid code, the upper case letter "X" indicates that any naturally occurring amino acid is acceptable
 10 at that particular location. Lower case letters identify groups of amino acids, in accordance with the pattern definition table set forth in Fig. 10, that also may be introduced into that position without affecting the structure of the resulting morphon construct.

Fig. 7D shows stereo alpha carbon traces illustrating the whole finger 1 region whereas, Figs. 7E, 7F, and 7G, show stereo alpha carbon traces of the finger 1 large, medium, and small
 15 peptides, respectively. In Fig. 7D, the lines labeled 72, 73, and 74 pass through the alpha carbons that are cyclized to form the large, medium, and small peptides of the finger 1 region, respectively. The lines with primed labels pass through the cyclized alpha carbons and correspond to the similarly numbered unprimed lines in Fig. 7D. It is apparent from Figs. 7D-7G that the structural features indicative of the finger 1 region can be maintained while reducing the overall
 20 size of the finger 1 element.

It is contemplated that large finger 1 peptides useful in the practice of the instant invention may be selected from a finger 1 sequence belonging any one of the TGF- β superfamily members identified herein. Large finger 1 peptides useful in the practice of the instant invention are set forth below and include, for example:

25	TGF- β 1	SEQ. ID. No. 1, residues 5 through 28,
	TGF- β 2	SEQ. ID. No. 2, residues 5 through 28,
	TGF- β 3	SEQ. ID. No. 3, residues 5 through 28,
	TGF- β 4	SEQ. ID. No. 4, residues 5 through 28,
	TGF- β 5	SEQ. ID. No. 5, residues 5 through 28,
30	dpp	SEQ. ID. No. 6, residues 5 through 28,
	Vg-1	SEQ. ID. No. 7, residues 5 through 28,
	Vgr-1	SEQ. ID. No. 8, residues 5 through 28,
	60A	SEQ. ID. No. 9, residues 5 through 28,
	BMP-2A	SEQ. ID. No. 10, residues 5 through 28,
35	BMP-3	SEQ. ID. No. 11, residues 5 through 28,

- 22 -

	BMP-4	SEQ. ID. No. 12, residues 5 through 28,
	BMP-5	SEQ. ID. No. 13, residues 5 through 28,
	BMP-6	SEQ. ID. No. 14, residues 5 through 28,
	Dorsalin	SEQ. ID. No. 15, residues 5 through 28,
5	OP-1	SEQ. ID. No. 16, residues 5 through 28,
	OP-2	SEQ. ID. No. 17, residues 5 through 28,
	OP-3	SEQ. ID. No. 18, residues 5 through 28,
	GDF-1	SEQ. ID. No. 19, residues 5 through 28,
	GDF-3	SEQ. ID. No. 20, residues 5 through 28,
10	GDF-9	SEQ. ID. No. 21, residues 5 through 28,
	Inhibin α	SEQ. ID. No. 22, residues 5 through 28,
	Inhibin β A	SEQ. ID. No. 23, residues 5 through 28, and
	Inhibin β B	SEQ. ID. No. 24, residues 5 through 28,

In addition, it is contemplated that medium finger 1 peptides useful in the practice of the instant invention may be selected from a finger 1 sequence belonging any one of the TGF- β superfamily members identified herein. Medium finger 1 peptides useful in the practice of the instant invention are set forth below and include, for example:

	TGF- β 1	SEQ. ID. No. 1, residues 7 through 26,
	TGF- β 2	SEQ. ID. No. 2, residues 7 through 26,
20	TGF- β 3	SEQ. ID. No. 3, residues 7 through 26,
	TGF- β 4	SEQ. ID. No. 4, residues 7 through 26,
	TGF- β 5	SEQ. ID. No. 5, residues 7 through 26,
	dpp	SEQ. ID. No. 6, residues 7 through 26,
	Vg-1	SEQ. ID. No. 7, residues 7 through 26,
25	Vgr-1	SEQ. ID. No. 8, residues 7 through 26,
	60A	SEQ. ID. No. 9, residues 7 through 26,
	BMP-2A	SEQ. ID. No. 10, residues 7 through 26,
	BMP-3	SEQ. ID. No. 11, residues 7 through 26,
	BMP-4	SEQ. ID. No. 12, residues 7 through 26,
30	BMP-5	SEQ. ID. No. 13, residues 7 through 26,
	BMP-6	SEQ. ID. No. 14, residues 7 through 26,
	Dorsalin	SEQ. ID. No. 15, residues 7 through 26,
	OP-1	SEQ. ID. No. 16, residues 7 through 26,
	OP-2	SEQ. ID. No. 17, residues 7 through 26,
35	OP-3	SEQ. ID. No. 18, residues 7 through 26,
	GDF-1	SEQ. ID. No. 19, residues 7 through 26,

- 23 -

	GDF-3	SEQ. ID. No. 20, residues 7 through 26,
	GDF-9	SEQ. ID. No. 21, residues 7 through 26,
	Inhibin α	SEQ. ID. No. 22, residues 7 through 26,
	Inhibin β A	SEQ. ID. No. 23, residues 7 through 26, and
5	Inhibin β B	SEQ. ID. No. 24, residues 7 through 26,

In addition, it is contemplated that small finger 1 peptides useful in the practice of the instant invention may be selected from a finger 1 sequence belonging any one the TGF- β superfamily members identified herein. Small finger 1 peptides useful in the practice of the instant invention are set forth below and include, for example:

10	TGF- β 1	SEQ. ID. No. 1, residues 11 through 22,
	TGF- β 2	SEQ. ID. No. 2, residues 11 through 22,
	TGF- β 3	SEQ. ID. No. 3, residues 11 through 22,
	TGF- β 4	SEQ. ID. No. 4, residues 11 through 22,
	TGF- β 5	SEQ. ID. No. 5, residues 11 through 22,
15	dpp	SEQ. ID. No. 6, residues 11 through 22,
	Vg-1	SEQ. ID. No. 7, residues 11 through 22,
	Vgr-1	SEQ. ID. No. 8, residues 11 through 22,
	60A	SEQ. ID. No. 9, residues 11 through 22,
	BMP-2A	SEQ. ID. No. 10, residues 11 through 22,
20	BMP-3	SEQ. ID. No. 11, residues 11 through 22,
	BMP-4	SEQ. ID. No. 12, residues 11 through 22,
	BMP-5	SEQ. ID. No. 13, residues 11 through 22,
	BMP-6	SEQ. ID. No. 14, residues 11 through 22,
	Dorsalin	SEQ. ID. No. 15, residues 11 through 22,
25	OP-1	SEQ. ID. No. 16, residues 11 through 22,
	OP-2	SEQ. ID. No. 17, residues 11 through 22,
	OP-3	SEQ. ID. No. 18, residues 11 through 22,
	GDF-1	SEQ. ID. No. 19, residues 11 through 22,
	GDF-3	SEQ. ID. No. 20, residues 11 through 22,
30	GDF-9	SEQ. ID. No. 21, residues 11 through 22,
	Inhibin α	SEQ. ID. No. 22, residues 11 through 22,
	Inhibin β A	SEQ. ID. No. 23, residues 11 through 22, and
	Inhibin β B	SEQ. ID. No. 24, residues 11 through 22.

Similarly, it is contemplated that the large, medium and small subgroup peptide patterns
 35 shown in Figs. 7A, 7B, and 7C, respectively, for the TGF- β subgroup, the vg/dpp subgroup, the

- 24 -

GDF subgroup, and the Inhibin subgroup, likewise may be used in the practice of the instant invention.

Fig. 8 shows preferred amino acid sequences, in a single letter code, for the heel large peptide (Fig. 8A), the heel medium peptide (Fig. 8B) and the heel small peptide (Fig. 8C) for each member of the TGF- β superfamily. Consensus sequence patterns for each subgroup are shown also at the bottom of each subgroup. In the patterns, upper case letters identify conserved amino acid residues in the standard single letter amino acid code, upper case letter "X" indicates that any naturally occurring amino acid is acceptable at that location, lower case letter "z" indicates that any naturally occurring amino acid or a peptide bond is acceptable at that location, and the other lower case letters identify groups of amino acids defined in accordance with the pattern definition table set forth in Fig. 10, that may be introduced at a pre-selected position in the amino acid sequence without affecting the structure of the resulting morphon construct.

Fig. 8D shows stereo alpha carbon traces illustrating the whole heel region, whereas Figs. 8E, 8F, and 8G show stereo alpha carbon traces of the heel region large, medium, and small peptides, respectively. In Fig. 8D, the lines labeled 82, 83, and 84 pass through the alpha carbons that are cyclized to form the large, medium, and small peptides of the heel region, respectively. The lines with primed labels pass through the cyclized alpha carbons and correspond to the similarly numbered unprimed lines in Fig. 8D. It is apparent from Figs. 8D-8G that the structural features indicative of the heel region can be maintained while reducing the overall size of the heel element.

It is contemplated that large heel peptides useful in the practice of the instant invention may be selected from a heel region sequence belonging any one of the TGF- β superfamily members identified herein. Large heel peptides useful in the practice of the instant invention are set forth below and include, for example:

25	TGF- β 1	SEQ. ID. No. 1, residues 46 through 61,
	TGF- β 2	SEQ. ID. No. 2, residues 46 through 61,
	TGF- β 3	SEQ. ID. No. 3, residues 46 through 61,
	TGF- β 4	SEQ. ID. No. 4, residues 46 through 61,
	TGF- β 5	SEQ. ID. No. 5, residues 46 through 61,
30	dpp	SEQ. ID. No. 6, residues 49 through 64,
	Vg-1	SEQ. ID. No. 7, residues 49 through 64,
	Vgr-1	SEQ. ID. No. 8, residues 49 through 64,
	60A	SEQ. ID. No. 9, residues 49 through 64,
	BMP-2A	SEQ. ID. No. 10, residues 49 through 63,
35	BMP-3	SEQ. ID. No. 11, residues 49 through 65,

- 25 -

	BMP-4	SEQ. ID. No. 12, residues 49 through 63,
	BMP-5	SEQ. ID. No. 13, residues 49 through 64,
	BMP-6	SEQ. ID. No. 14, residues 49 through 64,
	Dorsalin	SEQ. ID. No. 15, residues 49 through 64,
5	OP-1	SEQ. ID. No. 16, residues 49 through 64,
	OP-2	SEQ. ID. No. 17, residues 49 through 64,
	OP-3	SEQ. ID. No. 18, residues 49 through 64,
	GDF-1	SEQ. ID. No. 19, residues 53 through 69,
	GDF-3	SEQ. ID. No. 20, residues 49 through 63,
10	GDF-9	SEQ. ID. No. 21, residues 49 through 64,
	Inhibin α	SEQ. ID. No. 22, residues 51 through 64,
	Inhibin β A	SEQ. ID. No. 23, residues 51 through 68, and
	Inhibin β B	SEQ. ID. No. 24, residues 51 through 67.

In addition, it is contemplated that medium heel peptides useful in the practice of the instant invention may be selected from a heel sequence belonging any one of the TGF- β superfamily members identified herein. Medium heel peptides useful in the practice of the instant invention are set forth below and include, for example:

	TGF- β 1	SEQ. ID. No. 1, residues 49 through 61,
	TGF- β 2	SEQ. ID. No. 2, residues 49 through 61,
20	TGF- β 3	SEQ. ID. No. 3, residues 49 through 61,
	TGF- β 4	SEQ. ID. No. 4, residues 49 through 61,
	TGF- β 5	SEQ. ID. No. 5, residues 49 through 61,
	dpp	SEQ. ID. No. 6, residues 52 through 64,
	Vg-1	SEQ. ID. No. 7, residues 52 through 64,
25	Vgr-1	SEQ. ID. No. 8, residues 52 through 64,
	60A	SEQ. ID. No. 9, residues 52 through 64,
	BMP-2A	SEQ. ID. No. 10, residues 52 through 63,
	BMP-3	SEQ. ID. No. 11, residues 52 through 65,
	BMP-4	SEQ. ID. No. 12, residues 52 through 63,
30	BMP-5	SEQ. ID. No. 13, residues 52 through 64,
	BMP-6	SEQ. ID. No. 14, residues 52 through 64,
	Dorsalin	SEQ. ID. No. 15, residues 52 through 64,
	OP-1	SEQ. ID. No. 16, residues 52 through 64,
	OP-2	SEQ. ID. No. 17, residues 52 through 64,
35	OP-3	SEQ. ID. No. 18, residues 52 through 64,
	GDF-1	SEQ. ID. No. 19, residues 56 through 69,

- 26 -

	GDF-3	SEQ. ID. No. 20, residues 52 through 63,
	GDF-9	SEQ. ID. No. 21, residues 52 through 64,
	Inhibin α	SEQ. ID. No. 22, residues 54 through 64,
	Inhibin β A	SEQ. ID. No. 23, residues 54 through 68, and
5	Inhibin β B	SEQ. ID. No. 24, residues 54 through 67.

Furthermore, it is contemplated that small heel peptides useful in the practice of the instant invention may be selected from a heel sequence belonging any one of the TGF- β superfamily members identified herein. Small heel peptides useful in the practice of the instant invention are set forth below and include, for example:

10	TGF- β 1	SEQ. ID. No. 1, residues 53 through 59,
	TGF- β 2	SEQ. ID. No. 2, residues 53 through 59,
	TGF- β 3	SEQ. ID. No. 3, residues 53 through 59,
	TGF- β 4	SEQ. ID. No. 4, residues 53 through 59,
	TGF- β 5	SEQ. ID. No. 5, residues 53 through 59,
15	dpp	SEQ. ID. No. 6, residues 56 through 62,
	Vg-1	SEQ. ID. No. 7, residues 56 through 62,
	Vgr-1	SEQ. ID. No. 8, residues 56 through 62,
	60A	SEQ. ID. No. 9, residues 56 through 62,
	BMP-2A	SEQ. ID. No. 10, residues 56 through 61,
20	BMP-3	SEQ. ID. No. 11, residues 56 through 63,
	BMP-4	SEQ. ID. No. 12, residues 56 through 61,
	BMP-5	SEQ. ID. No. 13, residues 56 through 62,
	BMP-6	SEQ. ID. No. 14, residues 56 through 62,
	Dorsalin	SEQ. ID. No. 15, residues 56 through 62,
25	OP-1	SEQ. ID. No. 16, residues 56 through 62,
	OP-2	SEQ. ID. No. 17, residues 56 through 62,
	OP-3	SEQ. ID. No. 18, residues 56 through 62,
	GDF-1	SEQ. ID. No. 19, residues 60 through 67,
	GDF-3	SEQ. ID. No. 20, residues 56 through 61,
30	GDF-9	SEQ. ID. No. 21, residues 56 through 62,
	Inhibin α	SEQ. ID. No. 22, residues 58 through 62,
	Inhibin β A	SEQ. ID. No. 22, residues 58 through 66, and
	Inhibin β B	SEQ. ID. No. 23, residues 58 through 65.

Similarly, it is contemplated that the large, medium and small heel subgroup peptide patterns shown in Figs. 8A, 8B, and 8C, respectively, for the TGF- β subgroup, the vg/dpp subgroup, the

- 27 -

GDF subgroup, and the Inhibin subgroup, also may be used in the practice of the instant invention.

Fig. 9 shows preferred amino acid sequences, in a single amino acid code for the finger 2 large peptide (Fig. 9A), the finger 2 medium peptide (Fig. 9B) and the finger 2 small peptide (Fig. 9C) for each member of the TGF- β superfamily. Consensus sequence patterns for each subgroup are shown also at the bottom of each subgroup. In the patterns, upper case letters identify conserved amino acids in the standard single letter amino acid code, upper case letter "X" indicates that any naturally occurring amino acid is acceptable at that location, lower case letter "z" indicates that any naturally occurring amino acid or a peptide bond is acceptable at that location, and the other lower case letters identify groups of amino acids, in accordance with the pattern definition table set forth in Fig. 10, that may be introduced at a pre-selected position in the amino acid sequence without affecting the structure of the resulting morphon construct.

Fig. 9D shows stereo alpha carbon traces illustrating the whole finger 2 region, whereas Figs. 9E, 9F, and 9G show stereo alpha carbon traces of the finger 2 large, medium, and small peptides, respectively. In Fig. 9D, the lines labeled 92, 93, and 94 pass through the alpha carbons that are cyclized to form the large, medium, and small peptides of the finger 2 region, respectively. The lines with primed labels pass through the cyclized alpha carbons and correspond to the similarly numbered unprimed lines in Fig. 9D. It is apparent from Figs. 9D-9G that the structural features indicative of the finger 2 region can be maintained while reducing the overall size of the finger 2 element.

It is contemplated that large finger 2 peptides useful in the practice of the instant invention may be selected from a finger 2 sequence belonging any one of the TGF- β superfamily members identified herein. Large finger 2 peptides useful in the practice of the instant invention are set forth below and include, for example:

25	TGF- β 1	SEQ. ID. No. 1, residues 72 through 87,
	TGF- β 2	SEQ. ID. No. 2, residues 72 through 87,
	TGF- β 3	SEQ. ID. No. 3, residues 72 through 87,
	TGF- β 4	SEQ. ID. No. 4, residues 72 through 87,
	TGF- β 5	SEQ. ID. No. 5, residues 72 through 87,
30	dpp	SEQ. ID. No. 6, residues 75 through 91,
	Vg-1	SEQ. ID. No. 7, residues 75 through 91,
	Vgr-1	SEQ. ID. No. 8, residues 75 through 91,
	60A	SEQ. ID. No. 9, residues 75 through 91,
	BMP-2A	SEQ. ID. No. 10, residues 74 through 90,
35	BMP-3	SEQ. ID. No. 11, residues 76 through 92,

- 28 -

	BMP-4	SEQ. ID. No. 12, residues 74 through 90,
	BMP-5	SEQ. ID. No. 13, residues 75 through 91,
	BMP-6	SEQ. ID. No. 14, residues 75 through 91,
	Dorsalin	SEQ. ID. No. 15, residues 75 through 92,
5	OP-1	SEQ. ID. No. 16, residues 75 through 91,
	OP-2	SEQ. ID. No. 17, residues 75 through 91,
	OP-3	SEQ. ID. No. 18, residues 75 through 91,
	GDF-1	SEQ. ID. No. 19, residues 80 through 96,
	GDF-3	SEQ. ID. No. 20, residues 74 through 90,
10	GDF-9	SEQ. ID. No. 21, residues 75 through 91,
	Inhibin α	SEQ. ID. No. 22, residues 77 through 94,
	Inhibin β A	SEQ. ID. No. 23, residues 79 through 95, and
	Inhibin β B	SEQ. ID. No. 24, residues 78 through 94.

15 In addition, it is contemplated that medium finger 2 peptides useful in the practice of the instant invention may be selected from a finger 2 sequence belonging any one of the TGF- β superfamily members identified herein. Medium finger 2 peptides useful in the practice of the instant invention are set forth below and include, for example:

	TGF- β 1	SEQ. ID. No. 1, residues 74 through 85,
	TGF- β 2	SEQ. ID. No. 2, residues 74 through 85,
20	TGF- β 3	SEQ. ID. No. 3, residues 74 through 85,
	TGF- β 4	SEQ. ID. No. 4, residues 74 through 85,
	TGF- β 5	SEQ. ID. No. 5, residues 74 through 85,
	dpp	SEQ. ID. No. 6, residues 77 through 89,
	Vg-1	SEQ. ID. No. 7, residues 77 through 89,
25	Vgr-1	SEQ. ID. No. 8, residues 77 through 89,
	60A	SEQ. ID. No. 9, residues 77 through 89,
	BMP-2A	SEQ. ID. No. 10, residues 76 through 88,
	BMP-3	SEQ. ID. No. 11, residues 78 through 90,
	BMP-4	SEQ. ID. No. 12, residues 76 through 88,
30	BMP-5	SEQ. ID. No. 13, residues 77 through 89,
	BMP-6	SEQ. ID. No. 14, residues 77 through 89,
	Dorsalin	SEQ. ID. No. 15, residues 77 through 90,
	OP-1	SEQ. ID. No. 16, residues 77 through 89,
	OP-2	SEQ. ID. No. 17, residues 77 through 89,
35	OP-3	SEQ. ID. No. 18, residues 77 through 89,
	GDF-1	SEQ. ID. No. 19, residues 82 through 94,

- 29 -

	GDF-3	SEQ. ID. No. 20, residues 76 through 88,
	GDF-9	SEQ. ID. No. 21, residues 77 through 89,
	Inhibin α	SEQ. ID. No. 22, residues 79 through 92,
	Inhibin β A	SEQ. ID. No. 23, residues 81 through 93, and
5	Inhibin β B	SEQ. ID. No. 24, residues 80 through 92.

Furthermore, it is contemplated that small finger 2 peptides useful in the practice of the instant invention may be selected from a finger 2 sequence belonging any one of the TGF- β superfamily members identified herein. Small finger 2 peptides useful in the practice of the instant invention are set forth below and include, for example:

10	TGF- β 1	SEQ. ID. No. 1, residues 76 through 83,
	TGF- β 2	SEQ. ID. No. 2, residues 76 through 83,
	TGF- β 3	SEQ. ID. No. 3, residues 76 through 83,
	TGF- β 4	SEQ. ID. No. 4, residues 76 through 83,
	TGF- β 5	SEQ. ID. No. 5, residues 76 through 83,
15	dpp	SEQ. ID. No. 6, residues 79 through 87,
	Vg-1	SEQ. ID. No. 7, residues 79 through 87,
	Vgr-1	SEQ. ID. No. 8, residues 79 through 87,
	60A	SEQ. ID. No. 9, residues 79 through 87,
	BMP-2A	SEQ. ID. No. 10, residues 78 through 86,
20	BMP-3	SEQ. ID. No. 11, residues 80 through 88,
	BMP-4	SEQ. ID. No. 12, residues 78 through 86,
	BMP-5	SEQ. ID. No. 13, residues 79 through 87,
	BMP-6	SEQ. ID. No. 14, residues 79 through 87,
	Dorsalin	SEQ. ID. No. 15, residues 79 through 88,
25	OP-1	SEQ. ID. No. 16, residues 79 through 87,
	OP-2	SEQ. ID. No. 17, residues 79 through 87,
	OP-3	SEQ. ID. No. 18, residues 79 through 87,
	GDF-1	SEQ. ID. No. 19, residues 84 through 92,
	GDF-3	SEQ. ID. No. 20, residues 78 through 86,
30	GDF-9	SEQ. ID. No. 21, residues 79 through 87,
	Inhibin α	SEQ. ID. No. 22, residues 81 through 90,
	Inhibin β A	SEQ. ID. No. 23, residues 83 through 91, and
	Inhibin β B	SEQ. ID. No. 24, residues 82 through 90.

Similarly, it is contemplated that the large, medium and small finger 2 subgroup peptide patterns shown in Figs. 9A, 9B, and 9C, respectively, for the TGF- β subgroup, the vg/dpp

- 30 -

subgroup, the GDF subgroup, and the Inhibin subgroup, also may be used in the practice of the instant invention.

In addition, it is contemplated that the amino acid sequences of the respective finger and heel regions may be altered by amino acid substitution, especially by exploiting substitute residues selected in accordance with the principles disclosed in Smith *et al.* (1990), *supra*. Briefly, Smith *et al.* disclose an amino acid class hierarchy similar to the one summarized in Fig. 10, which may be used to rationally substitute one amino acid for another while minimizing gross conformational distortions of the type which would inactivate protein function. In any event, it is contemplated that many synthetic first finger, second finger, and heel region sequences, having only 70% homology with natural regions, preferably 80%, and most preferably at least 90%, can be used to produce morphon constructs.

Amino acid sequence patterns showing amino acids preferred at each location in the finger and heel regions, deduced in accordance with the principles described in Smith *et al.* (1990) *supra*, also are shown in Figs. 5-9, and are referred to as the: TGF- β ; Vg/dpp; GDF; and Inhibin subgroup patterns. The amino acid sequences defining the finger 1, heel and finger 2 sequence patterns of each subgroup are set forth in Figs. 5A, 5B, and 5C, respectively. In addition, the amino acid sequences defining the entire TGF- β , Vg/dpp, GDF and Inhibin subgroup patterns are set forth in the Sequence Listing as SEQ. ID. Nos. 25, 26, 27, and 28, respectively.

The preferred amino acid sequence patterns for each subgroup, disclosed in Figures 5A, 5B, and 5C, and summarized in Figure 6, enable one skilled in the art to identify alternative amino acids that may be incorporated at specific positions in the finger 1, heel, and finger 2 elements. The amino acids identified in upper case letters in a single letter amino acid code identify conserved amino acids that together are believed to define structural and functional elements of the finger and heel regions. The upper case letter "X" in Figs. 5 and 6 indicates that any naturally occurring amino acid is acceptable at that position. The lower case letter "z" in Figs. 5 and 6 indicates that either a gap or any of the naturally occurring amino acids is acceptable at that position. The lower case letters stand for the amino acids indicated in accordance with the pattern definition table set forth in Figure 10 and identify groups of amino acids which are useful in that location.

In accordance with the amino acid sequence subgroup patterns set forth in Figs. 5-9, it is contemplated, for example, that the skilled artisan may be able to predict that where applicable, one amino acid may be substituted by another without inducing disruptive stereochemical changes within the resulting protein construct. For example, in Fig 5A, in the TGF- β subgroup pattern at residue number 12 it is contemplated that either a lysine residue (K) or a glutamine residue (Q) may be present at this position without affecting the structure of the resulting construct.

- 31 -

Accordingly, the sequence pattern at position 12 contains an "n" which in accordance with Figure 10 defines an amino acid residue selected from the group consisting of lysine or glutamine. It is contemplated, therefore, that many synthetic finger 1, finger 2 and heel region amino acid sequences, having 70% homology, preferably 80%, and most preferably at least 90% with the natural regions, may be used to produce conformationally active constructs of the invention.

In accordance with these principles, it is contemplated that one may design a synthetic morphon construct by starting with the amino acid sequence patterns belonging to the TGF- β , Vg/dpp, GDF, or Inhibin subgroup patterns shown in Figs. 5 and 6. Thereafter, by using conventional recombinant DNA methodologies a preselected amino acid may be substituted by another as guided by the principles herein and the resulting protein construct tested for binding activity in combination with either agonist or antagonist activity.

The TGF- β subgroup pattern, SEQ. ID. No. 25, accommodates the homologies shared among members of the TGF- β subgroup identified to date including TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4, and TGF- β 5. The generic sequence, shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in Fig. 10.

TGF- β Subgroup Pattern

```

Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Xaa Asp Leu Gly Trp
1           5           10           15

Lys Trp Ile His Glu Pro Lys Gly Tyr Xaa Ala Asn Phe Cys Xaa Gly
          20           25           30

Xaa Cys Pro Tyr Xaa Trp Ser Xaa Asp Thr Gln Xaa Ser Xaa Val Leu
          35           40           45

Xaa Leu Tyr Asn Xaa Xaa Asn Pro Xaa Ala Ser Ala Xaa Pro Cys Cys
          50           55           60

Val Pro Gln Xaa Leu Glu Pro Leu Xaa Ile Xaa Tyr Tyr Val Gly Arg
65           70           75           80

Xaa Xaa Lys Val Glu Gln Leu Ser Asn Met Xaa Val Xaa Ser Cys Lys
          85           90           95

Cys Ser.
```

Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa12 is Arg or Lys; Xaa26 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa31 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa33 is Ala, Gly, Pro, Ser, or Thr; Xaa37 is Ile, Leu, Met or Val; Xaa40 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly,

- 32 -

His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa44 is His, Phe, Trp or Tyr; Xaa46 is Arg or Lys; Xaa49 is Ala, Gly, Pro, Ser, or Thr; Xaa53 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa54 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa57 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa61 is Ala, Gly, Pro, Ser, or Thr; Xaa68 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa73 is Ala, Gly, Pro, Ser, or Thr; Xaa75 is Ile, Leu, Met or Val; Xaa81 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa82 is Ala, Gly, Pro, Ser, or Thr; Xaa91 is Ile or Val; Xaa93 is Arg or Lys.

- 10 The Vg/dpp subgroup pattern, SEQ. ID. No. 26, accommodates the homologies shared among members of the Vg/dpp subgroup identified to date including dpp, vg-1, vgr-1, 60A, BMP-2A (BMP-2), Dorsalin, BMP-2B (BMP-4), BMP-3, BMP-5, BMP-6, OP-1 (BMP-7), OP-2 and OP-3. The generic sequence, below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the
- 15 sequence and defined by the rules set forth in Fig. 10.

Vg/dpp Subgroup Pattern

```

Cys Xaa Xaa Xaa Xaa Leu Tyr Val Xaa Phe Xaa Asp Xaa Gly Trp Xaa
  1          5          10          15

Asp Trp Ile Ile Ala Pro Xaa Gly Tyr Xaa Ala Xaa Tyr Cys Xaa Gly
      20          25          30

Xaa Cys Xaa Phe Pro Leu Xaa Xaa Xaa Xaa Asn Xaa Thr Asn His Ala
  35          40          45

Ile Xaa Gln Thr Leu Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro
  50          55          60

Lys Xaa Cys Cys Xaa Pro Thr Xaa Leu Xaa Ala Xaa Ser Xaa Leu Tyr
  65          70          75          80

Xaa Asp Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Tyr Xaa Xaa Met
      85          90          95

Xaa Val Xaa Xaa Cys Gly Cys Xaa.
      100

```

Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Arg or Lys; Xaa3 is Arg or Lys; Xaa4 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa5 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa9 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa11 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa13 is Ile, Leu, Met or Val; Xaa16 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa23 is Arg, Gln, Glu, or Lys; Xaa26 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met,

- 33 -

Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa28 is Phe, Trp or Tyr; Xaa31 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa33 is Asp or Glu; Xaa35 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa39 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa40 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa41 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa42 is Leu or Met; Xaa44 is Ala, Gly, Pro, Ser, or Thr; Xaa50 is Ile or Val; Xaa55 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa56 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa57 is Ile, Leu, Met or Val; Xaa58 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa59 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa60 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa61 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa62 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa63 is Ile or Val; Xaa66 is Ala, Gly, Pro, Ser, or Thr; Xaa69 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa72 is Arg, Gln, Glu, or Lys; Xaa74 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa76 is Ile or Val; Xaa78 is Ile, Leu, Met or Val; Xaa81 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa83 is Asn, Asp or Glu; Xaa84 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa85 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa86 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa87 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa89 is Ile or Val; Xaa91 is Arg or Lys; Xaa92 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa94 is Arg, Gln, Glu, or Lys; Xaa95 is Asn or Asp; Xaa97 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa99 is Arg, Gln, Glu, or Lys; Xaa100 is Ala, Gly, Pro, Ser, or Thr; Xaa104 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr.

The GDF subgroup pattern, SEQ. ID. No. 27, accommodates the homologies shared among members of the GDF subgroup identified to date including GDF-1, GDF-3, and GDF-9. The generic sequence, shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in Fig. 10.

GDF Subgroup Pattern

```

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Trp Xaa
 1           5           10           15

Xaa Trp Xaa Xaa Ala Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Gly
          20           25           30

Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

```

- 34 -

	35		40		45
	Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa				
	50		55		60
	Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Val Pro Xaa Xaa Xaa Ser Pro Xaa				
	65		70		75
	Ser Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr				
		85		90	95
	Glu Asp Met Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa.				
	100		105		

Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa3 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa4 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa5 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa6 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa7 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa8 is Ile, Leu, Met or Val; Xaa9 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa11 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa12 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa13 is Ile, Leu, Met or Val; Xaa14 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa16 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa17 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa19 is Ile or Val; Xaa20 is Ile or Val; Xaa23 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa24 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa25 is Phe, Trp or Tyr; Xaa26 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa27 is Ala, Gly, Pro, Ser, or Thr; Xaa28 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa29 is Phe, Trp or Tyr; Xaa31 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa33 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa35 is Ala, Gly, Pro, Ser, or Thr; Xaa36 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa37 is Ala, Gly, Pro, Ser, or Thr; Xaa38 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa39 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa40 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa41 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa42 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa43 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa44 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa45 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa46 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile,

- 35 -

Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa47 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa48 is Ala, Gly, Pro, Ser, or Thr; Xaa49 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa50 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa51 is His, Phe, Trp or Tyr; Xaa52 is Ala, Gly, Pro, Ser, or Thr; Xaa53 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa54 is Ile, Leu, Met or Val; Xaa55 is Arg, Gln, Glu, or Lys; Xaa56 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa57 is Ile, Leu, Met or Val; Xaa58 is Ile, Leu, Met or Val; Xaa59 is His, Phe, Trp or Tyr; Xaa60 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa61 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa62 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa63 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa64 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa66 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa67 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa68 is Ala, Gly, Pro, Ser, or Thr; Xaa69 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa70 is Ala, Gly, Pro, Ser, or Thr; Xaa71 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa75 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa76 is Arg or Lys; Xaa77 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa80 is Ile, Leu, Met or Val; Xaa82 is Ile, Leu, Met or Val; Xaa84 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa85 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa86 is Asp or Glu; Xaa87 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa88 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa89 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa90 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa91 is Ile or Val; Xaa92 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa93 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa94 is Arg or Lys; Xaa95 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa100 is Ile or Val; Xaa101 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa102 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa103 is Arg, Gln, Glu, or Lys; Xaa105 is Ala, Gly, Pro, Ser, or Thr; Xaa107 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val.

The Inhibin subgroup pattern, SEQ. ID. No. 28, accommodates the homologies shared among members of the Inhibin subgroup identified to date including Inhibin α , Inhibin β A and

- 36 -

Inhibin β B. The generic sequence, shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in Fig. 10.

Inhibin Subgroup pattern

```

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
1      5      10      15
Xaa Trp Ile Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Tyr Cys Xaa Gly
      20      25      30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      35      40      45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      50      55      60
Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa
65      70      75      80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      85      90      95
Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
      100      105

```

Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa3 is Arg or Lys; Xaa4 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa5 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa6 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa7 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa8 is Ile or Val; Xaa9 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa11 is Arg, Gln, Glu, or Lys; Xaa12 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa13 is Ile, Leu, Met or Val; Xaa16 is Asn, Asp or Glu; Xaa17 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa20 is Ile or Val; Xaa21 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa23 is Ala, Gly, Pro, Ser, or Thr; Xaa24 is Ala, Gly, Pro, Ser, or Thr; Xaa25 is Phe, Trp or Tyr; Xaa26 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa27 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa28 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa31 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa33 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa35 is Ala, Gly, Pro, Ser, or Thr; Xaa36 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys,

- 37 -

Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa37 is His, Phe, Trp or Tyr; Xaa38 is Ile, Leu, Met or Val; Xaa39 is Ala, Gly, Pro, Ser, or Thr; Xaa40 is Ala, Gly, Pro, Ser, or Thr; Xaa41 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa42 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa43 is Ala, Gly, Pro, Ser, or Thr; Xaa44 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa45 is Ala, Gly, Pro, Ser, or Thr; Xaa46 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa47 is Ala, Gly, Pro, Ser, or Thr; Xaa48 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa49 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa50 is Ala, Gly, Pro, Ser, or Thr; Xaa51 is Ala, Gly, Pro, Ser, or Thr; Xaa52 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa53 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa54 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa55 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa56 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa57 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa58 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa59 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa60 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa61 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa62 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa63 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa64 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa65 is Ala, Gly, Pro, Ser, or Thr; Xaa66 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa67 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa68 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa69 is Ala, Gly, Pro, Ser, or Thr; Xaa72 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa73 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa74 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa76 is Ala, Gly, Pro, Ser, or Thr; Xaa77 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa78 is Leu or Met; Xaa79 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa80 is Ala, Gly, Pro, Ser, or Thr; Xaa81 is Leu or Met; Xaa82 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa83 is Ile, Leu, Met or Val; Xaa84 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu,

- 38 -

Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa85 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa86 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa87 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa89 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa90 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or a peptide bond; Xaa91 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa92 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa93 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa94 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa95 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa96 is Arg, Gln, Glu, or Lys; Xaa97 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa98 is Ile or Val; Xaa99 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa101 is Leu or Met; Xaa102 is Ile, Leu, Met or Val; Xaa103 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa104 is Gln or Glu; Xaa105 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa107 is Ala or Gly; Xaa109 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val.

II. Polypeptide Linker Considerations.

In the morphon constructs, polypeptide linker sequences join and maintain the spatial relationship of the finger and heel regions thereby helping to maintain the cysteine structural motif, i.e., the cysteine pattern and knot structure, which characterizes and is believed to be important in maintaining the tertiary structure of each subunit of a TGF- β superfamily member.

It is contemplated that the polypeptide linkers preferably are about 2-20, and most preferably about 3-13 amino acids in length. The polypeptide linkers should be long enough to permit the finger and heel regions to assume their proper conformation as defined as being able to bind a receptor that typically binds a TGF- β superfamily member. The specific amino acid composition of the polypeptide linker may vary, however, cysteine residues preferably should be avoided. Cysteine residues in the linker sequence may disulfide bond with the cysteine residues that define the knot structure thereby affecting the cysteine structural motif. It is contemplated that the amino acid sequence of each linker may be based either in whole or in part upon: 1) the amino acid sequences normally present at the ends of the template finger and heel regions; 2) unrelated amino acid sequences, predicted by computer based algorithms to be sufficient to connect the ends of the finger and heel regions without affecting the spatial arrangement of the finger and heel regions in the morphon construct; 3) multiples or portions of pentameric repeat units of Gly₄Ser or Ser₄Gly; or 4) a combination thereof.

- 39 -

Accordingly, the artisan simply may choose an amino acid sequence, such as a β -turn, based upon the amino acid sequence that normally would connect the finger and heel regions within a template molecule. Alternatively, once the appropriate heel and finger regions have been chosen in accordance with the principles described above, the artisan may use a variety of commercially available computer-based algorithms to predict appropriate linker sequences capable of linking the finger and heel regions. Currently preferred, publicly available computer programs include, but are not limited to, CONGEN (Brucoleri *et al.* (1987) *Biopolymers* 26:137) and TWEAK (Shenkin *et al.* (1987) *Biopolymers* 26:2053-2085), the disclosures of which are incorporated herein by reference. Currently preferred, commercially available software packages include, but are not limited to, INSIGHTII, HOMOLOGY, and DISCOVER, all of which are available from Biosym, Inc. Other computer-based programs useful in producing appropriate linker sequences are disclosed in U.S. Patent Nos. 4,704,692; 4,881,175; 4,939,666; 4,946,778; and 5,260,203, the disclosures of which are incorporated herein by reference. The aforementioned programs and software packages enable the artisan to identify pre-existing amino acid sequences in protein structure databases or build using molecular simulation and/or thermodynamic calculations amino acid sequences for linking two polypeptide chains through designated N- and C-termini. In addition, as mentioned above, the artisan may simply link the ends of the appropriate finger and heel regions with an amino acid sequence based in whole, or in part, on the pentameric repeat units of Gly₄Ser or Ser₄Gly. Such repeats have been used successfully to construct single-chain antibody binding sites. Methodologies for designing, making, testing and using linkers based on the pentameric repeats of Gly₄Ser or Ser₄Gly are disclosed in U.S. Patent Nos. 5,132,405; 5,091,513; and 5,258,498 and PCT Application No. US88/01737, the disclosures of which are incorporated herein by reference.

It is contemplated that synthetic morphons may be joined through their N- or C- termini via a polypeptide linker to a second functional protein domain to produce a multifunctional protein construct. For example, a morphon construct may be linked by means of an additional polypeptide linker to a single-chain antibody binding site for targeting, or to a chemokine, hormone, toxin, or other physiologically active functional protein. For details of the construction of these multifunctional proteins using such linkers, see U.S. Patent Nos. 5,132,405 and 5,091,513.

III. Design and Production of Morphons

As mentioned above, the biosynthetic constructs of the invention preferably are manufactured by using conventional recombinant DNA methodologies well known and thoroughly documented in the art.

- 40 -

For example, the constructs may be manufactured by the assembly of synthetic nucleotide sequences and/or joining DNA restriction fragments to produce a synthetic DNA molecule. The DNA molecules then are ligated into an expression vehicle, for example an expression plasmid, and transfected into an appropriate host cell, for example *E. coli*. The protein encoded by the DNA molecule then is expressed, purified, folded if necessary, tested *in vitro* for binding activity with a receptor having binding affinity for the template TGF- β superfamily member, and subsequently tested to assess whether the biosynthetic construct mimics the activity of the template superfamily member.

Alternatively, a library of synthetic DNA constructs can be prepared simultaneously for example, by the assembly of synthetic nucleotide sequences that differ in nucleotide composition in a preselected region. For example, it is contemplated that during production of a morphon construct based upon a specific TGF- β superfamily member, the artisan may choose appropriate finger and heel regions for such a superfamily member (for example from Figs. 5-9). Once the appropriate finger and heel regions have been selected, the artisan then may produce synthetic DNA encoding these regions, which subsequently may be connected by linker sequences encoding polypeptide linkers. For example, if a plurality of DNA molecules encoding different linker sequences are included into a ligation reaction containing DNA molecules encoding finger and heel sequences, by judicious choice of appropriate restriction sites and reaction conditions, the artisan may produce a library of DNA constructs wherein each of the DNA constructs encode finger and heel regions but connected by different linker sequences. The resulting DNAs then are ligated into a suitable expression vehicle, i.e., a plasmid useful in the preparation of a phage display library, transfected into a host cell, and the polypeptides encoded by the synthetic DNAs expressed to generate a pool of candidate compounds. The pool of candidate compounds subsequently can be screened to identify lead compounds having binding affinity and/or selectivity for a pre-selected receptor.

Screening may be performed by passing a solution comprising the candidate compounds through a chromatography column containing surface immobilized receptor. Then lead compounds with the desired binding specificity are eluted, for example by means of a salt gradient and/or a concentration gradient of the template TGF- β superfamily member. Nucleotide sequences encoding the lead compounds subsequently may be isolated and characterized. Once the appropriate nucleotide sequences of the lead compounds have been identified, the lead compounds subsequently may be produced, either by conventional recombinant DNA or peptide synthesis methodologies, in quantities sufficient to test whether the particular construct mimics the activity of the template TGF- β superfamily member.

- 41 -

It is contemplated that, which ever approach is adopted to produce DNA molecules encoding morphons of the invention, the tertiary structure of the lead compound or compounds may subsequently be modulated in order to optimize binding and/or biological activity by, for example, using a combination of nucleotide mutagenesis methodologies aided by the principles described herein and phage display methodologies. Accordingly, an artisan may produce and test simultaneously large numbers of candidate compounds. The refined compounds produced by this approach subsequently may be screened for either agonist or antagonist activity by using conventional in vitro and/or in vivo assays similar to the assays discussed hereinbelow.

A. Gene Synthesis.

The processes for manipulating, amplifying, and recombining DNA which encode amino acid sequences of interest generally are well known in the art, and therefore, are not described in detail herein. Methods of identifying and isolating genes encoding members of the TGF- β superfamily and their cognate receptors also are well understood, and are described in the patent and other literature.

Briefly, the construction of DNAs encoding the biosynthetic constructs disclosed herein is performed using known techniques involving the use of various restriction enzymes which make sequence specific cuts in DNA to produce blunt ends or cohesive ends, DNA ligases, techniques enabling enzymatic addition of sticky ends to blunt-ended DNA, construction of synthetic DNAs by assembly of short or medium length oligonucleotides, cDNA synthesis techniques, polymerase chain reaction (PCR) techniques for amplifying appropriate nucleic acid sequences from libraries, and synthetic probes for isolating genes of members of the TGF-b superfamily and their cognate receptors. Various promoter sequences from bacteria, mammals, or insects to name a few, and other regulatory DNA sequences used in achieving expression, and various types of host cells are also known and available. Conventional transfection techniques, and equally conventional techniques for cloning and subcloning DNA are useful in the practice of this invention and known to those skilled in the art. Various types of vectors may be used such as plasmids and viruses including animal viruses and bacteriophages. The vectors may exploit various marker genes which impart to a successfully transfected cell a detectable phenotypic property that can be used to identify which of a family of clones has successfully incorporated the recombinant DNA of the vector.

One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer followed by ligation with appropriate ligases. For example, overlapping, complementary DNA fragments may be synthesized using phosphoramidite chemistry, with end segments left unphosphorylated to prevent polymerization during ligation. One end of the

- 42 -

synthetic DNA is left with a "sticky end" corresponding to the site of action of a particular restriction endonuclease, and the other end is left with an end corresponding to the site of action of another restriction endonuclease. The complimentary DNA fragments are ligated together to produce a synthetic DNA construct.

Alternatively nucleic acid strands encoding finger 1, finger 2 and heel regions may be isolated from libraries of nucleic acids, for example, by colony hybridization procedures such as those described in Sambrook et al. eds. (1989) "Molecular Cloning", Coldspring Harbor Laboratories Press, NY, and/or by PCR amplification methodologies, such as those disclosed in Innis et al. (1990) "PCR Protocols, A guide to methods and applications", Academic Press. The nucleic acids encoding the finger and heel regions then are joined together to produce a synthetic DNA encoding the biosynthetic single-chain morphon construct of interest.

It is appreciated, however, that a library of DNA constructs encoding a plurality of morphons may be produced simultaneously by standard recombinant DNA methodologies, such as the ones, described above. For example, the skilled artisan by the use of cassette mutagenesis or oligonucleotide directed mutagenesis may produce, for example, a series of DNA constructs each of which contain different DNA sequences within a predefined location, e.g., within a DNA cassette encoding a linker sequence. The resulting library of DNA constructs subsequently may be expressed, for example, in a phage display library (see section V below) and any protein constructs that binds to a specific receptor may be isolated by affinity purification, e.g., using a chromatographic column comprising surface immobilized receptor (see section V below). Once molecules that bind the preselected receptor have been isolated, their binding and agonist properties may be modulated using the empirical refinement techniques also discussed in section V, below.

B. Protein Expression

If a single DNA construct of interest has been synthesized, it may be integrated into an expression vector and transfected into an appropriate host cell for protein expression. Useful prokaryotic host cells include, but are not limited to, E. coli, and B. Subtilis. Useful eukaryotic host cells include, but are not limited to, yeast cells, insect cells, myeloma cells, fibroblast 3T3 cells, monkey kidney or COS cells, chinese hamster ovary (CHO) cells, mink-lung epithelial cells, human foreskin fibroblast cells, human glioblastoma cells, and teratocarcinoma cells. Alternatively, the synthetic genes may be expressed in a cell-free system such as the rabbit reticulocyte lysate system.

The vector additionally may include various sequences to promote correct expression of the recombinant protein, including transcriptional promoter and termination sequences, enhancer

- 43 -

sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred protein processing sequences, preferred signal sequences for protein secretion, and the like. The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The morphon proteins also may be expressed as fusion proteins. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium and then cleaved at a specific protease site if so desired.

For example, if the gene is to be expressed in E. coli, it is cloned into an appropriate expression vector. This can be accomplished by positioning the engineered gene downstream of a promoter sequence such as Trp or Tac, and/or a gene coding for a leader peptide such as fragment B of protein A (FB). During expression, the resulting fusion proteins accumulate in refractile bodies in the cytoplasm of the cells, and may be harvested after disruption of the cells by French press or sonication. The isolated refractile bodies then are solubilized, and the expressed proteins folded and the leader sequence cleaved, if necessary, by methods already established with many other recombinant proteins.

Expression of the engineered genes in eukaryotic cells requires cells and cell lines that are easy to transfect, are capable of stably maintaining foreign DNA with an unrearranged sequence, and which have the necessary cellular components for efficient transcription, translation, post-translation modification, and secretion of the protein. In addition, a suitable vector carrying the gene of interest also is necessary. DNA vector design for transfection into mammalian cells should include appropriate sequences to promote expression of the gene of interest as described herein, including appropriate transcription initiation, termination, and enhancer sequences, as well as sequences that enhance translation efficiency, such as the Kozak consensus sequence. Preferred DNA vectors also include a marker gene and means for amplifying the copy number of the gene of interest. A detailed review of the state of the art of the production of foreign proteins in mammalian cells, including useful cells, protein expression-promoting sequences, marker genes, and gene amplification methods, is disclosed in Bendig (1988) Genetic Engineering 7:91-127.

The best characterized transcription promoters useful for expressing a foreign gene in a particular mammalian cell are the SV40 early promoter, the adenovirus promoter (AdMLP), the mouse metallothionein-I promoter (mMT-I), the Rous sarcoma virus (RSV) long terminal repeat (LTR), the mouse mammary tumor virus long terminal repeat (MMTV-LTR), and the human cytomegalovirus major intermediate-early promoter (hCMV). The DNA sequences for all of these promoters are known in the art and are available commercially.

The use of a selectable DHFR gene in a dhfr⁻ cell line is a well characterized method useful in the amplification of genes in mammalian cell systems. Briefly, the DHFR gene is provided on

- 44 -

the vector carrying the gene of interest, and addition of increasing concentrations of the cytotoxic drug methotrexate, which is metabolized by DHFR, leads to amplification of the DHFR gene copy number, as well as that of the associated gene of interest. DHFR as a selectable, amplifiable marker gene in transfected chinese hamster ovary cell lines (CHO cells) is particularly well characterized in the art. Other useful amplifiable marker genes include the adenosine deaminase (ADA) and glutamine synthetase (GS) genes.

The choice of cells/cell lines is also important and depends on the needs of the experimenter. COS cells provide high levels of transient gene expression, providing a useful means for rapidly screening the biosynthetic constructs of the invention. COS cells typically are transfected with a simian virus 40 (SV40) vector carrying the gene of interest. The transfected COS cells eventually die, thus preventing the long term production of the desired protein product. However, transient expression does not require the time consuming process required for the development of a stable cell line, and thus provides a useful technique for testing preliminary constructs for binding activity.

The various cells, cell lines and DNA sequences that can be used for mammalian cell expression of the single-chain constructs of the invention are well characterized in the art and are readily available. Other promoters, selectable markers, gene amplification methods and cells also may be used to express the proteins of this invention. Particular details of the transfection, expression, and purification of recombinant proteins are well documented in the art and are understood by those having ordinary skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in mammalian cell expression systems can be found in a number of texts and laboratory manuals in the art, such as, for example, F.M. Ausubel *et al.*, ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989).

IV. Screening Binding and Biological Activity.

Depending upon the cell type used, the DNA encoding the morphon constructs may be expressed to produce morphons having either folded or unfolded conformations. For example, it is appreciated that the morphon may spontaneously fold into an active conformation during production in a host cell, such as a myeloma cell. However, during expression in prokaryotic organisms, such as *E. coli*, the protein may form unfolded protein aggregates called inclusion bodies. The inclusion bodies, once harvested are subjected *in vitro* to standard denaturing and renaturing conditions to produce a biologically active protein conformation.

Irrespective of which protein expression, harvesting, and, if necessary folding, methodologies are used, the resulting proteins that bind preferentially to a preselected receptor subsequently may

- 45 -

be identified using standard methodologies, i.e., ligand/receptor binding assays, well known, and thoroughly documented in the art. See for example: Legerski *et al.* (1992) Biochem. Biophys. Res. Comm. 183: 672-679; Frakar *et al.* (1978) Biochem. Biophys. Res. Comm. 80:849-857; Chio *et al.* (1990) Nature 343: 266-269; Dahlman *et al.* (1988) Biochem 27: 1813-1817; Strader *et al.* (1989) J. Biol. Chem. 264: 13572-13578; and D'Dowd *et al.* (1988) J. Biol. Chem. 263: 15985-15992.

Typically, in a ligand/receptor binding assay, the template TGF- β superfamily member of interest having a known, quantifiable affinity for a preselected receptor is labeled with a detectable moiety, for example, a radiolabel, a chromogenic label, or a fluorogenic label. Aliquots of purified receptor, receptor binding domain fragments, or cells expressing the receptor of interest on their surface are incubated with the labeled TGF- β superfamily member in the presence of various concentrations of the unlabeled morphon. The relative binding affinity of a candidate morphon may be measured by quantitating the ability of the candidate (unlabeled morphon) to inhibit the binding of the labeled template TGF- β superfamily member with the receptor. In performing the assay, fixed concentrations of the receptor and the TGF- β superfamily member are incubated in the presence and absence of unlabeled morphon. Sensitivity may be increased by pre-incubating the receptor with the candidate morphon before adding the labeled template TGF- β superfamily member. After the labeled competitor has been added, sufficient time is allowed for adequate competitor binding, and then free and bound labeled superfamily members are separated from one another, and one or the other measured.

Useful labels useful in the practice of the screening procedures include radioactive labels, i.e., ^{125}I , ^{131}I , ^{111}In or ^{77}Br , chromogenic labels, spectroscopic labels such as those disclosed in Haughland (1994) "Handbook of Fluorescent and Research Chemicals 5 ed." by Molecular Probes, Inc., Eugene, OR, or conjugated enzymes having high turnover rates, i.e., horseradish peroxidase, alkaline phosphatase, or β -galactosidase, used in combination with chemiluminescent or fluorogenic substrates.

The biological activity, namely the agonist or antagonist properties of the resulting constructs may subsequently be characterized using conventional *in vivo* and *in vitro* assays that have been developed to measure the biological activity of any TGF- β superfamily member. It is appreciated, however, the type of assay used will depend on the TGF- β superfamily member upon which the morphon is based. For example, morphon constructs based upon natural OP-1 protein may be assayed using any of the biological assays that have been developed to date for measuring OP-1 activity, see, for example, the exemplification's set forth below.

- 46 -

V. Enhancement of Binding Activity

Once lead compounds have been identified i.e., those having at least basal binding affinity for a receptor that normally binds the template TGF- β superfamily member, their affinities may be enhanced by a combination of computer-based protein structure modeling and rational drug design methodologies. For example, after computer modeling of the candidate morphon construct, solvent exposed surfaces of the finger and heel regions or alternatively linker sequences may be mutated to enhance or modulate binding activity and/or specificity.

During such an approach, it is appreciated that several structural elements may independently be mutated in separate constructs. After isolating morphons having the highest binding and/or biological activity, each of the elements giving rise to enhanced activity may be isolated, characterized and then combined in a single construct. This type of approach has been used successfully in the production of a human growth hormone analog that has an affinity for hormone receptor 400-fold greater than the wild type human growth hormone (Wells *et al.*, in "Advances in Gene Technology: Protein Engineering and Beyond" p105). Alternatively, a plurality of regions within the protein may be modified simultaneously in a single experiment and constructs having the highest binding affinity and/or specificity isolated. It is appreciated, however, that several rounds of mutagenesis and screening may be performed until a construct having the desired binding affinity is found.

An important aspect of the refinement process is that, when recombinant DNA methodologies are used it is necessary to establish and maintain a physical connection between the polypeptide of interest and the nucleic acid encoding it. A system useful in the practice of this aspect of the invention includes, for example, phage display methodologies wherein the peptide of interest is immobilized on the surface of the phage as a fusion with a phage coat protein, see for example, Scott *et al.* (1990) Science 249: 386-390; Parmely *et al.*, (1988) Gene 73: 305-318; Devlin *et al.*, (1990) Science 249: 404-406; McCafferty *et al.* (1990) Nature 348: 552-554; Marks *et al.* (1992) J. Biol. Chem. 267: 16007-16010; Lowman *et al.* (1991) Biochem. 30: 10832-10838; Wells *et al.* *supra*; Amberg *et al.* in Strategies in Molecular Biology 6:2-4; and the Recombinant Phage Antibody System instruction manual from Pharmacia, P-L Biochemicals.

Briefly, the DNAs encoding candidate morphon constructs are expressed on the surface of phage particles, typically as N-terminal fusions to a phage minor coat protein. In a typical refinement experiment, it is contemplated that nucleotides encoding specific portions of the synthetic gene, e.g., those encoding linker sequences, may be randomized so as to produce a library of nucleic acid sequences encoding constructs that have random amino acid sequences in that region (See Section 3A). Once a library of DNA molecules encoding morphons has been produced, the DNAs are ligated into the phage genome at a position adjacent to the gene

- 47 -

encoding a minor coat protein. The resulting DNAs are packaged, amplified in a host cell, and expressed to produce recombinant phage particles having on their cell surface minor coat proteins fused to the protein of interest. The recombinant phage particles that express morphons constructs having the desired binding affinity and/or specificity for a receptor of interest subsequently are isolated by several rounds of affinity enrichment followed by phage growth. By using these approaches, single phage particles expressing polypeptides having specific biological properties may be isolated routinely from phage libraries comprising more than 10^6 - 10^8 phage particles.

Affinity enrichment may, for example, be performed by passing a solution comprising recombinant phage particles through a chromatography column that comprises surface immobilized receptor under conditions which permit morphons expressed on the surface of recombinant phage particles to bind to the receptor. Then, the column is washed to remove residual and/or non-specifically bound phage. Phage expressing the conformationally active morphons are eluted by specific desorption, for example, by addition of excess of the template TGF- β superfamily member, or by non-specific desorption, for example, using pH, polarity-reducing agents or chaotropic salts. The highest binding particles may be eluted using concentration gradient of the desorption inducing reagent wherein the highest binding particles elute at higher concentrations of the reagent. The highest binding particles, once eluted are re-amplified, and the nucleic acid encoding the morphon of interest isolated and sequenced. Once the DNA sequence, and therefore the nucleic acid sequence of the highest binding morphons, has been determined, then the refinement process may be repeated, for example, by mutagenesis of another portion of the molecule, until morphon molecules having a preferred binding activity have been produced. The resulting constructs subsequently may be assayed for biological activity using *in vivo* or *in vitro* assays that have been developed for each of the template TGF- β superfamily members identified to date.

Following the identification of useful morphon constructs, the morphons may be produced in commercially useful quantities, for example, by producing cell lines that express the morphon of interest or by producing synthetic peptides defining the appropriate amino acid sequence. It is appreciated, however, that conventional methodologies for producing the appropriate cell lines and for producing synthetic peptides are well known and thoroughly documented in the art, and so are not discussed in detail herein.

VI. Formulation and Bioactivity

The resulting morphon constructs may be provided to an individual as part of a therapy to enhance, inhibit, or otherwise modulate the *in vivo* binding interaction between a TGF- β superfamily member and one or more of its cognate receptors. The constructs may be formulated

- 48 -

in a pharmaceutical composition, as described below, and may be administered by any suitable means, preferably directly or systematically, e.g., parentally or orally.

Where the morphon construct is to be provided directly (e.g., locally, as by injection, to a desired tissue site), or parentally, such as by intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intracisternal, intraperitoneal, buccal, rectal, vaginal, intranasal or by aerosol administration, the therapeutic composition preferably comprises part of an aqueous solution. The solution preferably is physiologically acceptable so that in addition to delivery of the desired construct to the patient, the solution does not otherwise adversely affect the patient's electrolyte and volume balance. The aqueous medium for the therapeutic molecule thus may comprise, for example, normal physiological saline (0.9% NaCl, 0.15M), pH 7-7.4 or other pharmaceutically acceptable salts thereof.

Useful solutions for oral or parenteral administration may be prepared by any of the methods well known in the pharmaceutical art, described, for example, in "Remington's Pharmaceutical Sciences", (Gennaro, A., ed.), Mack Pub., 1990. Formulations may include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. Formulations for direct administration, in particular, may include glycerol and other compositions of high viscosity. Biocompatible, preferably bioresorbable polymers, including, for example, hyaluronic acid, collagen, tricalcium phosphate, polybutyrate, polylactide, polyglycolide and lactide/glycolide copolymers, may be useful excipients to control the release of the morphogen in vivo.

Other potentially useful parenteral delivery systems for these therapeutic molecules include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.

Finally, therapeutic molecules may be administered alone or in combination with other molecules known to effect tissue morphogenesis, i.e., molecules capable of tissue repair and regeneration and/or inhibiting inflammation. Examples of useful cofactors for stimulating bone tissue growth in osteoporotic individuals, for example, include but are not limited to, vitamin D₃, calcitonin, prostaglandins, parathyroid hormone, dexamethasone, estrogen and IGF-I or IGF-II. Useful cofactors for nerve tissue repair and regeneration may include nerve growth factors. Other useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral and antifungal agents and analgesics and anesthetics.

- 49 -

Therapeutic molecules further can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers. As noted above, such compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops or aerosols. Where adhesion to a tissue surface is desired the composition may include the biosynthetic construct dispersed in a fibrinogen-thrombin composition or other bioadhesive such as is disclosed, for example in PCT US91/09275, the disclosure of which is incorporated herein by reference. The composition then may be painted, sprayed or otherwise applied to the desired tissue surface.

The compositions can be formulated for parenteral or oral administration to humans or other mammals in therapeutically effective amounts, e.g., amounts which provide appropriate concentrations of the morphon to target tissue for a time sufficient to induce the desired effect.

Where the therapeutic molecule comprises part of a tissue or organ preservation solution, any commercially available preservation solution may be used to advantage. For example, useful solutions known in the art include Collins solution, Wisconsin solution, Belzer solution, Eurocollins solution and lactated Ringer's solution. A detailed description of preservation solutions and useful components may be found, for example, in U.S. Patent No. 5,002,965, the disclosure of which is incorporated herein by reference.

It is contemplated also that some of the morphon constructs, for example morphons based upon members of the Vg/dpp subgroup, may exhibit the highest levels of activity *in vivo* when combined with carrier matrices i.e., insoluble polymer matrices. See for example, U.S. Patent No. 5,266,683 the disclosure of which is incorporated by reference herein. The currently preferred carrier matrices are xenogenic, allogenic or autogenic in nature. It is contemplated, however, that synthetic materials comprising polylactic acid, polyglycolic acid, polybutyric acid, derivatives and copolymers thereof may also be used to generate suitable carrier matrices. Preferred synthetic and naturally derived matrix materials, their preparation, methods for formulating them with the morphogenic proteins of the invention, and methods of administration are well known in the art and so are not discussed in detailed herein. See for example, U.S. Patent No. 5,266,683.

As will be appreciated by those skilled in the art, the concentration of the compounds described in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. The preferred dosage of drug to be administered also is likely to depend on such variables as the type and extent of a disease, tissue loss or defect, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the presence and types of excipients in

- 50 -

the formulation, and the route of administration. In general terms, the therapeutic molecules of this invention may be provided to an individual where typical doses range from about 10 ng/kg to about 1 g/kg of body weight per day; with a preferred dose range being from about 0.1 mg/kg to 100 mg/kg of body weight.

- 5 Practice of the invention will be more fully understood from the following examples which are for illustrative purposes only and, therefore, should not be construed as limiting the invention in any way.

Example I. Design and Production of Morphon Based Upon the TGF- β Superfamily Member OP-1.

- 10 An exemplary OP-1 based morphon designed in accordance with the principles described herein and having a DNA sequence defined in the Sequence Listing as SEQ. ID. NO. 29 and which encodes a protein sequence defined in the Sequence Listing as SEQ. ID. NO. 30 (and as shown in Figure 11) may be produced using standard recombinant DNA methodologies, such as those described hereinabove. The DNA sequence encoding the exemplary OP-1 morphon, SEQ.
15 ID. NO. 29, comprises a plurality of restriction sites which, should the need arise, simplifies subsequent steps, i.e., cassette mutagenesis, in the empirical refinement of the morphon structure.

- The OP-1 morphon protein sequence set forth in SEQ. ID. NO. 30 comprises from the N-terminus to the C-terminus, an OP-1 finger 1 sequence (amino acid residues 1-32 in SEQ. ID. NO. 30); a large linker sequence (amino acid residues 33-44 in SEQ. ID. NO. 30); an OP-1 heel
20 sequence (amino acid residues 45-75 in SEQ. ID. NO. 30); a small linker sequence (amino acid residues 76-79 in SEQ. ID. NO. 30) and an OP-1 finger 2 sequence (amino acid residues 80-115 in SEQ. ID. NO. 30).

- The DNA sequence encoding the OP-1 morphon (SEQ. ID. NO. 30) is defined in SEQ. ID. NO. 30 and may be produced by standard recombinant DNA methodologies, for example,
25 synthesis of synthetic DNA sequences followed by their ligation into an appropriate expression vector. It is contemplated, however, that in order to enhance the likelihood of producing an OP-1 morphon construct having binding and/or agonist properties, the following method may be used.

- Briefly, this method comprises the steps of inserting into a cDNA clone encoding human OP-1, an N-terminal linker, a C-terminal linker, a large loop connecting the finger 1 and heel regions,
30 and a small loop connecting the heel and finger 2 regions. The modified cDNA subsequently is excised from its vector and ligated into a phage display vector, e.g. pCANTAB 5 from Pharmacia, and then, in a series of independent mutagenesis steps, in combination with screening in the phage display system, the linker regions are mutated by oligonucleotide directed mutagenesis to produce

- 51 -

a pool of candidate morphon constructs. Phage which express on their virion surface morphon constructs that bind the OP-1 receptor are isolated and the gene encoding the morphon constructs sequenced. A final construct comprising finger and heel regions as well as linker regions identified from the highest binding individual constructs then are combined to produce an optimized OP-1 morphon construct. A C-terminal tail is introduced into the optimized morphon construct by oligonucleotide directed mutagenesis after which the resulting morphon construct is excised from its vector and inserted into an *E. coli* expression vector, e.g. pET from New England BioLabs, Beverly, MA. A detailed description of this method is set forth below.

A SmaI to BamHI fragment of the OP-1 cDNA defined in SEQ. ID. NO. 29 (Ozkaynak *et al.* (1990) EMBO J. 9: 2085-2093) is cloned into Bluescript KS+ (available from Stratagene Cloning Systems, La Jolla, CA) previously cleaved with EcoRV and BamHI. Once transformed into *E. coli*, the resulting colonies are screened by a blue-white selection process wherein the desired colonies are blue. The correct clone may be identified by restriction screening to give the following expected restriction fragments.

<u>Restriction Enzyme</u>	<u>Fragment size (bp)</u>
EcoR I	84, 789, 3425
Xho I	161, 1223, 2914
Sac II	97, 650, 3551

Using synthetic oligonucleotides and either PCR or the site-directed mutagenesis methods, see for example, Kunkel, (1985) Proc. Natl. Acad. Sci. USA 822: 488; Kunkel *et al.* (1985) Meth. Enzymol. 154: 367; and U.S. Patent No. 4,873,192, specific nucleotides are modified within the OP-1 cDNA to introduce large and small loops within the OP-1 gene and to introduce unique restriction sites at the ends of the OP-1 gene. With all of the following modifications, there is no frame shift and, therefore, *E. coli* transformed with the mutagenesis products that give white colonies indicate an error in the sequence.

In a first step, the large loop is introduced by oligonucleotide directed mutagenesis using the oligonucleotide set forth in SEQ. ID. NO. 34. The oligonucleotide for the large loop is designed so it that has N-terminal and C-terminal over lapping ends 15 bp long, and introduces a unique Bam HI restriction site which can be used to screen for incorporation.

Then, the small loop is introduced by oligonucleotide directed mutagenesis using the oligonucleotide set forth in SEQ. ID. NO. 33. The oligonucleotide for the small loop is designed so it that has N-terminal and C-terminal overlapping ends 18 bp long, and introduces a unique NheI restriction site which can be used to screen for incorporation.

- 52 -

Then, the C-terminus of the OP-1 gene is modified by oligonucleotide directed mutagenesis using the oligonucleotide set forth in SEQ. ID. NO. 35. The C-terminus is modified to remove the native stop codon and introduce a NotI site for cloning into a vector useful for producing a phage display library, specifically pCANTAB 5 phagemid from Pharmacia. The oligonucleotide designed for this purpose has N-terminal and C-terminal overlapping ends 14 bp long, and introduces both a unique NotI restriction site and a unique SphI restriction site. Both restriction sites can be used to screen for incorporation.

Then, the N-terminus of the OP-1 gene is modified by oligonucleotide directed mutagenesis using the oligonucleotide set forth in SEQ. ID. NO. 32. The N-terminus is modified to introduce a SfiI restriction site for cloning into the pCANTAB 5 phagemid and an NdeI restriction site for eventual cloning into an expression vector. The oligonucleotide designed for this purpose has N-terminal and C-terminal overlapping ends 22 bp long. Both the SfiI and the NdeI restriction sites can be used to screen for incorporation.

The OP-1 cDNA resulting from the previous four mutagenesis steps is set forth in SEQ. ID. NO. 37. In order to improve the efficiency of selecting OP-1 morphon constructs that bind an OP-1 receptor, mutagenesis of the large and small loops are performed in independent reactions. To enable this step, the resulting cDNA (SEQ. ID. NO. 37) is digested with the restriction enzymes SfiI and NotI, and the 376 bp SfiI to NotI fragment is cloned directly into the pCANTAB 5 phagemid previously digested with the restriction enzymes SfiI and NotI.

Mutations may be introduced into the small loop by oligonucleotide directed mutagenesis using oligonucleotides similar to those defined in SEQ. ID. Nos. 38 and 39. Mutations also may be introduced into the large loop by oligonucleotide directed mutagenesis using oligonucleotides similar to those set forth in SEQ. ID. Nos. 40, 41, 42, and 43. Oligonucleotides defined by SEQ. ID. Nos. 40 and 41 introduce changes in the first 20 base pairs defining the large loop while oligonucleotides defined by SEQ. ID. Nos. 42 and 43 introduce changes into the last half of the loop.

Libraries of phage expressing on their virion surfaces proteins produced by each of the separate loop mutagenesis steps are screened for binding activity with OP-1 receptor using a protocol set forth in the instructions for use with the "Recombinant Phage Antibody System" (Pharmacia). Briefly, the library of clones in pCANTAB 5 phagemid produced by each of the separate loop mutagenesis steps are transformed into competent *E. coli* TG1 and grown in the presence of KO7 helper phage. This step results in the production of phage expressing OP-1 morphons on their cell surface. The resulting phage are screened for binding activity with OP-1 receptor (Malpe *et al.* (1994) *Biochem. Biophys. Res. Comm.* 201: 1140-1147; tenDijke *et al.* (1994) *J. Biol. Chem.* 269: 16985-16988) previously immobilized on a solid surface, e.g., Affigel

- 53 -

15, Fractrogel, plastic surface, or a magnetic bead (Hermanson et al. in "Immobilized Affinity Ligand Techniques" (1992) Academic Press, Inc, San Diego). Phage that fail to bind the receptor are removed by washing exhaustively (more than 20 washes) with a buffer containing phosphate buffered saline (PBS), followed by exhaustive washes (more than 20 washes) with PBS containing
5 0.05% Triton X-100. Then, specific binding constructs are eluted from the solid surface with a buffer containing 0.1 M glycine, pH 3.0, and 0.05% Triton X-100 and the eluate neutralized with 1M Tris-HCl pH8.0, 0.05 % Triton X-100. Phage having specific affinity for OP-1 are harvested. At this stage, however, the eluate may contain several different phage where each phage particle can bind OP-1 receptor.

10 In order to isolate individual phage particles, E. coli then are reinfected with the eluted phage, and infected colonies are titrated out to give individual colonies into microtiter plates. Then, the infected E. coli are harvested from each well of the microtiter plate, infected with KO7 helper phage to reinduce the expression of the OP-1 morphon on the surface of the resulting phage, and the resulting mixture is added to individual wells of a second microtiter dish containing
15 surface immobilized OP-1 receptor. Using this approach, individual phage can be screened for binding activity with immobilized OP-1 receptor. Binding is visualized with an horse radish peroxidase conjugated antibody having binding specificity for an antigen on the surface of the phage. The individual phage subsequently are eluted from the OP-1 receptor bound to the surface of a well on the microtiter dish and the DNA isolated from them. After sequencing, the DNA
20 sequences encoding particular regions, for example, the small and large loops, that generate the high binding affinity are combined in a single morphon construct.

Then, a linker is introduced into the C-terminus of the penultimate morphon gene by oligonucleotide directed mutagenesis using the oligonucleotide set forth in SEQ. ID. NO. 36. The linker introduces the non-suppressible stop codon TAA at the end of the morphon gene
25 "...RACGSH*" and follows the stop codon with a unique BglII site (AGATCT). Success in making this change is determined by the absence of exported phage (the termination codon blocks the production of gene 3 protein) and the ability to cleave plasmid DNA with BglII. Then, the optimized OP-1 morphon gene is excised with NdeI and BglII and cloned into a pET vector (New England Biolabs, Beverly, MA) previously cleaved with NdeI and BamHI.

30 Expression of the morphon gene to produce the morphon gene product is induced after the expression of T7 RNA polymerase (initiated through infected with λ CE6 phage). During expression, the OP-1 morphon is produced in inclusion granules which are harvested from the cell paste. The protein then is dissolved in 6M guanidine-HCl, 0.2M Tris-HCl, pH 8.2, and 0.1 M 2-mercaptoethanol and dialyzed exhaustively against 6M urea, 2.5 mM Tris-HCl, pH 7.5 and 1 mM
35 EDTA. 2-mercaptoethanol is added to a final concentration of 0.1M and the solution incubated

- 54 -

at room temperature. Then, the mixture is dialyzed exhaustively against buffer containing 2.5 mM Tris-HCl, pH 7.5 and 1mM EDTA. Folded OP-1 morphon then is purified by affinity chromatography on a column packed with surface immobilized OP-1 receptor. Unbound material is removed by washing as described above and the specific OP-1 receptor binding material is eluted also as described above.

Example II. Determination of Binding Activity of an OP-1 Based Morphon.

Cells expressing an OP-1 receptor on their cell surface are plated into 35 mm dishes and incubated for 48 hours in DMEM (Dulbecco's modified Eagle medium) plus 10% fetal calf serum. Purified OP-1, or an OP-1-analog is iodinated with Na¹²⁵I by chloramine T oxidation, preferably having a specific activity of about 50-100 mCi/mg, by following essentially the protocol of Frolik et al. (1984) *J. Biol. Chem.* 595: 10995-11000. Labeled OP-1, or OP-1-analog, then is purified using a standard procedure, e.g., by chromatographic separation. The plated cells then are washed twice with physiologically buffered saline in the presence of 0.1% BSA, and incubated at 22°C in the presence of BSA, buffer and labeled OP-1 (1 ng) and various concentrations (e.g., 0-10mg/ml) of unlabelled competitor, e.g., unlabelled OP-1 or the candidate OP-1 based morphon. Following binding, the cells are washed three times with cold buffer, solubilized in 0.5 ml of 0.5 N NaOH, removed from the dish, and radioactivity determined by gamma or scintillation counter. Data then are expressed as percent inhibition, where 100% inhibition of specific binding is the difference between binding in the absence of competitor and binding in the presence of a 100-fold molar excess of unlabelled competitor. Binding parameters preferably are determined using a computer program such as LIGAND (Munsun et al. (1980) *Anal. Biochem.* 107: 220-259). Upon performance of the assay, it is contemplated that the OP-1 based morphon may have specific binding activity for the OP-1 receptor. Upon confirmation of binding activity, the morphon may be tested subsequently for biological activity.

Example III. Determination of Biological Activity of an OP-1 Based Morphon.

The biological activity of the resulting OP-1 based morphons may be determined using any of the using standard *in vivo* and *in vitro* assays, typically used for assessing native OP-1 activity. A variety of exemplary assays are set forth below.

A. Mitogenic Effect on Rat and Human Osteoblasts

The following example is designed to demonstrate the ability of OP-1 morphons to induce proliferation of osteoblasts *in vitro*. It is contemplated that in this, and all the other examples involving osteoblast cultures, rat osteoblast-enriched primary cultures preferably are used.

- 55 -

Although these cultures are heterogeneous in that the individual cells are at different stages of differentiation, the culture is believed to more accurately reflect the metabolism and function of osteoblasts in vivo than osteoblast cultures obtained from established cell lines. Unless otherwise indicated, all chemicals referenced are standard, commercially available reagents, readily available from a number of sources, including Sigma Chemical, Co., St. Louis; Calbiochem, Corp., San Diego and Aldrich Chemical Co., Milwaukee.

Briefly, rat osteoblast-enriched primary cultures are prepared by sequential collagenase digestion of newborn rat calvaria (e.g., from 1-2 day-old animals, Long-Evans strain, Charles River Laboratories, Wilmington, MA), following standard procedures, such as are described, for example, in Wong et al., (1975) Proc. Natl. Acad. Sci. USA 72: 3167-3171. Rat osteoblast single cell suspensions then are plated onto a multi-well plate (e.g., a 24 well plate at a concentration of 50,000 osteoblasts per well) in alpha MEM (modified Eagle's medium, Gibco, Inc., Long Island) containing 10% FBS (fetal bovine serum), L-glutamine and penicillin/streptomycin. The cells are incubated for 24 hours at 37°C, at which time the growth medium is replaced with alpha MEM containing 1% FBS and the cells incubated for an additional 24 hours so that cells are in serum-deprived growth medium at the time of the experiment.

The cultured cells are divided into four groups: (1) wells which receive, for example, 0.1, 1.0, 10.0, 40.0 and 80.0 ng of OP-1 morphon, (2) wells which receive 0.1, 1.0, 10.0 and 40.0 ng of wild type OP-1; (3) wells which receive 0.1, 1.0, 10.0, and 40.0 ng of TGF- β , and (4) the control group, which receive no growth factors. The cells then are incubated for an additional 18 hours after which the wells are pulsed with 2mCi/well of ^3H -thymidine and incubated for six more hours. The excess label then is washed off with a cold solution of 0.15 M NaCl and then 250 ml of 10% trichloroacetic acid is added to each well and the wells incubated at room temperature for 30 minutes. The cells then are washed three times with cold distilled water, and lysed by the addition of 250 ml of 1% sodium dodecyl sulfate (SDS) for a period of 30 minutes at 37°C. The resulting cell lysates are harvested using standard means and the incorporation of ^3H -thymidine into cellular DNA determined by liquid scintillation as an indication of mitogenic activity of the cells. In the experiment, it is contemplated that the OP-1 morphon construct like natural OP-1 will stimulate ^3H -thymidine incorporation into DNA, and therefore promote osteoblast cell proliferation. In contrast, the effect of the TGF- β is expected to be transient and biphasic. Furthermore, it is contemplated that at higher concentrations, TGF- β will have no significant effect on osteoblast cell proliferation.

The in vitro effect of the OP-1 morphon on osteoblast proliferation also may be evaluated using human primary osteoblasts (obtained from bone tissue of a normal adult patient and prepared as described above) and on human osteosarcoma-derived cell lines.

- 56 -

B. Progenitor Cell Stimulation.

The following example is designed to demonstrate the ability of OP-1 morphons to stimulate the proliferation of mesenchymal progenitor cells. Useful naive stem cells include pluripotential stem cells, which may be isolated from bone marrow or umbilical cord blood using conventional methodologies, (see, for example, Faradji *et al.* (1988) *Vox Sang.* 55 (3): 133-138 or Broxmeyer *et al.* (1989) *Proc. Natl. Acad. Sci. USA.* 86: 3828-3832), as well as naive stem cells obtained from blood. Alternatively, embryonic cells (e.g., from a cultured mesodermal cell line) may be used.

Another method for obtaining progenitor cells and for determining the ability of OP-1 morphons to stimulate cell proliferation is to capture progenitor cells from an *in vivo* source. For example, a biocompatible matrix material able to allow the influx of migratory progenitor cells may be implanted at an *in vivo* site long enough to allow the influx of migratory progenitor cells. For example, a bone-derived, guanidine-extracted matrix, formulated as disclosed for example in Sampath *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80: 6591-6595, or U.S. Patent No. 4,975,526, may be implanted into a rat at a subcutaneous site, essentially following the method of Sampath *et al.* After three days the implant is removed, and the progenitor cells associated with the matrix dispersed and cultured.

Progenitor cells, however obtained, then are incubated *in vitro* with the candidate OP-1 morphon under standard cell culture conditions, such as those described hereinbelow. In the absence of external stimuli, the progenitor cells do not, or only minimally, proliferate on their own in culture. It is contemplated, however, that progenitor cells cultured in the presence of a biologically active OP-1 morphon, like OP-1, will proliferate. Cell growth can be determined visually or spectrophotometrically using standard methods well known in the art.

C. Morphogen-Induced Cell Differentiation.

A variety of assays may be used to determine OP-1 based morphon-induced cellular differentiation.

(1) Embryonic Mesenchyme Differentiation

As with natural OP-1, it is contemplated that OP-1 morphons may be utilized to induce cell differentiation. The ability of OP-1 morphons to induce cell differentiation may be demonstrated by culturing early mesenchymal cells in the presence of OP-1 morphon and then studying the histology of the cultured cells by staining with toluidine blue using standard cell culturing and cell staining methodologies well described in the art. For example, it is known that rat mesenchymal cells destined to become mandibular bone, when separated from the overlying epithelial cells at

- 57 -

stage 11 and cultured in vitro under standard tissue culture conditions, e.g., in a chemically defined, serum-free medium, containing for example, 67% DMEM (Dulbecco's modified Eagle's medium), 22% F-12 medium, 10mM Hepes pH 7, 2mM glutamine, 50 mg/ml transferrin, 25 mg/ml insulin, trace elements, 2mg/ml bovine serum albumin coupled to oleic acid, with HAT (0.1 mM hypoxanthine, 10mM aminopterin, 12 mM thymidine, will not continue to differentiate. However, if these same cells are left in contact with the overlying endoderm for an additional day, at which time they become stage 12 cells, they will continue to differentiate on their own in vitro to form chondrocytes. Further differentiation into osteoblasts and, ultimately, mandibular bone, requires an appropriate local environment, e.g., a vascularized environment.

10 It is anticipated that, as with natural OP-1, stage 11 mesenchymal cells, cultured in vitro in the presence of OP-1 morphon, e.g., 10-100 ng/ml, will continue to differentiate in vitro to form chondrocytes just as they continue to differentiate in vitro if they are cultured with the cell products harvested from the overlying endodermal cells. This experiment may be performed with different mesenchymal cells to demonstrate the cell differentiation capability of OP-1 morphon in
15 different tissues.

As another example of morphogen-induced cell differentiation, the ability of OP-1 morphons to induce osteoblast differentiation may be demonstrated in vitro using primary osteoblast cultures, or osteoblast-like cells lines, and assaying for a variety of bone cell markers that are specific markers for the differentiated osteoblast phenotype, e.g., alkaline phosphatase activity, parathyroid hormone-mediated cyclic AMP (cAMP) production, osteocalcin synthesis, and
20 enhanced mineralization rates.

(2) Alkaline Phosphatase Induction of Osteoblasts.

Cultured osteoblasts in serum-free medium are incubated with, a range of OP-1 morphon concentrations, for example, 0.1, 1.0, 10.0, 40.0 or 80.0 ng OP-1 morphon/ml medium; or with a similar concentration range of natural OP-1 or TGF- β . After a 72 hour incubation the cell layer is
25 extracted with 0.5 ml of 1% Triton X-100. The resultant cell extract, is centrifuged, and 100 ml of the extract is added to 90 ml of paranitroso-phenylphosphate (PNPP)/glycerine mixture and incubated for 30 minutes in a 37°C water bath and the reaction stopped with 100 ml NaOH. The samples then are run through a plate reader (e.g., Dynatech MR700 plate reader, and absorbance
30 measured at 400 nm, using p-nitrophenol as a standard) to determine the presence and amount of alkaline phosphate activity. Protein concentrations are determined by the BioRad method. Alkaline phosphatase activity is calculated in units/mg protein, where 1 unit=1 nmol p-nitrophenol liberated/30 minutes at 37°C.

- 58 -

It is contemplated that the OP-1 morphon, like natural OP-1 alone, will stimulate the production of alkaline phosphatase in osteoblasts thereby promoting the growth and expression of the osteoblast differentiated phenotype.

5 The long term effect of OP-1 morphon on the production of alkaline phosphatase by rat osteoblasts also may be demonstrated as follows.

Rat osteoblasts are prepared and cultured in multi-well plates as described above. In this example six sets of 24 well plates are plated with 50,000 rat osteoblasts per well. The wells in each plate, prepared as described above, then are divided into three groups: (1) those which receive, for example, 1 ng of OP-1 morphon per ml of medium; (2) those which receive 40 ng of
10 OP-1 morphon per ml of medium; and (3) those which received 80 ng of OP-1 morphon per ml of medium. Each plate then is incubated for different lengths of time: 0 hours (control time), 24 hours, 48 hours, 96 hours, 120 hours and 144 hours. After each incubation period, the cell layer is extracted with 0.5 ml of 1% Triton X-100. The resultant cell extract is centrifuged, and alkaline phosphatase activity determined using paranitroso-phenylphosphate (PNPP), as above. It
15 is contemplated that the OP-1 morphon, like natural OP-1, will stimulate the production of alkaline phosphatase in osteoblasts in dose-dependent manner so that increasing doses of OP-1 morphon will further increase the level of alkaline phosphatase production. Moreover, it is contemplated that the OP-1 morphon-stimulated elevated levels of alkaline phosphatase in the treated osteoblasts will last for an extended period of time.

20 (3) Induction of PTH-Mediated cAMP.

This experiment is designed to test the effect of OP-1 morphons on parathyroid hormone-mediated cAMP production in rat osteoblasts in vitro. Briefly, rat osteoblasts are prepared and cultured in a multiwell plate as described above. The cultured cells then are divided into four groups: (1) wells which receive, for example, 1.0, 10.0 and 40.0 ng OP-1 morphon/ml medium);
25 (2) wells which receive for example, natural OP-1, at similar concentration ranges; (3) wells which receive for example, TGF- β , at similar concentration ranges; and (4) a control group which receives no growth factors. The plate then is incubated for another 72 hours. At the end of the 72 hours the cells are treated with medium containing 0.5% bovine serum albumin (BSA) and 1mM 3-isobutyl-1-methylxanthine for 20 minutes followed by the addition into half of the wells of
30 human recombinant parathyroid hormone (hPTH, Sigma, St. Louis) at a concentration of 200 ng/ml for 10 minutes. The cell layer then is extracted from each well with 0.5 ml of 1% Triton X-100. The cAMP levels then are determined using a radioimmunoassay kit (e.g., Amersham, Arlington Heights, Illinois). It is contemplated that OP-1 morphon alone, like OP-1, will stimulate an increase in the PTH-mediated cAMP response, thereby promoting the growth
35 and expression of the osteoblast differentiated phenotype.

- 59 -

(4) Induction of Osteocalcin Production

Osteocalcin is a bone-specific protein synthesized by osteoblasts which plays an integral role in the rate of bone mineralization in vivo. Circulating levels of osteocalcin in serum are used as a marker for osteoblast activity and bone formation in vivo. Induction of osteocalcin synthesis in osteoblast-enriched cultures can be used to demonstrate OP-1 morphon efficacy in vitro.

Rat osteoblasts are prepared and cultured in a multi-well plate as above. In this experiment the medium is supplemented with 10%FBS, and on day 2, cells are fed with fresh medium supplemented with fresh 10 mM β -glycerophosphate (Sigma, Inc.). Beginning on day 5 and twice weekly thereafter, cells are fed with a complete mineralization medium containing all of the above components plus fresh L(+)-ascorbate, at a final concentration of 50mg/ml medium. OP-1 morphon then is added to the wells directly, e.g., in 50% acetonitrile (or 50% ethanol) containing 0.1% trifluoroacetic acid (TFA), at no more than 5ml morphon/ml medium. Control wells receive solvent vehicle only. The cells then are re-fed and the conditioned medium sample diluted 1:1 in standard radioimmunoassay buffer containing standard protease inhibitors and stored at -20°C until assayed for osteocalcin. Osteocalcin synthesis is measured by standard radioimmunoassay using a commercially available osteocalcin-specific antibody.

Mineralization is determined on long term cultures (13 day) using a modified von Kossa staining technique on fixed cell layers: cells are fixed in fresh 4% paraformaldehyde at 23°C for 10 min, following rinsing cold 0.9% NaCl. Fixed cells then are stained for endogenous alkaline phosphatase at pH 9.5 for 10 min, using a commercially available kit (Sigma, Inc.). Purple stained cells then are dehydrated with methanol and air dried. After 30 min incubation in 3% AgNO₃ in the dark, H₂O-rinsed samples are exposed for 30 sec to 254 nm UV light to develop the black silver-stained phosphate nodules. Individual mineralized foci (at least 20 mm in size) are counted under a dissecting microscope and expressed as nodules/culture.

It is contemplated that the OP-1 morphon, like natural OP-1, will stimulate osteocalcin synthesis in osteoblast cultures. Furthermore, it is contemplated that the increased osteocalcin synthesis in response to OP-1 morphon will be in a dose dependent manner thereby showing a significant increase over the basal level after 13 days of incubation. The enhanced osteocalcin synthesis also may be confirmed by detecting the elevated osteocalcin mRNA message (20-fold increase) using a rat osteocalcin-specific probe. In addition, the increase in osteocalcin synthesis correlates with increased mineralization in long term osteoblast cultures as determined by the appearance of mineral nodules. It is contemplated also that OP-1 morphon, like natural OP-1, will increase significantly the initial mineralization rate as compared to untreated cultures.

- 60 -

(5) Morphogen-Induced CAM Expression

Members of the vg/dpp subgroup induce CAM expression, particularly N-CAM expression, as part of their induction of morphogenesis (see copending USSN 922,813). CAMs are morphoregulatory molecules identified in all tissues as an essential step in tissue development. N-CAMs, which comprise at least 3 isoforms (N-CAM-180, N-CAM-140 and N-CAM-120, where "180", "140" and "120" indicate the apparent molecular weights of the isoforms as measured by SDS polyacrylamide gel electrophoresis) are expressed at least transiently in developing tissues, and permanently in nerve tissue. Both the N-CAM-180 and N-CAM-140 isoforms are expressed in both developing and adult tissue. The N-CAM-120 isoform is found only in adult tissue. Another neural CAM is L1.

The ability of OP-1 based morphons to stimulate CAM expression may be demonstrated using the following protocol, using NG108-15 cells. NG108-15 is a transformed hybrid cell line (neuroblastoma x glioma, America Type Tissue Culture (ATCC), Rockville, MD), exhibiting a morphology characteristic of transformed embryonic neurons. As described in Example D, below, untreated NG108-15 cells exhibit a fibroblastic, or minimally differentiated, morphology and express only the 180 and 140 isoforms of N-CAM normally associated with a developing cell. Following treatment with members of the vg/dpp subgroup these cells exhibit a morphology characteristic of adult neurons and express enhanced levels of all three N-CAM isoforms.

In this example, NG108-15 cells are cultured for 4 days in the presence of increasing concentrations of either the OP-1 morphon or natural OP-1 using standard culturing procedures, and standard Western blots performed on whole cell extracts. N-CAM isoforms are detected with an antibody which crossreacts with all three isoforms, mAb H28.123, obtained from Sigma Chemical Co., St. Louis, the different isoforms being distinguishable by their different mobilities on an electrophoresis gel. Control NG108-15 cells (untreated) express both the 140 kDa and the 180 kDa isoforms, but not the 120 kDa, as determined by Western blot analyses using up to 100 mg of protein. It is contemplated that treatment of NG108-15 cells with OP-1 morphon, like natural OP-1 may result in a dose-dependent increase in the expression of the 180 kDa and 140 kDa isoforms, as well as the induction of the 120 kDa isoform induced. In addition, it is contemplated that the OP-1 morphon, like natural OP-1-induced CAM expression may correlate with cell aggregation, as determined by histology.

(D) OP-1 Morphon-Induced Redifferentiation of Transformed Phenotype

It is contemplated that OP-1 morphon, like natural OP-1, also induces redifferentiation of transformed cells to a morphology characteristic of untransformed cells. The examples provided below detail morphogen-induced redifferentiation of a transformed human cell line of neuronal

- 61 -

origin (NG108-15); as well as mouse neuroblastoma cells (N1E-115), and human embryo carcinoma cells, to a morphology characteristic of untransformed cells.

As described above, NG108-15 is a transformed hybrid cell line produced by fusing neuroblastoma x glioma cells (obtained from ATTC, Rockville, MD), and exhibiting a morphology characteristic of transformed embryonic neurons, e.g., having a fibroblastic morphology. Specifically, the cells have polygonal cell bodies, short, spike-like processes and make few contacts with neighboring cells. Incubation of NG108-15 cells, cultured in a chemically defined, serum-free medium, with 0.1 to 300 ng/ml of OP-1 morphon natural or OP-1 for four hours induces an orderly, dose-dependent change in cell morphology.

For example, NG108-15 cells are subcultured on poly-L-lysine coated 6 well plates. Each well contains 40-50,000 cells in 2.5 ml of chemically defined medium. On the third day, 2.5 ml of OP-1 morphon or natural OP-1 in 60% ethanol containing 0.025% trifluoroacetic is added to each well. The media is changed daily with new aliquots of morphogen. It is contemplated that OP-1 morphon like OP-1 may induce a dose-dependent redifferentiation of the transformed cells, including a rounding of the soma, an increase in phase brightness, extension of the short neurite processes, and other significant changes in the cellular ultrastructure. After several days it is contemplated also that treated cells may begin to form epithelioid sheets that then become highly packed, multi-layered aggregates, as determined visually by microscopic examination.

Moreover, it is contemplated that the redifferentiation may occur without any associated changes in DNA synthesis, cell division, or cell viability, making it unlikely that the morphologic changes are secondary to cell differentiation or a toxic effect of the morphogen. In addition, it is contemplated that the morphon-induced redifferentiation may not inhibit cell division, as determined by ³H-thymidine uptake, unlike other molecules such as butyrate, DMSO, retinoic acid or Forskolin which have been shown to stimulate differentiation of transformed cells, in analogous experiments. Thus, it is contemplated that the OP-1 morphon like natural OP-1 may maintain cell stability and viability after inducing redifferentiation.

The morphogen described herein would, therefore, provide useful therapeutic agents for the treatment of neoplasias and neoplastic lesions of the nervous system, particularly in the treatment of neuroblastomas, including retinoblastomas, and gliomas.

(E) Maintenance of Phenotype.

OP-1 morphons, like natural OP-1 also may be used to maintain a cell's differentiated phenotype. This application is particularly useful for inducing the continued expression of phenotype in senescent or quiescent cells.

- 62 -

(1) In Vitro Model for Phenotypic Maintenance

The phenotypic maintenance capability of morphogens is determined readily. A number of differentiated cells become senescent or quiescent after multiple passages in vitro under standard tissue culture conditions well described in the art (e.g., Culture of Animal Cells: A Manual of Basic Techniques, C.R. Freshney, ed., Wiley, 1987). However, if these cells are cultivated in vitro in association with a morphogen such as OP-1, cells are stimulated to maintain expression of their phenotype through multiple passages. For example, the alkaline phosphatase activity of cultured osteoblasts, such as cultured osteosarcoma cells and calvaria cells, is significantly reduced after multiple passages in vitro. However, if the cells are cultivated in the presence of OP-1 alkaline phosphatase activity is maintained over extended periods of time. Similarly, phenotypic expression of myocytes also is maintained in the presence of a morphogen. In the experiment, osteoblasts are cultured as described in Example A. The cells are divided into groups, incubated with varying concentrations of either OP-1 morphon or natural OP-1 (e.g., 0-300 ng/ml) and passaged multiple times (e.g., 3-5 times) using standard methodology. Passaged cells then are tested for alkaline phosphatase activity, as described in Example C as an indication of differentiated cell metabolic function. It is contemplated that osteoblasts cultured in the absence of OP-1 morphon, like natural OP-1, may have reduced alkaline phosphatase activity, as compared to OP-1 morphon, or natural OP-1-treated cells.

(2) In Vivo Model for Phenotypic Maintenance

Phenotypic maintenance capability also may be demonstrated in vivo, using a standard rat model for osteoporosis. Long Evans female rats (Charles River Laboratories, Wilmington, MA) are Sham-operated (control animals) or ovariectomized using standard surgical techniques, to produce an osteoporotic condition resulting from decreased estrogen production. Following surgery, e.g., 200 days after ovariectomy, rats are systemically provided with phosphate buffered saline (PBS) or morphogen, (e.g., OP-1 morphon, or natural OP-1, 1-100 mg) for 21 days (e.g., by daily tail vein injection.) The rats then are sacrificed and serum alkaline phosphatase levels, serum calcium levels, and serum osteocalcin levels are determined, using standard methodologies as described therein and above. It is contemplated that the OP-1 morphon treated rats, like the OP-1 treated rats may exhibit elevated levels of osteocalcin and alkaline phosphatase activity. It is contemplated also that histomorphometric analysis on the tibial diaphyseal bone may show improved bone mass in OP-1 morphon treated animals as compared with untreated, ovariectomized rats.

- 63 -

F. Proliferation of Progenitor Cell Populations

Progenitor cells may be stimulated to proliferate in vivo or ex vivo. It is contemplated that cells may be stimulated in vivo by injecting or otherwise providing a sterile preparation containing the OP-1 morphon into the individual. For example, the hemopoietic pluripotent stem cell
5 population of an individual may be stimulated to proliferate by injecting or otherwise providing an appropriate concentration of OP-1 morphon to the individual's bone marrow.

Progenitor cells may be stimulated ex vivo by contacting progenitor cells of the population to be enhanced with a morphogenically active OP-1 morphon under sterile conditions at a concentration and for a time sufficient to stimulate proliferation of the cells. Suitable
10 concentrations and stimulation times may be determined empirically, essentially following the procedure described in Example A, above. It is contemplated that a OP-1 morphon concentration of between about 0.1-100 ng/ml and a stimulation period of from about 10 minutes to about 72 hours, or, more generally, about 24 hours, typically should be sufficient to stimulate a cell population of about 10^4 to 10^6 cells. The stimulated cells then may be provided to the individual
15 as, for example, by injecting the cells to an appropriate in vivo locus. Suitable biocompatible progenitor cells may be obtained by any of the methods known in the art or described hereinabove.

G. Regeneration of Damaged or Diseased Tissue

It is contemplated that OP-1 morphons may be used to repair diseased or damaged
20 mammalian tissue. The tissue to be repaired preferably is assessed first, and excess necrotic or interfering scar tissue removed as needed, e.g., by ablation or by surgical, chemical, or other methods known in the medical arts.

OP-1 morphon then may be provided directly to the tissue locus as part of a sterile, biocompatible composition, either by surgical implantation or injection. The morphon also may
25 be provided systemically, as by oral or parenteral administration. Alternatively, a sterile, biocompatible composition containing progenitor cells stimulated by a morphogenically active OP-1 morphon may be provided to the tissue locus. The existing tissue at the locus, whether diseased or damaged, provides the appropriate matrix to allow the proliferation and tissue-specific differentiation of progenitor cells. In addition, a damaged or diseased tissue locus, particularly
30 one that has been further assaulted by surgical means, provides a morphogenically permissive environment. Systemic provision of OP-1 morphon may be sufficient for certain applications (e.g., in the treatment of osteoporosis and other disorders of the bone remodeling cycle, as an example).

- 64 -

In some circumstances, particularly where tissue damage is extensive, the tissue may not be capable of providing a sufficient matrix for cell influx and proliferation. In these instances, it may be necessary to provide progenitor cells stimulated by the OP-1 morphon to the tissue locus in association with a suitable, biocompatible, formulated matrix, prepared by any of the means described below. The matrix preferably is in vivo biodegradable. The matrix also may be tissue-specific and/or may comprise porous particles having dimensions within the range of 70-850mm, most preferably 150-420mm.

OP-1 morphon also may be used to prevent or substantially inhibit immune/inflammatory response-mediated tissue damage and scar tissue formation following an injury. OP-1 morphon may be provided to a newly injured tissue locus, to induce tissue morphogenesis at the locus, preventing the aggregation of migrating fibroblasts into non-differentiated connective tissue. Preferably the OP-1 morphon may be provided as a sterile pharmaceutical preparation injected into the tissue locus within five hours of the injury. Where an immune/inflammatory response is unavoidably or deliberately induced, as part of, for example, a surgical or other aggressive clinical therapy, OP-1 morphon preferably may be provided prophylactically to the patient, prior to, or concomitant with, the therapy.

Below are several examples, describing protocols for demonstrating OP-1 morphon-induced tissue morphogenesis in bone, liver, nerve, dentin, cementum and periodontal tissue.

(1) OP-1 Morphon-Induced Bone Morphogenesis.

A particularly useful mammalian tissue model system for demonstrating and evaluating the morphogenic activity of a protein is the endochondral bone tissue morphogenesis model known in the art and described, for example, in U.S. Pat. No. 4,968,590 and incorporated herein by reference. The ability to induce endochondral bone formation includes the ability to induce proliferation and differentiation of progenitor cells into chondroblasts and osteoblasts, the ability to induce cartilage matrix formation, cartilage calcification, and bone remodeling, and the ability to induce formation of an appropriate vascular supply and hematopoietic bone marrow differentiation.

The local environment in which the morphogenic material is placed is important for tissue morphogenesis. As used herein, "local environment" is understood to include the tissue structural matrix and the environment surrounding the tissue. For example, in addition to needing an appropriate anchoring substratum for their proliferation, the cells stimulated by morphogens need signals to direct the tissue-specificity of their differentiation. These signals vary for the different tissues and may include cell surface markers. In addition, vascularization of new tissue requires a local environment which supports vascularization.

- 65 -

The following sets forth various procedures for evaluating the in vivo morphogenic utility of OP-1 morphon and OP-1 morphon containing compositions. The compositions may be injected or surgically implanted in a mammal, following any of a number of procedures well known in the art. For example, surgical implant bioassays may be performed essentially following the
5 procedure of Sampath et al. (1983) Proc. Natl. Acad. Sci. USA 80: 6591-6595 and U.S. Pat No. 4,968,590.

Histological sectioning and staining is preferred to determine the extent of morphogenesis in vivo, particularly in tissue repair procedures. Excised implants are fixed in Bouins Solution, embedded in paraffin, and cut into 6-8 mm sections. Staining with toluidine blue or
10 hemotoxylin/eosin demonstrates clearly the ultimate development of the new tissue. Twelve day implants are usually sufficient to determine whether the implants contain newly induced tissue.

Successful implants exhibit a controlled progression through the stages of induced tissue development allowing one to identify and follow the tissue-specific events that occur. For example, in endochondral bone formation the stages include: (1) leukocytes on day one;
15 (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoclastic cells, and the commencement of bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and
20 (8) hematopoietic bone marrow differentiation in the resulting ossicles on day twenty-one.

In addition to histological evaluation, biological markers may be used as markers for tissue morphogenesis. Useful markers include tissue-specific enzymes whose activities may be assayed (e.g., spectrophotometrically) after homogenization of the implant. These assays may be useful for quantitation and for rapidly obtaining an estimate of tissue formation after the implants are
25 removed from the animal. For example, alkaline phosphatase activity may be used as a marker for osteogenesis.

Incorporation of systemically provided OP-1 morphon may be followed using labelled protein (e.g., radioactively labelled) and determining its localization in the new tissue, and/or by monitoring their disappearance from the circulatory system using a standard labeling protocol and
30 pulse-chase procedure. OP-1 morphon also may be provided with a tissue-specific molecular tag, whose uptake may be monitored and correlated with the concentration of OP-1 morphon provided. As an example, ovary removal in female rats results in reduced bone alkaline phosphatase activity, and renders the rats predisposed to osteoporosis (as described in Example E). If the female rats now are provided with OP-1 morphon, a reduction in the systemic

- 66 -

concentration of calcium may be seen, which correlates with the presence of the provided OP-1 morphon and which is anticipated to correspond with increased alkaline phosphatase activity.

(2) OP-1 Morphon-Induced Liver Regeneration.

As another example, a method for inducing morphogenesis of substantially injured liver tissue following a partial hepatectomy utilizing OP-1 morphon is presented. Variations on this general protocol may be used to test morphogen activity of OP-1 morphon in other different tissues. The general method involves excising an essentially nonregenerating portion of a tissue and providing OP-1 morphon, preferably as a soluble pharmaceutical preparation to the excised tissue locus, closing the wound, and examining the site at a future date. Like bone, liver has a potential to regenerate upon injury during post-fetal life.

OP-1 morphon, e.g., 1 mg/ml, in a biocompatible solution, for example, a purified OP-1 morphon, is solubilized in 50% ethanol, or compatible solvent, containing 0.1% trifluoroacetic acid, or compatible acid. The injectable OP-1 morphon solution is prepared, e.g., by diluting one volume of OP-1 morphon solvent-acid stock solution with 9 volumes of 0.2% rat serum albumin in sterile PBS (phosphate-buffered saline).

In the experiment, growing rats or aged rats (e.g., Long Evans, Charles River Laboratories, Wilmington) are anesthetized by using ketamine. Two of the liver lobes (left and right) are cut out (approximately 1/3 of the lobe) and the OP-1 morphon is injected locally at multiple sites along the cut ends. The amount of OP-1 morphon injected may be, e.g., 20-100 μ g in 100-1000 μ l PBS/RSA (phosphate buffered saline/rat serum albumin) injection buffer. Placebo samples comprise injection buffer only. In experimental essays, five rats in each group preferably are used. The wound is closed and the rats are allowed to eat normal food and drink tap water.

After 12 days, the rats are sacrificed and liver regeneration is observed visually, to evaluate the effects of the OP-1 morphon on liver regeneration most effectively. It is contemplated that the OP-1 morphon injected group may show complete liver tissue regeneration with no sign remaining of any cut in the liver. By contrast, the control group into which only PBS is injected, show typically only minimal regeneration with the incision remaining in the sample.

(3) OP-1 Morphon-Induced Dentin, Cementum and Periodontal Ligament Regeneration.

As still another example, the ability of OP-1 morphons to induce dentinogenesis also may be demonstrated. To date, the unpredictable response of dental pulp tissue to injury is a basic clinical problem in dentistry. Cynomolgus monkeys are chosen as primate models as monkeys are presumed to be more indicative of human dental biology than models based on lower non-primate mammals.

- 67 -

Using standard dental surgical procedures, small areas (e.g., 2mm) of dental pulps are surgically exposed by removing the enamel and dentin immediately above the pulp (by drilling) of sample teeth, performing a partial amputation of the coronal pulp tissue, inducing hemostasis, application of the pulp treatment, and sealing and filling the cavity by standard procedures.

- 5 Pulp treatments used may include: an OP-1 morphon dispersed in a carrier matrix; carrier matrix alone, and no treatment. Twelve teeth per animal (four for each treatment) are prepared, and two animals are used. At four weeks, teeth are extracted and processed histologically for analysis of dentin formation, and/or ground to analyze dentin mineralization. The effect of OP-1 morphon on osteodentin reparation may be observed visually by comparing with the control
10 samples. It is contemplated that the OP-1 morphon, like natural OP-1, plus a carrier matrix may induce formation of reparative, osteodentin bridges, traversing on surgically exposed healthy dental pulps. By contrast, pulps treated with carrier matrix alone, do not form reparative dentin.

(4) OP-1 Morphon-Induced Nerve Tissue Repair

- As yet another example, the induction of regenerative effects on central nervous system
15 (CNS) repair, by a morphogenically active OP-1 morphon, may be demonstrated using a rat brain stab model. Briefly, male Long Evans rats are anesthetized and the head area prepared for surgery. The calvariae is exposed using standard surgical procedures and a hole drilled toward the center of each lobe using a 0.035K wire, just piercing the calvariae. 25ml solutions containing either OP-1 morphon (25mg), natural OP-1 (25mg) or PBS then is provided to each of the holes
20 by Hamilton syringe. Solutions are delivered to a depth approximately 3 mm below the surface, into the underlying cortex, corpus callosum and hippocampus. The skin then is sutured and the animal allowed to recover.

- Three days post surgery, rats are sacrificed by decapitation and their brains processed for sectioning. Scar tissue formation is evaluated by immunofluorescence staining for glial fibrillary
25 acidic protein, a marker protein for glial scarring, to qualitatively determine the degree of scar formation. It is contemplated that the OP-1 morphon, like natural OP-1, may result in reduced levels of glial fibrillary acidic protein in the tissue sections of animals treated with OP-1 morphon, evidencing the ability of the morphogen to inhibit glial scar formation, thereby stimulating nerve regeneration.

- 30 The ability of OP-1 morphon to stimulate peripheral nervous system axonal growth over extended distances may be demonstrated using the following model. Neurons of the peripheral nervous system can sprout new processes on their own following injury, but without guidance these sproutings typically fail to connect appropriately and die. Where the break is extensive, e.g., greater than 5 or 10 mm, regeneration is poor or nonexistent. Previous experiments with OP-1,

- 68 -

show that morphogens stimulate peripheral nervous system axonal growth over extended distances, allowing repair and regeneration of damaged peripheral neural pathways.

In this example OP-1 morphon stimulation of nerve regeneration may be demonstrated using the rat sciatic nerve model. The rat sciatic nerve can regenerate spontaneously across a 5 mm gap, and occasionally across a 10 mm gap, provided that the severed ends are inserted in a saline-filled nerve guidance channel. In this experiment, nerve regeneration across at least a 12mm gap is tested.

Adult female Sprague-Dawley rats (Charles River Laboratories, Inc.) weighing 230-250 g are anesthetized with intraperitoneal injections of sodium pentobarbital (35 mg/kg body weight). A skin incision is made parallel and just posterior to the femur. The avascular intermuscular plane between vastus lateralis and hamstring muscles are entered and followed to the loose fibroareolar tissue surrounding the sciatic nerve. The loose tissue is divided longitudinally thereby freeing the sciatic nerve over its full extent without devascularizing any portion. Under a surgical microscope the sciatic nerves are transected with microscissors at mid-thigh and grafted with an OP-1 morphon gel graft that separates the nerve stumps by 12 mm. The graft region is encased in a silicone tube 20 mm in length with a 1.5 mm inner diameter, the interior of which is filled with the morphon solution. Specifically, the central 12 mm of the tube consists of an OP-1 morphon gel prepared by mixing 1 to 5 mg of substantially pure OP-1 morphon produced with approximately 100 ml of MATRIGEL™ (from Collaborative Research, Inc., Bedford, MA), an extracellular matrix extract derived from mouse sarcoma tissue; and containing solubilized tissue basement membrane, including laminin, type IV collagen, heparin sulfate, proteoglycan and entactin, in phosphate-buffered saline. The morphon-filled tube then is implanted directly into the defect site, allowing 4 mm on each end to insert the nerve stumps. Each stump is abutted against the morphon gel and is secured in the silicone tube by three stitches of commercially available surgical 10-0 nylon through the epineurium, the fascicle protective sheath.

In addition to OP-1 morphon gel grafts, control grafts of empty silicone tubes, silicone tubes filled with gel only and "reverse" autografts, wherein 12 mm transected segments of the animal's sciatic nerve are rotated 180° prior to suturing, preferably also are grafted. All experiments preferably are performed in quadruplicate. All wounds preferably are closed by wound clips that are removed after 10 days. Rats can be grafted on both legs. At 3 weeks the animals are sacrificed, and the grafted segments removed and frozen on dry ice immediately. Frozen sections then are cut throughout the graft site, and examined for axonal regeneration by immunofluorescent staining using anti-neurofilament antibodies labeled with flurocein (obtained, for example, from Sigma Chemical Co., St. Louis).

- 69 -

It is contemplated that regeneration of the sciatic nerve may occur across the entire 12 mm distance in all graft sites when the gap is filled with the OP-1 morphon gel. By contrast, empty silicone tubes, gel alone and reverse autografts do not show nerve regeneration.

5 The invention may be embodied in other specific forms without departing from the spirit and scope thereof. Accordingly, other embodiments are within the following claims.

- 70 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: CREATIVE BIOMOLECULES, INC
- (B) STREET: 45 SOUTH STREET
- (C) CITY: HOPKINTON
- (D) STATE: MA
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 01748
- (G) TELEPHONE: 1-508-435-9001
- (H) TELEFAX: 1-508-435-0454
- (I) TELEX:

(ii) TITLE OF INVENTION: SINGLE-CHAIN ANALOGS OF TGF-B
SUPERFAMILY (MORPHONS)

(iii) NUMBER OF SEQUENCES: 43

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: PATENT ADMINISTRATOR; TESTA, HURWITZ &
THIBEAULT
- (B) STREET: 125 HIGH STREET, HIGH STREET TOWER
- (C) CITY: BOSTON
- (D) STATE: MA
- (E) COUNTRY: USA
- (F) ZIP: 02210

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: PITCHER ESQ, EDMUND R
- (B) REGISTRATION NUMBER: 27,829
- (C) REFERENCE/DOCKET NUMBER: CRP-080

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 617-248-7000
- (B) TELEFAX: 617-248-7100

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- 71 -

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..98
 (D) OTHER INFORMATION: /note= "TGF-B1 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp
 1 5 10 15
 Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly
 20 25 30
 Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu
 35 40 45
 Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys
 50 55 60
 Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg
 65 70 75 80
 Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys
 85 90 95
 Cys Ser

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 98 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..98
 (D) OTHER INFORMATION: /note= "TGF-B2 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Cys Leu Arg Pro Leu Tyr Ile Asp Phe Lys Arg Asp Leu Gly Trp
 1 5 10 15
 Lys Trp Ile His Glu Pro Lys Gly Tyr Asn Ala Asn Phe Cys Ala Gly
 20 25 30
 Ala Cys Pro Tyr Leu Trp Ser Ser Asp Thr Gln His Ser Arg Val Leu
 35 40 45
 Ser Leu Tyr Asn Thr Ile Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys
 50 55 60
 Val Ser Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Ile Gly Lys
 65 70 75 80

- 72 -

Thr Pro Lys Ile Glu Gln Leu Ser Asn Met Ile Val Lys Ser Cys Lys
 85 90 95

Cys Ser

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 98 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..98
 (D) OTHER INFORMATION: /note= "TGF-B3 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Glu
 1 5 10 15
 Lys Trp Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly
 20 25 30
 Pro Cys Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr Val Leu
 35 40 45
 Gly Leu Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys
 50 55 60
 Val Pro Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg
 65 70 75 80
 Thr Pro Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser Cys Lys
 85 90 95

Cys Ser

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 98 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..98
 (D) OTHER INFORMATION: /note= "TGF-B4 SEQUENCE"

- 73 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gln Trp
 1 5 10 15
 Lys Trp Ile His Glu Pro Lys Gly Tyr Met Ala Asn Phe Cys Met Gly
 20 25 30
 Pro Cys Pro Tyr Ile Trp Ser Ala Asp Thr Gln Tyr Thr Lys Val Leu
 35 40 45
 Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro Cys Cys
 50 55 60
 Val Pro Gln Thr Leu Asp Pro Leu Pro Ile Ile Tyr Tyr Val Gly Arg
 65 70 75 80
 Asn Val Arg Val Glu Gln Leu Ser Asn Met Val Val Arg Ala Cys Lys
 85 90 95
 Cys Ser

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..98
- (D) OTHER INFORMATION: /note= "TGF-B5 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Cys Cys Val Lys Pro Leu Tyr Ile Asn Phe Arg Lys Asp Leu Gly Trp
 1 5 10 15
 Lys Trp Ile His Glu Pro Lys Gly Tyr Glu Ala Asn Tyr Cys Leu Gly
 20 25 30
 Asn Cys Pro Tyr Ile Trp Ser Met Asp Thr Gln Tyr Ser Lys Val Leu
 35 40 45
 Ser Leu Tyr Asn Gln Asn Asn Pro Gly Ala Ser Ile Ser Pro Cys Cys
 50 55 60
 Val Pro Asp Val Leu Glu Pro Leu Pro Ile Ile Tyr Tyr Val Gly Arg
 65 70 75 80
 Thr Ala Lys Val Glu Gln Leu Ser Asn Met Val Val Arg Ser Cys Asn
 85 90 95
 Cys Ser

- 74 -

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "DPP SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp
1          5          10          15
Asp Trp Ile Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly
20          25          30
Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala
35          40          45
Val Val Gln Thr Leu Val Asn Asn Met Asn Pro Gly Lys Val Pro Lys
50          55          60
Ala Cys Cys Val Pro Thr Gln Leu Asp Ser Val Ala Met Leu Tyr Leu
65          70          75          80
Asn Asp Gln Ser Thr Val Val Leu Lys Asn Tyr Gln Glu Met Thr Val
85          90          95
Val Gly Cys Gly Cys Arg
100

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "VG1 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gln
1          5          10          15

```

- 75 -

```

Asn Trp Val Ile Ala Pro Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly
    20                      25                      30

Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala
    35                      40                      45

Ile Leu Gln Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu
    50                      55                      60

Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr
    65                      70                      75                      80

Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val
    85                      90                      95

Asp Glu Cys Gly Cys Arg
    100

```

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "VGR1 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gln
  1                      5                      10                      15

Asn Trp Val Ile Ala Pro Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly
    20                      25                      30

Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala
    35                      40                      45

Ile Leu Gln Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu
    50                      55                      60

Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr
    65                      70                      75                      80

Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val
    85                      90                      95

Asp Glu Cys Gly Cys Arg
    100

```

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
 - (B) TYPE: amino acid

- 76 -

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 (D) OTHER INFORMATION: /note= "60A SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys	Gln	Met	Gln	Thr	Leu	Tyr	Ile	Asp	Phe	Lys	Asp	Leu	Gly	Trp	His
1				5					10					15	
Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Gly	Ala	Phe	Tyr	Cys	Ser	Gly
			20					25					30		
Glu	Cys	Asn	Phe	Pro	Leu	Asn	Ala	His	Met	Asn	Ala	Thr	Asn	His	Ala
		35					40					45			
Ile	Val	Gln	Thr	Leu	Val	His	Leu	Leu	Glu	Pro	Lys	Lys	Val	Pro	Lys
	50					55					60				
Pro	Cys	Cys	Ala	Pro	Thr	Arg	Leu	Gly	Ala	Leu	Pro	Val	Leu	Tyr	His
65					70					75				80	
Leu	Asn	Asp	Glu	Asn	Val	Asn	Leu	Lys	Lys	Tyr	Arg	Asn	Met	Ile	Val
				85					90					95	
Lys	Ser	Cys	Gly	Cys	His										
				100											

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein
 (B) LOCATION: 1..101
 (D) OTHER INFORMATION: /note= "BMP-2A SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys	Lys	Arg	His	Pro	Leu	Tyr	Val	Asp	Phe	Ser	Asp	Val	Gly	Trp	Asn
1				5					10					15	
Asp	Trp	Ile	Val	Ala	Pro	Pro	Gly	Tyr	His	Ala	Phe	Tyr	Cys	His	Gly
			20					25					30		
Glu	Cys	Pro	Phe	Pro	Leu	Ala	Asp	His	Leu	Asn	Ser	Thr	Asn	His	Ala
		35					40					45			

- 77 -

Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala
 50 55 60

Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
 65 70 75 80

Glu Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu
 85 90 95

Gly Cys Gly Cys Arg
 100

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 103 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) FEATURE:
 - (A) NAME/KEY: Protein
 - (B) LOCATION: 1..103
 - (D) OTHER INFORMATION: /note= "BMP3 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala Asp Ile Gly Trp Ser
 1 5 10 15

Glu Trp Ile Ile Ser Pro Lys Ser Phe Asp Ala Tyr Tyr Cys Ser Gly
 20 25 30

Ala Cys Gln Phe Pro Met Pro Lys Ser Leu Lys Pro Ser Asn His Ala
 35 40 45

Thr Ile Gln Ser Ile Val Arg Ala Val Gly Val Val Pro Gly Ile Pro
 50 55 60

Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser Ile Leu Phe
 65 70 75 80

Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met Thr
 85 90 95

Val Glu Ser Cys Ala Cys Arg
 100

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 101 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

- 78 -

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..101
- (D) OTHER INFORMATION: /note= "BMP-4 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
1           5           10           15
Asp Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly
20           25           30
Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
35           40           45
Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala
50           55           60
Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
65           70           75           80
Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met Val Val Glu
85           90           95
Gly Cys Gly Cys Arg
100

```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "BMP-5 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
1           5           10           15
Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly
20           25           30
Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
35           40           45
Ile Val Gln Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys
50           55           60

```


- 79 -

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
 65 70 75 80
 Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 85 90 95
 Arg Ser Cys Gly Cys His
 100

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "BMP-6 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Gln
 1 5 10 15
 Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly
 20 25 30
 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
 35 40 45
 Ile Val Gln Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys
 50 55 60
 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
 65 70 75 80
 Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 85 90 95
 Arg Ala Cys Gly Cys His
 100

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 103 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..103

- 80 -

(D) OTHER INFORMATION: /note= "DORSALIN SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Cys Arg Arg Thr Ser Leu His Val Asn Phe Lys Glu Ile Gly Trp Asp
1           5           10           15
Ser Trp Ile Ile Ala Pro Lys Asp Tyr Glu Ala Phe Glu Cys Lys Gly
20           25           30
Gly Cys Phe Phe Pro Leu Thr Asp Asn Val Thr Pro Thr Lys His Ala
35           40           45
Ile Val Gln Thr Leu Val His Leu Gln Asn Pro Lys Lys Ala Ser Lys
50           55           60
Ala Cys Cys Val Pro Thr Lys Leu Asp Ala Ile Ser Ile Leu Tyr Lys
65           70           75           80
Asp Asp Ala Gly Val Pro Thr Leu Ile Tyr Asn Tyr Glu Gly Met Lys
85           90           95
Val Ala Glu Cys Gly Cys Arg
100

```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "OP-1 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
1           5           10           15
Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly
20           25           30
Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala Thr Asn His Ala
35           40           45
Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Glu Thr Val Pro Lys
50           55           60
Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser Val Leu Tyr Phe
65           70           75           80
Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
85           90           95

```

- 81 -

Arg Ala Cys Gly Cys His
100

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "OP-2 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Cys	Arg	Arg	His	Glu	Leu	Tyr	Val	Ser	Phe	Gln	Asp	Leu	Gly	Trp	Leu
1				5					10					15	
Asp	Trp	Val	Ile	Ala	Pro	Gln	Gly	Tyr	Ser	Ala	Tyr	Tyr	Cys	Glu	Gly
			20					25					30		
Glu	Cys	Ser	Phe	Pro	Leu	Asp	Ser	Cys	Met	Asn	Ala	Thr	Asn	His	Ala
			35				40					45			
Ile	Leu	Gln	Ser	Leu	Val	His	Leu	Met	Lys	Pro	Asn	Ala	Val	Pro	Lys
	50					55					60				
Ala	Cys	Cys	Ala	Pro	Thr	Lys	Leu	Ser	Ala	Thr	Ser	Val	Leu	Tyr	Tyr
65					70					75				80	
Asp	Ser	Ser	Asn	Asn	Val	Ile	Leu	Arg	Lys	His	Arg	Asn	Met	Val	Val
			85						90					95	
Lys	Ala	Cys	Gly	Cys	His										
					100										

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "OP-3 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

- 82 -

Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Leu
 1 5 10 15
 Asp Ser Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Ala Gly
 20 25 30
 Glu Cys Ile Tyr Pro Leu Asn Ser Cys Met Asn Ser Thr Asn His Ala
 35 40 45
 Thr Met Gln Ala Leu Val His Leu Met Lys Pro Asp Ile Ile Pro Lys
 50 55 60
 Val Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Leu Leu Tyr Tyr
 65 70 75 80
 Asp Arg Asn Asn Asn Val Ile Leu Arg Arg Glu Arg Asn Met Val Val
 85 90 95
 Gln Ala Cys Gly Cys His
 100

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..107
- (D) OTHER INFORMATION: /note= "GDF-1 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Cys Arg Thr Arg Arg Leu His Val Ser Phe Arg Glu Val Gly Trp His
 1 5 10 15
 Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Phe Cys Gln Gly
 20 25 30
 Thr Cys Ala Leu Pro Glu Thr Leu Arg Gly Pro Gly Gly Pro Pro Ala
 35 40 45
 Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro Thr
 50 55 60
 Pro Gly Ala Gly Ser Pro Cys Cys Val Pro Glu Arg Leu Ser Pro Ile
 65 70 75 80
 Ser Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg His Tyr
 85 90 95
 Glu Asp Met Val Val Asp Glu Cys Gly Cys Arg
 100 105

(2) INFORMATION FOR SEQ ID NO:20:

- 83 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..101
- (D) OTHER INFORMATION: /note= "GDF-3 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

Cys His Arg His Gln Leu Phe Ile Asn Phe Gln Asp Leu Gly Trp His
1          5          10          15
Lys Trp Val Ile Ala Pro Lys Gly Phe Met Ala Asn Tyr Cys His Gly
          20          25          30
Glu Cys Pro Phe Ser Met Thr Thr Tyr Leu Asn Ser Ser Asn Tyr Ala
          35          40          45
Phe Met Gln Ala Leu Met His Met Ala Asp Pro Lys Val Pro Lys Ala
          50          55          60
Val Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Met Leu Tyr Gln Asp
65          70          75          80
Ser Asp Lys Asn Val Ile Leu Arg His Tyr Glu Asp Met Val Val Asp
          85          90          95
Glu Cys Gly Cys Gly
          100

```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..102
- (D) OTHER INFORMATION: /note= "GDF-9 SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

Cys Glu Leu His Asp Phe Arg Leu Ser Phe Ser Gln Leu Lys Trp Asp
1          5          10          15

```

- 84 -

```

Asn Trp Ile Val Ala Pro His Arg Tyr Asn Pro Arg Tyr Cys Lys Gly
      20                      25                      30
Asp Cys Pro Arg Ala Val Arg His Arg Tyr Gly Ser Pro Val His Thr
      35                      40                      45
Met Val Gln Asn Ile Ile Tyr Glu Lys Leu Asp Pro Ser Val Pro Arg
      50                      55                      60
Pro Ser Cys Val Pro Gly Lys Tyr Ser Pro Leu Ser Val Leu Thr Ile
      65                      70                      75                      80
Glu Pro Asp Gly Ser Ile Ala Tyr Lys Glu Tyr Glu Asp Met Ile Ala
      85                      90                      95
Thr Arg Cys Thr Cys Arg
      100

```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..105
- (D) OTHER INFORMATION: /note= "INHIBIN-A SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Cys His Arg Val Ala Leu Asn Ile Ser Phe Gln Glu Leu Gly Trp Glu
1          5          10          15
Arg Trp Ile Val Tyr Pro Pro Ser Phe Ile Phe His Tyr Cys His Gly
      20          25          30
Gly Cys Gly Leu His Ile Pro Pro Asn Leu Ser Leu Pro Val Pro Gly
      35          40          45
Ala Pro Pro Thr Pro Ala Gln Pro Tyr Ser Leu Leu Pro Gly Ala Gln
      50          55          60
Pro Cys Cys Ala Ala Leu Pro Gly Thr Met Arg Pro Leu His Val Arg
      65          70          75          80
Thr Thr Ser Asp Gly Gly Tyr Ser Phe Lys Tyr Glu Thr Val Pro Asn
      85          90          95
Leu Leu Thr Gln His Cys Ala Cys Ile
      100          105

```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 106 amino acids

- 85 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..106
- (D) OTHER INFORMATION: /note= "INHIBIN-BA SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Cys Cys Lys Lys Gln Phe Phe Val Ser Phe Lys Asp Ile Gly Trp Asn
1      5      10      15
Asp Trp Ile Ile Ala Pro Ser Gly Tyr His Ala Asn Tyr Cys Glu Gly
20      25      30
Glu Cys Pro Ser His Ile Ala Gly Thr Ser Gly Ser Ser Leu Ser Phe
35      40      45
His Ser Thr Val Ile Asn His Tyr Arg Met Arg Gly His Ser Pro Phe
50      55      60
Ala Asn Leu Lys Ser Cys Cys Val Pro Thr Lys Leu Arg Pro Met Ser
65      70      75      80
Met Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile Lys Lys Asp Ile Gln
85      90      95
Asn Met Ile Val Glu Glu Cys Gly Cys Ser
100      105

```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..105
- (D) OTHER INFORMATION: /note= "INHIBIN-BB SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```

Cys Cys Arg Gln Gln Phe Phe Ile Asp Phe Arg Leu Ile Gly Trp Asn
1      5      10      15
Asp Trp Ile Ile Ala Pro Thr Gly Tyr Tyr Gly Asn Tyr Cys Glu Gly
20      25      30
Ser Cys Pro Ala Tyr Leu Ala Gly Val Pro Gly Ser Ala Ser Ser Phe
35      40      45

```

- 86 -

```

His Thr Ala Val Val Asn Gln Tyr Arg Met Arg Gly Leu Asn Pro Gly
 50                      55                      60

Thr Val Asn Ser Cys Cys Ile Pro Thr Lys Leu Ser Thr Met Ser Met
65                      70                      75                      80

Leu Tyr Phe Asp Asp Glu Tyr Asn Ile Val Lys Arg Asp Val Pro Asn
                      85                      90                      95

Met Ile Val Glu Glu Cys Gly Cys Ala
          100                      105

```

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 98 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) FEATURE:
 - (A) NAME/KEY: Protein
 - (B) LOCATION: 1..98
 - (D) OTHER INFORMATION: /note= "TGF-B SUBGROUP SEQUENCE PATTERN. Each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Xaa Asp Leu Gly Trp
 1                      5                      10                      15

Lys Trp Ile His Glu Pro Lys Gly Tyr Xaa Ala Asn Phe Cys Xaa Gly
          20                      25                      30

Xaa Cys Pro Tyr Xaa Trp Ser Xaa Asp Thr Gln Xaa Ser Xaa Val Leu
          35                      40                      45

Xaa Leu Tyr Asn Xaa Xaa Asn Pro Xaa Ala Ser Ala Xaa Pro Cys Cys
          50                      55                      60

Val Pro Gln Xaa Leu Glu Pro Leu Xaa Ile Xaa Tyr Tyr Val Gly Arg
65                      70                      75                      80

Xaa Xaa Lys Val Glu Gln Leu Ser Asn Met Xaa Val Xaa Ser Cys Lys
          85                      90                      95

Cys Ser

```

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 104 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

- 87 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..104

(D) OTHER INFORMATION: /note= "VG/DPP SUBGROUP SEQUENCE
PATTERN. Each Xaa is independently selected from
a group of one or more specified amino acids as
defined in the specification"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Cys	Xaa	Xaa	Xaa	Xaa	Leu	Tyr	Val	Xaa	Phe	Xaa	Asp	Xaa	Gly	Trp	Xaa	1	5	10	15
Asp	Trp	Ile	Ile	Ala	Pro	Xaa	Gly	Tyr	Xaa	Ala	Xaa	Tyr	Cys	Xaa	Gly	20	25	30	
Xaa	Cys	Xaa	Phe	Pro	Leu	Xaa	Xaa	Xaa	Xaa	Asn	Xaa	Thr	Asn	His	Ala	35	40	45	
Ile	Xaa	Gln	Thr	Leu	Val	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Pro	50	55	60	
Lys	Xaa	Cys	Cys	Xaa	Pro	Thr	Xaa	Leu	Xaa	Ala	Xaa	Ser	Xaa	Leu	Tyr	65	70	75	80
Xaa	Asp	Xaa	Xaa	Xaa	Xaa	Xaa	Val	Xaa	Leu	Xaa	Xaa	Tyr	Xaa	Xaa	Met	85	90	95	
Xaa	Val	Xaa	Xaa	Cys	Gly	Cys	Xaa									100			

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 107 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..107

(D) OTHER INFORMATION: /note= "GDF SUBGROUP PATTERN.
Each Xaa is independently selected from a group
of one or more specified amino acids as defined
in the specification"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Cys	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Phe	Xaa	Xaa	Xaa	Xaa	Trp	Xaa	1	5	10	15
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---	---	----	----

- 88 -

```

Xaa Trp Xaa Xaa Ala Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Gly
      20                      25                      30

Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      35                      40                      45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      50                      55                      60

Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Val Pro Xaa Xaa Xaa Ser Pro Xaa
65                      70                      75                      80

Ser Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr
      85                      90                      95

Glu Asp Met Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
      100                      105

```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 109 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..109
- (D) OTHER INFORMATION: /note= "INHIBIN SUBGROUP PATTERN.
Each Xaa is independently selected from a group of
one or more specified amino acids as defined in
the specification"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
1                      5                      10                      15

Xaa Trp Ile Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Tyr Cys Xaa Gly
      20                      25                      30

Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      35                      40                      45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      50                      55                      60

Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa
65                      70                      75                      80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      85                      90                      95

Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
      100                      105

```

- 89 -

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..348
- (D) OTHER INFORMATION: /product= "DNA ENCODING OP-1 MORPHON"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

ATGGCTTGTA AGAAGCACGA GCTGTATGTC AGCTTCCGAG ACCTGGGCTG GCAGGACTGG      60
ATCATCGCGC CTGAAGGCTA CGCCGCCTAC TACTGTGGCG GCTCTGGAGG TGGATCCGGT      120
GGAGGCTCCG GTGCCTTCCC TCTGAACTCC TACATGAACG CCACCAACCA CGCCATCGTG      180
CAGACGCTGG TCCACTTCAT CAACCCGGAA ACGGTGCCCC AGCCCGCTAG CGGTGGTTGT      240
GCGCCACGC AGCTCAATGC CATCTCCGTC CTCTACTTCG ATGACAGCTC CAACGTCATC      300
CTGAAGAAAT ACAGAAACAT GGTGGTCCGG GCATGCGGCT CCCACTAA                    348

```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 115 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..115
- (D) OTHER INFORMATION: /note= "OP-1 MORPHON PROTEIN"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```

Met Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly
 1             5             10             15
Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys
 20             25             30
Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Ala Phe Pro Leu
 35             40             45
Asn Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val
 50             55             60

```

- 90 -

His Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Ala Ser Gly Gly Cys
 65 70 75 80
 Ala Pro Thr Gln Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser
 85 90 95
 Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys
 100 105 110
 Gly Ser His
 115

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1878 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..1878
- (D) OTHER INFORMATION: /product= "OP-1 cDNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GGGCGCAGCG GGGCCCGTCT GCAGCAAGTG ACCGACGGCC GGGACGGCCG CCTGCCCCCT	60
CTGCCACCTG GGGCGGTGCG GGCCCGGAGC CCGGAGCCCG GGTAGCGCGT AGAGCCGGCG	120
CGATGCACGT GCGCTCACTG CGAGCTGCGG CGCCGCACAG CTTCGTGGCG CTCTGGGCAC	180
CCCTGTTCCT GCTGCGCTCC GCCCTGGCCG ACTTCAGCCT GGACAACGAG GTGCACTCGA	240
GCTTCATCCA CCGGCGCCTC CGCAGCCAGG AGCGGCGGGA GATGCAGCGC GAGATCCTCT	300
CCATTTTGGG CTTGCCCCAC CGCCCGCGCC CGCACCTCCA GGGCAAGCAC AACTCGGCAC	360
CCATGTTCAT GCTGGACCTG TACAACGCCA TGGCGGTGGA GGAGGGCGGC GGGCCCGGCG	420
GCCAGGGCTT CTCCTACCCC TACAAGGCCG TCTTCAGTAC CCAGGGCCCC CCTCTGGCCA	480
GCCTGCAAGA TAGCCATTTC CTCACCGACG CCGACATGGT CATGAGCTTC GTCAACCTCG	540
TGGAACATGA CAAGGAATTC TTCCACCCAC GCTACCACCA TCGAGAGTTC CGGTTTGATC	600
TTTCCAAGAT CCCAGAAGGG GAAGCTGTCA CGGCAGCCGA ATTCCGGATC TACAAGGACT	660
ACATCCGGGA ACGCTTCGAC AATGAGACGT TCCGGATCAG CGTTTATCAG GTGCTCCAGG	720
AGCACTTGGG CAGGGAATCG GATCTCTTCC TGCTCGACAG CCGTACCCTC TGGGCCTCGG	780
AGGAGGGCTG GCTGGTGTTC GACATCACAG CCACCAGCAA CCACTGGGTG GTCAATCCGC	840
GGCACAACCT GGGCCTGCAG CTCTCGGTGG AGACGCTGGA TGGGCAGAGC ATCAACCCCA	900
AGTTGGCGGG CCTGATTGGG CGGCACGGGC CCCAGAACAA GCAGCCCTTC ATGGTGGCTT	960

- 91 -

TCTTCAAGGC CACGGAGGTC CACTTCCGCA GCATCCGGTC CACGGGGAGC AAACAGCGCA	1020
GCCAGAACCG CTCCAAGACG CCCAAGAACC AGGAAGCCCT GCGGATGGCC AACGTGGCAG	1080
AGAACAGCAG CAGCGACCAG AGGCAGGCCT GTAAGAAGCA CGAGCTGTAT GTCAGCTTCC	1140
GAGACCTGGG CTGGCAGGAC TGGATCATCG CGCCTGAAGG CTACGCCGCC TACTACTGTG	1200
AGGGGGAGTG TGCCTTCCCT CTGAACTCCT ACATGAACGC CACCAACCAC GCCATCGTGC	1260
AGACGCTGGT CCACTTCATC AACCCGGAAA CGGTGCCCAA GCCCTGCTGT GCGCCACGC	1320
AGCTCAATGC CATCTCCGTC CTCTACTTCG ATGACAGCTC CAACGTCATC CTGAAGAAAT	1380
ACAGAAACAT GGTGGTCCGG GCCTGTGGCT GCCACTAGCT CCTCCGAGAA TTCAGACCCT	1440
TTGGGGCCAA GTTTTTCTGG ATCCTCCATT GCTCGCCTTG GCCAGGAACC AGCAGACCAA	1500
CTGCCTTTTG TGAGACCTTC CCCTCCCTAT CCCCAACTTT AAAGGTGTGA GAGTATTAGG	1560
AAACATGAGC AGCATATGGC TTTTGATCAG TTTTTCAGTG GCAGCATCCA ATGAACAAGA	1620
TCCTACAAGC TGTGCAGGCA AAACCTAGCA GGAAAAAAA ACAACGCATA AAGAAAAATG	1680
GCCGGGCCAG GTCATTGGCT GGGAAGTCTC AGCCATGCAC GGA CTGTTT CCAGAGGTAA	1740
TTATGAGCGC CTACCAGCCA GGCCACCCAG CCGTGGGAGG AAGGGGGCGT GGCAAGGGGT	1800
GGGCACATTG GTGTCTGTGC GAAAGGAAAA TTGACCCGGA AGTTCCTGTA ATAAATGTCA	1860
CAATAAACG AATGAATG	1878

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..60
- (D) OTHER INFORMATION: /product= "N TERMINAL LINKER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GCCAACGTGG CAGAGAACAG GGCCGAGCGG GCCCATATGG CTTGTAAGAA GCACGAGCTG	60
---	----

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 92 -

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..48
- (D) OTHER INFORMATION: /product= "SMALL LOOP LINKER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GAAACGGTGC CCAAGCCCCG TAGCGGTGGT TGTGCGCCCA CGCAGCTC

48

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..66
- (D) OTHER INFORMATION: /product= "LONG LOOP LINKER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GCCGCCTACT ACTGTGGCGG CTCTGGAGGT GGATCCGGTG GAGGCTCCGG TGCCTTCCCT
CTGAAC

60

66

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 52 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..52
- (D) OTHER INFORMATION: /product= "C-TERMINAL LINKER 1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CATGGTGGTC CGGGCATGCG GCTCCCACGG TGCGGCCGCA GAATTCAGAC CC

52

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

- 93 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..42

(D) OTHER INFORMATION: /product= "C-TERMINAL LINKER 2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CGGGCATGCG GCTCCCACTA AAGATCTGCA GAATTCAGAC CC

42

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1392 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..1392

(D) OTHER INFORMATION: /product= "MODIFIED OP-1 DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CCCCGGTAGC GCGTAGAGCC GGCGCGATGC ACGTGCGCTC ACTGCGAGCT GCGGCGCCGC	60
ACAGCTTCGT GGCGCTCTGG GCACCCCTGT TCCTGCTGCG CTCCGCCCTG GCCGACTTCA	120
GCCTGGACAA CGAGGTGCAC TCGAGCTTCA TCCACCGGCG CCTCCGCAGC CAGGAGCGGC	180
GGGAGATGCA GCGCGAGATC CTCTCCATTT TGGGCTTGCC CCACCGCCCG CGCCCGCACC	240
TCCAGGGCAA GCACAACTCG GCACCCATGT TCATGCTGGA CCTGTACAAC GCCATGGCGG	300
TGGAGGAGGG CGGCGGGCCC GGCGGCCAGG GCTTCTCCTA CCCCTACAAG GCCGTCTTCA	360
GTACCCAGGG CCCCCCTCTG GCCAGCCTGC AAGATAGCCA TTTCCTCACC GACGCCGACA	420
TGGTCATGAG CTTCGTCAAC CTCGTGGAAC ATGACAAGGA ATTCTTCCAC CCACGCTACC	480
ACCATCGAGA GTTCCGGTTT GATCTTTCCA AGATCCCAGA AGGGGAAGCT GTCACGGCAG	540
CCGAATTCCG GATCTACAAG GACTACATCC GGAACGCTT CGACAATGAG ACGTTCCGGA	600
TCAGCGTTTA TCAGGTGCTC CAGGAGCACT TGGGCAGGGA ATCGGATCTC TTCCTGCTCG	660
ACAGCCGTAC CCTCTGGGCC TCGGAGGAGG GCTGGCTGGT GTTTGACATC ACAGCCACCA	720
GCAACCACTG GGTGGTCAAT CCGCGGCACA ACCTGGGCCT GCAGCTCTCG GTGGAGACGC	780
TGGATGGGCA GAGCATCAAC CCAAGTTGG CGGGCCTGAT TGGCGGGCAC GGGCCCCAGA	840
ACAAGCAGCC CTTCATGGTG GCTTTCTTCA AGGCCACGGA GGTCCACTTC CGCAGCATCC	900

- 94 -

```

GGTCCACGGG GAGCAAACAG CGCAGCCAGA ACCGCTCCAA GACGCCCAAG AACCAGGAAG      960
CCCTGCGGAT GGCCAACAGC CCGGCCGAGC GGGCCCATAT GGCTTGTAAG AAGCACGAGC      1020
TGTATGTCAG CTTCCGAGAC CTGGGCTGGC AGGACTGGAT CATCGCGCCT GAAGGCTACG      1080
CCGCCTACTA CTGTGGCGGC TCTGGAGGTG GATCCGGTGG AGGCTCCGGT GCCTTCCCTC      1140
TGAACTCCTA CATGAACGCC ACCAACCACG CCATCGTGCA GACGCTGGTC CACTTCATCA      1200
ACCCGGAAC GGTGCCCAAG CCCGCTAGCG GTGGTTGTGC GCCCACGCAG CTCAATGCCA      1260
TCTCCGTCCT CTA CTCTCGAT GACAGCTCCA ACGTCATCCT GAAGAAATAC AGAAACATGG      1320
TGGTCCGGGC ATGCGGCTCC CACGGTGCGG CCGCAGAATT CAGACCCTTT GGGGCCAAGT      1380
TTTTCTGGAT CC                                          1392

```

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..48
- (D) OTHER INFORMATION: /product= "SMALL LOOP MUTAGENESIS SEQUENCE A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```

GAAACGGTGC CCAAGNNCNN TNNCNTNTNT NNTNNGCCCA CGCAGCTC      48

```

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..48
- (D) OTHER INFORMATION: /product= "SMALL LOOP MUTAGENESIS SEQUENCE B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

```

GAAACGGTGC CCAAGCCCN NNNNNNNNNN TGTGCGCCCA CGCAGCTC      48

```


- 95 -

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..66
- (D) OTHER INFORMATION: /product= "LARGE LOOP MUTAGENESIS
SEQUENCE A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

```
GCCGCCTACT ACTGTNNCNN CNNTNNANNT NNANNCGGTG GAGGCTCCGG TGCCTTCCCT    60
CTGAAC                                                                    66
```

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..66
- (D) OTHER INFORMATION: /product= "LARGE LOOP MUTAGENESIS
SEQUENCE B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

```
GCCGCCTACT ACTGTNNNNN NNNNNNNNNN NNNTCCGGTG GAGGCTCCGG TGCCTTCCCT    60
CTGAAC                                                                    66
```

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..66
- (D) OTHER INFORMATION: /product= "LARGE LOOP MUTAGENESIS
SEQUENCE C"

- 96 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GCCGCCTACT ACTGTGGCGG CTCTGGAGGT NNANNCNNTN NANNCNNCNN TNNCTTCCCT 60
CTGAAC 66

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..66
- (D) OTHER INFORMATION: /product= "LARGE LOOP MUTAGENESIS
SEQUENCE D"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GCCGCCTACT ACTGTGGCGG CTCTGGAGGT GGANNNNNNNN NNNNNNNNNN NNNNTTCCCT 60
CTGAAC 66

- 97 -

What is claimed is:

- 1 1. A single-chain synthetic amino acid biopolymer construct comprising an amino acid
2 sequence
3 defining finger 1, finger 2, and heel regions together complementary to the ligand
4 binding interactive surface of a TGF- β superfamily member receptor structure and
5 having an amino acid sequence which mimics the structure of a member of the TGF-
6 β superfamily such that said construct preferentially binds said receptor.
- 1 2. The construct of claim 1 wherein, upon binding with said receptor structure, said
2 construct mimics the bioactivity of a TGF- β superfamily member.
- 1 3. The construct of claim 2 wherein, upon binding with said receptor structure, said
2 construct initiates a morphogenic cascade.
- 1 4. The construct of claim 1 wherein:
2 the amino acid sequence of the finger 1 region is folded to define a
3 secondary structure comprising, in order from the N to C direction, a first beta sheet, a helical
4 turn, a loop, and a second beta sheet disposed substantially anti-parallel to said first beta sheet;
5 the amino acid sequence of the heel region is folded to define a secondary
6 structure comprising an alpha helical coil; and
7 the amino acid sequence of the finger 2 region is folded to define a
8 secondary structure comprising, in order from the N to C direction, a beta sheet, a loop, and a
9 second beta sheet disposed substantially anti-parallel to said first beta sheet.
- 1 5. The construct of claim 1 or 4, wherein said finger 1 and finger 2 regions comprise anti-
2 parallel β pleated sheets which extend along adjacent, substantially parallel axes, and said heel
3 region comprises a helical coil disposed about an axes transverse to said parallel axes.
- 1 6. The construct of claim 4, wherein the finger 1 sequence is selected from the group of
2 finger 1 sequences consisting of
3 TGF- β 1 SEQ. ID. No. 1, residues 2 through 29,
4 TGF- β 2 SEQ. ID. No. 2, residues 2 through 29,
5 TGF- β 3 SEQ. ID. No. 3, residues 2 through 29,
6 TGF- β 4 SEQ. ID. No. 4, residues 2 through 29,
7 TGF- β 5 SEQ. ID. No. 5, residues 2 through 29,
8 dpp SEQ. ID. No. 6, residues 2 through 29,
9 Vg-1 SEQ. ID. No. 7, residues 2 through 29,
10 Vgr-1 SEQ. ID. No. 8, residues 2 through 29,

- 98 -

11	60A	SEQ. ID. No. 9, residues 2 through 29,
12	BMP-2A	SEQ. ID. No. 10, residues 2 through 29,
13	BMP3	SEQ. ID. No. 11, residues 2 through 29,
14	BMP-4	SEQ. ID. No. 12, residues 2 through 29,
15	BMP-5	SEQ. ID. No. 13, residues 2 through 29,
16	BMP-6	SEQ. ID. No. 14, residues 2 through 29,
17	Dorsalin	SEQ. ID. No. 15, residues 2 through 29,
18	OP-1	SEQ. ID. No. 16, residues 2 through 29,
19	OP-2	SEQ. ID. No. 17, residues 2 through 29,
20	OP-3	SEQ. ID. No. 18, residues 2 through 29,
21	GDF-1	SEQ. ID. No. 19, residues 2 through 29,
22	GDF-3	SEQ. ID. No. 20, residues 2 through 29,
23	GDF-9	SEQ. ID. No. 21, residues 2 through 29,
24	Inhibin α	SEQ. ID. No. 22, residues 2 through 29,
25	Inhibin β A	SEQ. ID. No. 23, residues 2 through 29, and
26	Inhibin β B	SEQ. ID. No. 24, residues 2 through 29.

1 7. The construct of claim 4 or 6, wherein the heel sequence is selected from the group of
2 heel sequences consisting of

3	TGF- β 1	SEQ. ID. No. 1, residues 35 through 62,
4	TGF- β 2	SEQ. ID. No. 2, residues 35 through 62,
5	TGF- β 3	SEQ. ID. No. 3, residues 35 through 62,
6	TGF- β 4	SEQ. ID. No. 4, residues 35 through 62,
7	TGF- β 5	SEQ. ID. No. 5, residues 35 through 62,
8	dpp	SEQ. ID. No. 6, residues 35 through 65,
9	Vg-1	SEQ. ID. No. 7, residues 35 through 65,
10	Vgr-1	SEQ. ID. No. 8, residues 35 through 65,
11	60A	SEQ. ID. No. 9, residues 35 through 65,
12	BMP-2A	SEQ. ID. No. 10, residues 35 through 64,
13	BMP3	SEQ. ID. No. 11, residues 35 through 66,
14	BMP-4	SEQ. ID. No. 12, residues 35 through 64,
15	BMP-5	SEQ. ID. No. 13, residues 35 through 65,
16	BMP-6	SEQ. ID. No. 14, residues 35 through 65,
17	Dorsalin	SEQ. ID. No. 15, residues 35 through 65,
18	OP-1	SEQ. ID. No. 16, residues 35 through 65,
19	OP-2	SEQ. ID. No. 17, residues 35 through 65,
20	OP-3	SEQ. ID. No. 18, residues 35 through 65,
21	GDF-1	SEQ. ID. No. 19, residues 35 through 70,

- 99 -

22	GDF-3	SEQ. ID. No. 20, residues 35 through 64,
23	GDF-9	SEQ. ID. No. 21, residues 35 through 65,
24	Inhibin α	SEQ. ID. No. 22, residues 35 through 65,
25	Inhibin β A	SEQ. ID. No. 23, residues 35 through 69, and
26	Inhibin β B	SEQ. ID. No. 24, residues 35 through 68.

1 8. The construct of claim 4 or 6, wherein the finger 2 sequence is selected from the
 2 group of finger 2 sequences consisting of

3	TGF- β 1	SEQ. ID. No. 1, residues 65 through 94,
4	TGF- β 2	SEQ. ID. No. 2, residues 65 through 94,
5	TGF- β 3	SEQ. ID. No. 3, residues 65 through 94,
6	TGF- β 4	SEQ. ID. No. 4, residues 65 through 94,
7	TGF- β 5	SEQ. ID. No. 5, residues 65 through 94,
8	dpp	SEQ. ID. No. 6, residues 68 through 98,
9	Vg-1	SEQ. ID. No. 7, residues 68 through 98,
10	Vgr-1	SEQ. ID. No. 8, residues 68 through 98,
11	60A	SEQ. ID. No. 9, residues 68 through 98,
12	BMP-2A	SEQ. ID. No. 10, residues 67 through 97,
13	BMP3	SEQ. ID. No. 11, residues 69 through 99,
14	BMP-4	SEQ. ID. No. 12, residues 67 through 97,
15	BMP-5	SEQ. ID. No. 13, residues 68 through 98,
16	BMP-6	SEQ. ID. No. 14, residues 68 through 98,
17	Dorsalin	SEQ. ID. No. 15, residues 68 through 99,
18	OP-1	SEQ. ID. No. 16, residues 68 through 98,
19	OP-2	SEQ. ID. No. 17, residues 68 through 98,
20	OP-3	SEQ. ID. No. 18, residues 68 through 98,
21	GDF-1	SEQ. ID. No. 19, residues 73 through 103,
22	GDF-3	SEQ. ID. No. 20, residues 67 through 97,
23	GDF-9	SEQ. ID. No. 21, residues 68 through 98,
24	Inhibin α	SEQ. ID. No. 22, residues 68 through 101,
25	Inhibin β A	SEQ. ID. No. 23, residues 72 through 102, and
26	Inhibin β B	SEQ. ID. No. 24, residues 71 through 101.

1 9. The construct of claim 7, wherein the finger 2 sequence is selected from the group of
 2 finger 2 sequences consisting of

3	TGF- β 1	SEQ. ID. No. 1, residues 65 through 94,
4	TGF- β 2	SEQ. ID. No. 2, residues 65 through 94,
5	TGF- β 3	SEQ. ID. No. 3, residues 65 through 94,

- 100 -

6	TGF- β 4	SEQ. ID. No. 4, residues 65 through 94,
7	TGF- β 5	SEQ. ID. No. 5, residues 65 through 94,
8	dpp	SEQ. ID. No. 6, residues 68 through 98,
9	Vg-1	SEQ. ID. No. 7, residues 68 through 98,
10	Vgr-1	SEQ. ID. No. 8, residues 68 through 98,
11	60A	SEQ. ID. No. 9, residues 68 through 98,
12	BMP-2A	SEQ. ID. No. 10, residues 67 through 97,
13	BMP3	SEQ. ID. No. 11, residues 69 through 99,
14	BMP-4	SEQ. ID. No. 12, residues 67 through 97,
15	BMP-5	SEQ. ID. No. 13, residues 68 through 98,
16	BMP-6	SEQ. ID. No. 14, residues 68 through 98,
17	Dorsalin	SEQ. ID. No. 15, residues 68 through 99,
18	OP-1	SEQ. ID. No. 16, residues 68 through 98,
19	OP-2	SEQ. ID. No. 17, residues 68 through 98,
20	OP-3	SEQ. ID. No. 18, residues 68 through 98,
21	GDF-1	SEQ. ID. No. 19, residues 73 through 103,
22	GDF-3	SEQ. ID. No. 20, residues 67 through 97
23	GDF-9	SEQ. ID. No. 21, residues 68 through 98,
24	Inhibin α	SEQ. ID. No. 22, residues 68 through 101,
25	Inhibin β A	SEQ. ID. No. 23, residues 72 through 102, and
26	Inhibin β B	SEQ. ID. No. 24, residues 71 through 101.

10. The construct of claim 4, wherein the finger 1 sequence is selected from the group of sequences consisting of

3	dpp	SEQ. ID. No. 6, residues 2 through 29,
4	Vg-1	SEQ. ID. No. 7, residues 2 through 29,
5	Vgr-1	SEQ. ID. No. 8, residues 2 through 29,
6	60A	SEQ. ID. No. 9, residues 2 through 29,
7	BMP-2A	SEQ. ID. No. 10, residues 2 through 29,
8	BMP3	SEQ. ID. No. 11, residues 2 through 29,
9	BMP-4	SEQ. ID. No. 12, residues 2 through 29,
10	BMP-5	SEQ. ID. No. 13, residues 2 through 29,
11	BMP-6	SEQ. ID. No. 14, residues 2 through 29,
12	Dorsalin	SEQ. ID. No. 15, residues 2 through 29,
13	OP-1	SEQ. ID. No. 16, residues 2 through 29,
14	OP-2	SEQ. ID. No. 17, residues 2 through 29, and
15	OP-3	SEQ. ID. No. 18, residues 2 through 29.

- 101 -

1 11. The construct of claim 4 or 10, wherein the heel sequence is selected from the group
2 of sequences consisting of

3	dpp	SEQ. ID. No. 6, residues 35 through 65,
4	Vg-1	SEQ. ID. No. 7, residues 35 through 65,
5	Vgr-1	SEQ. ID. No. 8, residues 35 through 65,
6	60A	SEQ. ID. No. 9, residues 35 through 65,
7	BMP-2A	SEQ. ID. No. 10, residues 35 through 64,
8	BMP3	SEQ. ID. No. 11, residues 35 through 66,
9	BMP-4	SEQ. ID. No. 12, residues 35 through 64,
10	BMP-5	SEQ. ID. No. 13, residues 35 through 65,
11	BMP-6	SEQ. ID. No. 14, residues 35 through 65,
12	Dorsalin	SEQ. ID. No. 15, residues 35 through 65,
13	OP-1	SEQ. ID. No. 16, residues 35 through 65,
14	OP-2	SEQ. ID. No. 17, residues 35 through 65, and
15	OP-3	SEQ. ID. No. 18, residues 35 through 65.

1 12. The construct of claim 4 or 10, wherein the finger 2 sequence is selected from the
2 group of sequences consisting of

3	dpp	SEQ. ID. No. 6, residues 68 through 98,
4	Vg-1	SEQ. ID. No. 7, residues 68 through 98,
5	Vgr-1	SEQ. ID. No. 8, residues 68 through 98,
6	60A	SEQ. ID. No. 9, residues 68 through 98,
7	BMP-2A	SEQ. ID. No. 10, residues 67 through 97,
8	BMP3	SEQ. ID. No. 11, residues 69 through 99,
9	BMP-4	SEQ. ID. No. 12, residues 67 through 97,
10	BMP-5	SEQ. ID. No. 13, residues 68 through 98,
11	BMP-6	SEQ. ID. No. 14, residues 68 through 98,
12	Dorsalin	SEQ. ID. No. 15, residues 68 through 99,
13	OP-1	SEQ. ID. No. 16, residues 68 through 98,
14	OP-2	SEQ. ID. No. 17, residues 68 through 98, and
15	OP-3	SEQ. ID. No. 18, residues 68 through 98.

1 13. The construct of claim 11, wherein the finger 2 sequence is selected from the group of
2 sequences consisting of

3	dpp	SEQ. ID. No. 6, residues 68 through 98,
4	Vg-1	SEQ. ID. No. 7, residues 68 through 98,
5	Vgr-1	SEQ. ID. No. 8, residues 68 through 98,

- 102 -

6	60A	SEQ. ID. No. 9, residues 68 through 98,
7	BMP-2A	SEQ. ID. No. 10, residues 67 through 97,
8	BMP-3	SEQ. ID. No. 11, residues 69 through 99,
9	BMP-4	SEQ. ID. No. 12, residues 67 through 97,
10	BMP-5	SEQ. ID. No. 13, residues 68 through 98,
11	BMP-6	SEQ. ID. No. 14, residues 68 through 98,
12	Dorsalin	SEQ. ID. No. 15, residues 68 through 99,
13	OP-1	SEQ. ID. No. 16, residues 68 through 98,
14	OP-2	SEQ. ID. No. 17, residues 68 through 98, and
15	OP-3	SEQ. ID. No. 18, residues 68 through 98.

1 14. The construct of claim 4, wherein the finger 1 sequence is OP-1 finger 1 sequence
2 [SEQ. ID. No. 16, residues 2 through 29].

1 15. The construct of claim 4 or 14, wherein the heel sequence is OP-1 heel sequence
2 [SEQ. ID. No. 16, residues 35 through 65].

1 16. The construct of claim 4 or 14, wherein the finger 2 sequence is OP-1 finger 2
2 sequence [SEQ. ID. No. 16, residues 68 through 98].

1 17. The construct of claim 15, wherein the finger 2 sequence is OP-1 finger 2 sequence
2 [SEQ. ID. No. 16, residues 68 through 98].

1 18. The construct of claim 4, wherein:
2 the finger 1 sequence is OP-1 finger 1 sequence [SEQ. ID. No. 16, residues
3 2 through 29];
4 the heel sequence is OP-1 heel sequence [SEQ. ID. No. 16, residues 35
5 through 65]; and
6 the finger 2 sequence is OP-1 finger 2 sequence [SEQ. ID. No. 16, residues
7 68 through 98].

1 19. The construct of claim 1 wherein:
2 the finger 1 region comprises a sequence selected from the group consisting of
3 OP-1 finger 1 large peptide [SEQ. ID. No. 16, residues 5 through 28],
4 OP-1 finger 1 medium peptide [SEQ. ID. No. 16, residues 7 through 26], and
5 OP-1 finger 1 small peptide [SEQ. ID. No. 16, residues 11 through 22];
6 the heel region comprises a sequence selected from the group consisting of
7 OP-1 heel large peptide [SEQ. ID. No. 16, residues 49 through 64],
8 OP-1 heel medium peptide [SEQ. ID. No. 16, residues 52 through 64], and

- 103 -

9 OP-1 heel small peptide [SEQ. ID. No. 16, residues 56 through 62]; and
10 the finger 2 region comprises a sequence selected from the group consisting of
11 OP-1 finger 2 large peptide [SEQ. ID. No. 16, residues 75 through 91],
12 OP-1 finger 2 medium peptide [SEQ. ID. No. 16, residues 77 through 89], and
13 OP-1 finger 2 small peptide [SEQ. ID. No. 16, residues 79 through 87].

1 20. The construct of claim 1 or 4, wherein said finger 1 region, said heel region, and said
2 finger 2 region are joined by a pair of polypeptide linkers to produce said single-chain amino acid
3 construct.

1 21. The construct of claim 20, wherein each of said linkers comprises between 3 and 13
2 amino acids.

1 22. The construct of claim 1, wherein said regions are defined by amino acid sequences
2 selected from the group consisting of

- 3 (a) F1-linker-F2-linker-H;
4 (b) F1-linker-H-linker-F2;
5 (c) F2-linker-F1-linker-H;
6 (d) F2-linker-H-linker-F1;
7 (e) H-linker-F1-linker-F2; and
8 (f) H-linker-F2-linker-F1,

9 wherein H comprises an alpha helical region comprising said heel region, F1 comprises a
10 pair of anti-parallel β strand structures defining said finger 1 region, F2 comprises a pair of anti-
11 parallel β strands structures defining said finger 2 region, each finger and heel region begins and
12 ends with a cysteine residue, each linker comprises an amino acid sequence having 3-13 amino
13 acids, and wherein group a) and b) optionally further comprise an N-terminal sequence.

1 23. The construct of claim 22, wherein F1 comprises, in order from the N to C direction, a
2 first β strand, a helical loop, a loop, and a second β strand antiparallel to the first β strand.

1 24. The construct of claim 22, wherein F2 comprises, in order from the N to C direction, a
2 first β strand, a loop, and a second β strand anti-parallel to the first β strand.

1 25. The DNA encoding the amino acid sequence of the construct of claim 1, 4, or 22.

26. A cell line expressing a DNA of claim 25.

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D






FIG. 2A*FIG. 2B*

FIG. 3B







FIG. 3A



5/23

FIG. 4A**FIG. 4B**

TGF-β Subgroup	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1488	1489	1490	1491	1492	1493	1494	1495	1496	1497	14
----------------	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----

	TGF-β Subgroup	V - P Q A L E P L P I V Y Y V G - R K P K V E Q L S N M I V R B C K C S TGF-B1: V - S Q D L E P L T I L Y Y V G - K T P K I E Q L S N M I V R B C K C S TGF-B2: V - P Q D L E P L T I L Y Y V G - R T V R V E Q L S N M V V R A C K C S TGF-B3: V - P Q T L D P L P I I Y Y V G - R T A K V E Q L S N M V V R S C N C S TGF-B5: V - P D V L E P L P I I Y Y V G - R j J K V E Q L S N M a v n s c k c s Pattern: V - P Q X L E P L j i c y y v g - r j j k v e q l s n m a v n s c k c s	BETA	FINGER 2	RING	KNOT2
	vq/dpp Subgroup	dpp: V - P T Q L D S V A M L Y L N D Q - S T V V L K N Y Q E M T V V G C G C R Vg-1: V - P T K M S P I S M L F Y D N N - D N V V L R H Y E N M A V D E C G C R Vgr-1: A - P T K L N A I S V L Y F D D N - S N V I L K K Y R N M V V R A C G C H 60A: A - P T R L G A L P V L Y H L N D - E N V I L K K Y R N M I V K S C G C H BMP-2A: V - P T K L S A I S M L Y L D E N - E K V I L K N Y Q E M V V A E C G C R DORAL IN: V - P T K L D A I S I L Y K D E A G V P T L I Y N Y E Q E M K V A E C G C R BMP-2B/BMP-4: V - P T E L S A I S M L Y L D E Y - D K V V L K N Y Q E M V V E G C G C R BMP-3: V - P E K M S S L S I L F F D E N - K N V V L K K Y P N M T V E S C A C R BMP-5: A - P T K L N A I S V L Y F D D S - S N V I L K K Y R N M V V R S C G C H BMP-6: A - P T K L N A I S V L Y F D D N - S N V I L K K Y R N M V V R A C G C H OP-1/BMP-7: A - P T Q L N A I S V L Y F D D S - S N V I L K K Y R N M V V R A C G C H OP-2: A - P T K L S A I S V L Y Y D S S - N N V I L R K K H R N M V V K A C G C H OP-3: V - P T E L S A I S L L Y Y D R N - N N V I L R R E R N M V V Q A C G C H Pattern: X - P T p L r A a s c L y f d m r z r v i a L n r y p l m x v p j c g c r	BETA	FINGER 2	RING	KNOT2
	GDF Subgroup	GDF-1: V - P E R L S P I S V L F I F D N S - D N V V L R H Y E D M V V D E C G C R GDF-3: V - P T K L S P I S M L Y Q D S D - K N V I L R H Y E D M V V D E C G C R GDF-9: V - P G K Y S P L S V L T I E P D - G S I A Y K E Y E D M I A T R I C T C R Pattern: V - P X n f S P c s c L X X k X r - X r a X f n r y E D M a X r p i c j C X	BETA	FINGER 2	RING	KNOT2
	Inhibin Subgroup	Inhibin α: A A L P G T M R P L H V R T T S D G G Y S F K Y E T V P N L L T Q H C A C I Inhibin βA: V - P T K L R P M S M L Y Y D D G - Q N I I K K D I Q N M I V E E C G C S Inhibin βB: I - P T K L S T M S M L Y F D D E - Y N I I V K R D V P N M I V E E C G C A Pattern: X z z p j b r j b r c X X X r D X z X r f X X p r a X N b c X o r C h C X	BETA	FINGER 2	RING	KNOT2

9/23

FIG. 6

TGF-β Subgroup	C C V R P L Y I D F R n D L G W K - W I H E P K G Y X A N F C X G j C									
Pattern:	C C V R P L Y I D F R n D L G W K - W I H E P K G Y X A N F C X G j C									
Vg/dpp Subgroup	C n n r l y v r f r - d e c w r d w l l a p p g v x a d y c - c h c									
Pattern:	C n n r l y v r f r - d e c w r d w l l a p p g v x a d y c - c h c									
GDF Subgroup	C r x r r f x c r f r - r c x w r r w a a p r x d x j r d c r g r c									
Pattern:	C r x r r f x c r f r - r c x w r r w a a p r x d x j r d c r g r c									
Inhibin Subgroup	C x n x x f x a r f p - x c g w m r w i a x p j j d x x r y c r g x c									
Pattern:	C x n x x f x a r f p - x c g w m r w i a x p j j d x x r y c r g x c									
	1	10	20	30						
	BETA	HELIX	LOOP	BETA						
	K	FINGER 1								
TGF-β Subgroup	P y c w s - - - - x d t Q e s n v l j l y n r x n p - - x a s a j p c c									
Pattern:	P y c w s - - - - x d t Q e s n v l j l y n r x n p - - x a s a j p c c									
Vg/dpp Subgroup	X f p l x x x b - - - - n j t n u a i a q t l v r x c r z z - r x a p k j c c									
Pattern:	X f p l x x x b - - - - n j t n u a i a q t l v r x c r z z - r x a p k j c c									
GDF Subgroup	j x j x r x x x z z z x j x x e j f c p x c c e x x x z z - p x x j r j x c									
Pattern:	j x j x r x x x z z z x j x x e j f c p x c c e x x x z z - p x x j r j x c									
Inhibin Subgroup	j x e c j j x x j x - - j x j x x j j x x x r x x x x z z z x j x x r j c c									
Pattern:	j x e c j j x x j x - - j x j x x j j x x x r x x x x z z z x j x x r j c c									
	40	50	60	70						
		HEEL	HEEL							
TGF-β Subgroup	V - - P Q X L E P L j i c y y v g - - R r j k v e Q L S N M a v n s c k c s									
Pattern:	V - - P Q X L E P L j i c y y v g - - R r j k v e Q L S N M a v n s c k c s									
Vg/dpp Subgroup	X - - P T p L r A a S c L y f d m r z r r v a l n r y p l m x v p j c g c r									
Pattern:	X - - P T p L r A a S c L y f d m r z r r v a l n r y p l m x v p j c g c r									
GDF Subgroup	V - - P X n f S P c S c L X x k x r - X r a x f n r y E D M a x r p c j c x									
Pattern:	V - - P X n f S P c S c L X x k x r - X r a x f n r y E D M a x r p c j c x									
Inhibin Subgroup	X z p j r b r j b r c x x x r d x z x r f x x p r a x n b c x o r c h c x									
Pattern:	X z p j r b r j b r c x x x r d x z x r f x x p r a x n b c x o r c h c x									
	80	90	100	110						
	BETA	LOOP	BETA	RING						
		FINGER 2		KNOT 2						

10/23

FIG. 7A

Finger 1 Fragment: Large Peptide

TGF- β Subgroup											
TGF- β 1:	Q L Y I D F R K D L G W K - W I H E P K G Y H A N N										
TGF- β 2:	P L Y I D F R K R D L G W K - W I H E P K G Y N A N N										
TGF- β 3:	P L Y I D F R Q D L G W K - W V H E P K G Y Y A N N										
TGF- β 4:	P L Y I D F R K D L Q W K - W I H E P K G Y M A N N										
TGF- β 5:	P L Y I N F R K D L G W K - W I H E P K G Y E A N N										
Pattern:	P L Y I D F R n D L G W K - W I H E P K G Y X A N										
Vg/dpp Subgroup											
dpp:	S L Y V D F S - D V G W D D W I V A P L G Y D A Y										
Vg-1:	H L Y V E F K - D V G W Q N W V I A P Q G Y M A N N										
Vgr-1:	E L Y V S F Q - D L G W Q D W I I A P K G Y A A N N										
60A:	T L Y I D F K - D L G W H D W I I A P E G Y G A F										
BMP-2A:	P L Y V D F S - D V G W N D W I V A P P G Y H A F										
DORSALIN:	S L Y V N F K - E I G W D S W I I A P K D Y E A F										
BMP-2B/BMP-4:	S L Y V D F S - D V G W N D W I V A P P G Y Q A F										
BMP-3:	Y L Y V D F A - D I G W S E W I I S P K S F D A Y										
BMP-5:	E L Y V S F R - D L G W Q D W I I A P E G Y A A F										
BMP-6:	E L Y V S F Q - D L G W Q D W I I A P K G Y A A N										
OP-1/BMP-7:	E L Y V S F R - D L G W Q D W I I A P E G Y A A Y										
OP-2:	E L Y V S F Q - D L G W L D W V I A P Q G Y S A Y										
OP-3:	E L Y V S F R - D L G W L D S V I A P Q G Y S A Y										
Pattern:	r L Y V r F r - D c G W r D W I I A P p G Y X a d										
GDF Subgroup											
GDF-1:	R L Y V S F R - E V G W H R W V I A P R G F L A N N										
GDF-3:	Q L F I N F Q - D L G W H K W V I A P K G Y F M A N N										
GDF-9:	D F F L S F S - Q L K W D N W V I A P H R Y N F R										
Pattern:	r f Y c r F r - r c X W r r W a a A P r X d X j r										
Inhibin Subgroup											
Inhibin α :	A L Y I S F Q - E L G W E R W I V Y P P S F I F H										
Inhibin β A:	Q F F Y S F K - D I G W N D W I I A P S G Y H A N N										
Inhibin β B:	Q F F I D F R - L I G W N D W I I A P T G Y Y C N										
Pattern:	X f Y a r F p - X c G W m r W I a X P j j d X Y r										

10

20

11/23

FIG. 7B**Finger 1 Fragment: Medium Peptide**

TGF-β Subgroup		
TGF- β 1:	Y I D F R K D L G W K - W I H E P K G Y H	
TGF- β 2:	Y I D F K P D L G W K - W I H E P K G Y N	
TGF- β 3:	Y I D F R Q D L G W K - W V H E P K G Y Y	
TGF- β 4:	Y I D F R K D L G W K - W I H E P K G Y M	
TGF- β 5:	Y I N F R K D L G W K - W I H E P K G Y E	
Pattern:	Y I D F R n D L G W K - W I H E P K G Y X	
Vg/dpp Subgroup		
dpp:	Y V D F S - D V G W D D W I V A P L G Y D	
Vg-1:	Y V E F K - D V G W Q N W V I A P Q G Y M	
Vgr-1:	Y V S F Q - D L G W Q D W I I A P K G Y A	
60A:	Y I D F K - D L G W H D W I I A P E G Y G	
BMP-2A:	Y V D F S - D V G W N D W I V A P P G Y H	
DORSALIN:	H V N F K - E I G W D S W I I A P K D Y E	
BMP-1B/BMP-4:	Y V D F S - D V G W N D W I V A P P G Y Q	
BMP-3:	X V D F A - D I G W S E W I I S P K S F D	
BMP-5:	Y V S F R - D L G W Q D W I I A P E G Y A	
BMP-6:	Y V S F Q - D L G W Q D W I I A P K G Y A	
OP-1/BMP-7:	Y V S F R - D L G W Q D W I I A P E G Y A	
OP-2:	Y V S F Q - D L G W L D W V I A P Q G Y S	
OP-3:	Y V S F R - D L G W L D S V I A P Q G Y S	
Pattern:	Y V r F r - D c G W r D W I I A P p G Y X	
GDF Subgroup		
GDF-1:	H V S F R - E V G W H R W V I A P R G F L	
GDF-3:	F I N F Q - D L G W H K W V I A P K G F M	
GDF-9:	R L S F S - Q L G W D N W I V A P H R Y N	
Pattern:	X c r F r - r c I W r r W a a A P r X d X	
Inhibin Subgroup		
Inhibin α :	N I S F Q - E L G W E R W I V Y P P S F I	
Inhibin β A:	F V S F K - D I G W N D W I I A P S G Y H	
Inhibin β B:	F I D F R - L I G W N D W I I A P T G Y Y	
Pattern:	X a r F p - Y c G W m r W I a X P j j d X	

10

20

1

12/23

FIG. 7C

Finger 1 Fragment: Small Peptide

```




TGF-β Subgroup -----
TGF-β1: R K D L G W K - W I H E P
TGF-β2: K R D L G W K - W I H E P
TGF-β3: R Q D L G W K - W V H E P
TGF-β4: R K D L Q W K - W I H E P
TGF-β5: R K D L G W K - W I H E P
Pattern: R n D L G W K - W I H E P

Vg/dpp Subgroup -----
dpp: S - D V G W D L W I V A P
Vg-1: K - D V G W Q L W V I A P
Vgr-1: Q - D L G W Q L W I I A P
60A: K - D L G W H L W I I A P
BMP-2A: S - D V G W N L W I V A P
DORSALIN: K - E L G W D E W I I A P
BMP-2B/BMP-4: S - D V G W N L W I V A P
BMP-3: A - D L G W S E W I I S P
BMP-5: R - D L G W Q L W I I A P
BMP-6: Q - D L G W Q L W I I A P
OP-1/BMP-7: R - D L G W Q L W I I A P
OP-2: Q - D L G W L L W V I A P
OP-3: R - D L G W L L W V I A P
Pattern: r - D c G W r L W I I A P

GDF Subgroup -----
GDF-1: R - E V G W H L W I A P
GDF-3: Q - D L G W H L W V I A P
GDF-9: S - Q L K W D L W I V A P
Pattern: r - r c X W r L W a a A P

Inhibin Subgroup -----
Inhibin α: Q - E L G W E L W I V Y P
Inhibin βA: K - D L G W N L W I I A P
Inhibin βB: R - L L G W N L W I I A P
Pattern: p - X c G W m L W I a X P

```

FIG. 7D**FIG. 7E****FIG. 7F****FIG. 7G**

14/23

FIG. 8A**Heel Fragment: Large Peptide**

TGF-β Subgroup	
TGF- β 1:	K V L A L Y N Q H N P - - G A S A A
TGF- β 2:	R V L S L Y N T I N P - - E A S A S
TGF- β 3:	T V L G L Y N T L N P - - E A S A S
TGF- β 4:	K V L A L Y N Q H N P - - G A S A A
TGF- β 5:	K V L S L Y N Q N N P - - G A S I S
Pattern:	n V L j L Y N r X N P - - X A S A j
Vg/dpp Subgroup	
dpp:	V V Q T L V N N M N P - - G X V P K
Vg-1:	I L Q T L V H S I E P - - E D I P L
Vgr-1:	I V Q T L V H L M N P - - E X V P K
60A:	I V Q T L V H L L E P - - K X V P K
BMP-2A:	I V Q T L V N S V N - - S X I P K
DORSALIN:	I V Q T L V H L Q N P - - K X A S K
BMP-2B/BMP-4:	I V Q T L V N S V N - - S S I P K
BMP-3:	T I Q S I V R A V G V V - P G I P E
BMP-5:	I V Q T L V H L M F P - - D H V P K
BMP-6:	I V Q T L V H L M N P - - E X V P K
OP-1/BMP-7:	I V Q T L V H F I N P - - E X V P K
OP-2:	I L Q S L V H L M K P - - N A V P K
OP-3:	T M Q A L V H L M K P - - D I I P K
Pattern:	I a Q T L V r X c r z z - r Y a P K
GDF Subgroup	
GDF-1:	V L R A L M H A A A P T - P G A G S
GDF-3:	F M Q A L M H M A D - - P H V P K
GDF-9:	M V Q N I I Y E K L D - - P S V P R
Pattern:	f c p X c c e X X X z z - P X X j r
Inhibin Subgroup	
Inhibin α :	P T P A Q P Y S L - - - L P G A Q
Inhibin β A:	T V I N H Y R M R G H S P F A N L K
Inhibin β B:	A V V N Q Y R M R G L N - P G T V N
Pattern:	j X X X r X X X X z z z X j Y X r

60

70

15/23

FIG. 8B**Heel Fragment: Medium Peptide**

```

TGF- $\beta$  Subgroup-----
TGF- $\beta$ 1: A L Y N Q H N P - - G A S A A
TGF- $\beta$ 2: S L Y N T I N P - - E A S A S
TGF- $\beta$ 3: G L Y N T L N P - - E A S A S
TGF- $\beta$ 4: A L Y N Q H N P - - G A S A A
TGF- $\beta$ 5: S L Y N Q N N P - - G A S I S
Pattern: j L Y N r X N P - - X A S A j

Vg/dpp Subgroup-----
dpp: T L V N M M N P - - G K V P K
Vg-1: T L V H S I E P - - E D I P L
Vgr-1: T L V H L M N P - - E Y V P K
60A: T L V H L L E P - - K K V P K
BMP-2A: T L V N S V N - - - S K I P K
BMP-2B: T L V H L Q N P - - K K I S K
BMP-1B BMP-4: T L V N S V N - - S S I P K
BMP-3: S I V R A V G V V - P G I P E
BMP-5: T L V H L M F P - - D H V P K
BMP-6: T L V H L M N P - - E Y V P K
OP-1 BMP-7: T L V H F I N P - - E T V P K
OP-2: S L V H L M K P - - N A V P K
OP-3: A L V H L M K P - - D I I P K
Pattern: T L V r X c r z : - r X a P K

GDF Subgroup-----
GDF-1: A L M H A A A P T - P G A G S
GDF-3: A L M H M A D - - - P K V P K
GDF-9: N I I Y E K L D - - P S V P R
Pattern: X c c e I X X z : - P X I j r

Inhibitor Subgroup-----
Inhibitor A: A Q F Y S L - - - L P G A Q
Inhibitor BA: N H Y R M R G H E F F A N L K
Inhibitor BB: N Q Y R M R G L - - P G I V N
Pattern: X r X X X X z z : X j I X r

```


16/23

FIG. 8C**Heel Fragment: Small Peptide**

```

TGF-β Subgroup-----
TGF-β1: Q H N P - - G A S
TGF-β2: T I N P - - E A S
TGF-β3: T L N P - - E A S
TGF-β4: Q H N P - - G A S
TGF-β5: Q N N P - - G A S
Pattern: r X N P - - X A S

Vg/dpp Subgroup-----
Vg: N M N P - - G K V
Vg-1: S I E P - - E D I
Vg-1: L M N P - - E Y V
Vg-2: L L E P - - K K V
BMP-2A: S V N - - - S K I
DORSALIN: L Q N P - - K K A
BMP-2B/BMP-4: S V N - - - S S I
BMP-5: A V G V V - P G I
BMP-6: L M F P - - D H V
BMP-6: L M N P - - E Y V
OP-1/BMP-7: F I N P - - E T V
CP-2: L M K P - - N A V
CP-3: L M K P - - D I I
Pattern: X c r z z - r X a

GDF Subgroup-----
GDF-1: A A A P T - P G A
GDF-3: M A D - - - P K V
GDF-3: E K L - - - P S V
Pattern: X X X : z - P X X

Inhibin Subgroup-----
Inhibin A: S L - - - L P G
Inhibin BA: M R G E S P F A N
Inhibin BB: M R G L N - P G T
Pattern: X X z : z z X j X

```

FIG. 8D




FIG. 8E




FIG. 8F





FIG. 8G



18/23

FIG. 9A

Finger 2 Fragment: Large Peptide

```

TGF-β Subgroup-----
TGF-β1: L P I V Y Y V G - - R K F K V E C C
TGF-β2: L T I L Y Y I G - - K T F K I E C C
TGF-β3: L T I L Y Y V G - - R T F K V E C C
TGF-β4: L P I I Y Y V G - - R N F R V E C C
TGF-β5: L P I I Y Y V G - - R T A K V E C C
Pattern: L j I c Y Y V G - - R r F K V E C C

Vg/dpp Subgroup-----
dpp: V A M L Y L N D Q - S T V V L K F Y
Vg-1: I S M L F Y D N N - D N V V L R E Y
Vgr-1: I S V L Y F D D N - S N V I L K F Y
60A: L P V L Y H L N D - E N V N L K F Y
BMP-2A: I S M L Y L D E N - E K V V L K F Y
DORSALIN: I S I L Y K D D G V P E L I Y F Y
BMP-2B/BMP-4: I S M L Y L D E Y - D K V V L K F Y
BMP-3: L S I L F F D E N - K N V V L K F Y
BMP-5: I S V L Y F D D S - S N V I L K F Y
BMP-6: I S V L Y F D D N - S N V I L K F Y
OP-1/BMP-7: I S V L Y F D D S - S N V I L K F Y
OP-2: T S V L Y Y D S S - N N V I L R F E
OP-3: I S L L Y Y D R N - N N V I L R F E
Pattern: a S c L Y f D m r z t r v a l n = Y

GDF Subgroup-----
GDF-1: I S V L F F D N S - D N V V L R E Y
GDF-3: I S M L Y Q D S D - E N V I L R E Y
GDF-9: I S V L F I E P D - G S D A Y K F Y
Pattern: c S c L Y X k Y r - I r a X f n = Y

Inhibin Subgroup-----
Inhibin α: L H V R T T S D G G Y S F X Y E I V
Inhibin βA: M S M L Y Y D D G - C N I I K K I I
Inhibin βB: M S M L Y F D D E - E N I V E R I V
Pattern: b r c Y X X r D Y z Y r F I I p r a

```

90

100

19/23

FIG. 9B**Finger 2 Fragment: Medium Peptide**

```

TGF-β Subgroup-----
TGF-β1: I V Y Y V G - - R K P K V E
TGF-β2: I L Y Y I G - - K T P K I E
TGF-β3: I L Y Y V G - - R T P K V E
TGF-β4: I I Y Y V G - - R N V R V E
TGF-β5: I I Y Y V G - - R T A K V E
Pattern: I c Y Y V G - - R r j K V E
Vg/dpp Subgroup-----
dpp: M L Y L N D Q - S T V V L K
Vg-1: M L F Y D N N - D N V V L R
Vgr-1: V L Y F D D N - S N V I L K
60A: V L Y H L N D - E N V N L K
BMP-2A: M L Y L D E N - E K V V L K
DORSALIN: I L Y K D D A G V P T L I Y
BMP-2B/BMP-4: M L Y L D E Y - D K V V L K
BMP-3: I L F F D E N - K N V V L K
BMP-5: V L Y F D D S - S N V I L K
BMP-6: V L Y F D D N - S N V I L K
OP-1/BMP-7: V L Y F D D S - S N V I L K
OP-2: V L Y Y D S S - N N V I L R
OP-3: L L Y Y D R N - N N V I L R
Pattern: c L Y f D m r z r r V a L n
GDF Subgroup-----
GDF-1: V L F F D N S - D N V V L R
GDF-3: M L Y Q D S D - K N V I L R
GDF-9: V L T I E P D - G S I A Y K
Pattern: c L X X k X r - X r a X f n
Inhibin Subgroup-----
Inhibin α: V R T T S D G G Y S F K Y E
Inhibin βA: M L Y Y D D G - Q N I I K K
Inhibin βB: M L Y F D D E - Y N I V K R
Pattern: c X X X r D Y z X r f X X p

```

20/23

*FIG. 9C***Finger 2 Fragment: Small Peptide**

TGF-β Subgroup												
TGF- β 1:	Y	Y	V	G	-	-	R	K	P	K		
TGF- β 2:	Y	Y	I	G	-	-	R	T	P	K		
TGF- β 3:	Y	Y	V	G	-	-	R	T	P	K		
TGF- β 4:	Y	Y	V	G	-	-	R	N	V	R		
TGF- β 5:	Y	Y	V	G	-	-	R	T	A	K		
Pattern:	Y	Y	V	G	-	-	R	r	j	K		
Vg/dpp Subgroup												
dpp:	Y	L	N	D	Q	-	S	T	V	V		
Vg-1:	F	Y	D	N	N	-	S	N	V	V		
Vgr-1:	Y	F	D	D	N	-	S	N	V	I		
60A:	Y	H	L	N	D	-	S	N	V	N		
BMP-2A:	Y	L	D	E	N	-	E	K	V	V		
DORSALIN:	Y	K	D	D	A	G	T	P	T	L		
BMP-2B/BMP-4:	Y	L	D	E	Y	-	E	K	V	V		
BMP-3:	F	F	D	E	N	-	S	N	V	V		
BMP-5:	Y	F	D	D	S	-	S	N	V	I		
BMP-6:	Y	F	D	D	N	-	S	N	V	I		
OP-1/BMP-7:	Y	F	D	D	S	-	S	N	V	I		
OP-2:	Y	Y	D	S	S	-	S	N	V	I		
OP-3:	Y	Y	D	R	N	-	S	N	V	I		
Pattern:	Y	f	D	m	r	z	r	r	V	a		
GDF Subgroup												
GDF-1:	F	F	D	K	S	-	S	N	V	I		
GDF-3:	Y	Q	D	S	D	-	S	N	V	I		
GDF-9:	T	I	E	P	D	-	S	S	I	A		
Pattern:	X	X	k	X	r	-	E	r	a	X		
Inhibin Subgroup												
Inhibin α :	T	T	S	D	G	G	Y	S	F	N		
Inhibin β A:	Y	Y	D	D	G	-	S	N	V	I		
Inhibin β B:	Y	F	D	D	E	-	S	N	V	I		
Pattern:	X	X	r	D	X	z	Y	r	f	X		

21/23

FIG. 9D




FIG. 9E




FIG. 9F





FIG. 9G



22/23

FIG. 10





FIG. 11



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/09293

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/495 C07K14/51 C07K14/575 C12N15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 15966 (JOHNS HOPKINS UNIVERSITY SCHOO ;LEE SE JIN (US)) 21 July 1994 see the whole document ---	1-9, 20-26
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 5, 15 February 1993, MD US, pages 3444-3449, XP002016203 A.C.MCPHERRON E.A.: "GDF-3 and GDF-9:two new members of the TGFA superfamily containing a novel pattern of cysteines" see the whole document ---	1-9, 20-26
X	WO,A,88 05789 (BIOTECH AUSTRALIA PTY LTD ;UNIV MONASH (AU); MONASH MEDICAL CENTRE) 11 August 1988 see the whole document ---	1-5
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

17 October 1996

Date of mailing of the international search report

05. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 96/09293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 433 225 (CIBA GEIGY AG) 19 June 1991 see examples 1-3,4A-F ---	1,20,21, 25,26
X	WO,A,91 05802 (CREATIVE BIOMOLECULES INC) 2 May 1991 see page 41, paragraph II - page 44 ---	1,20,21
A	WO,A,88 09344 (CREATIVE BIOMOLECULES INC) 1 December 1988 cited in the application see the whole document ---	1-26
A	WO,A,91 05565 (CREATIVE BIOMOLECULES INC) 2 May 1991 see the whole document ---	1-26
A	EP,A,0 132 021 (TODARO GEORGE JOSEPH) 23 January 1985 see the whole document ---	1-24
A	WO,A,94 17099 (CELTRIX PHARMA) 4 August 1994 see the whole document ---	1-24
A	WO,A,90 14359 (GENENTECH INC) 29 November 1990 see the whole document -----	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/09293

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-5, 20-26
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: * see continuation-sheet PCT/ISA/210 *
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark:

The scope of the claims 1-5 and 20-26 is very broad and speculative. Compounds which are almost exclusively defined by a tertiary structure that "mimicks" the structure of a TGF β superfamily member and some additional secondary structural features, lacking any sequential features, cannot be considered to represent a clear and concise definition of patentable subject-matter (Art.6 PCT).

Furthermore the available experimental data actually only comprise a very small part of the compounds claimed, which part is moreover not evenly distributed over the whole claimed area. Therefore said claims can also not be considered to represent a permissible generalization which is fairly based on experimental evidence, that is, they are also not adequately supported by the description (Art.6 PCT).

Therefore a meaningful and economically feasible search could not encompass the complete subject-matter of the claims. Consequently the search has been limited to the subject-matter of the claims 6-19 (Art.17(2)(a)(ii) PCT).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09293

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9415966	21-07-94	EP-A- 0678101	25-10-95
WO-A-8805789	11-08-88	AT-T- 120209	15-04-95
		AU-B- 610858	30-05-91
		AU-A- 1242188	24-08-88
		DE-D- 3853383	27-04-95
		DE-T- 3853383	27-07-95
		EP-A- 0299050	18-01-89
		JP-T- 1502662	14-09-89
		US-A- 5470826	28-11-95
EP-A-0433225	19-06-91	AU-B- 638075	17-06-93
		AU-A- 6701890	13-06-91
		CA-A- 2031430	07-06-91
		JP-A- 3191791	21-08-91
WO-A-9105802	02-05-91	US-A- 5171574	15-12-92
		AU-B- 648997	12-05-94
		AU-A- 6648190	16-05-91
		CA-A- 2042577	18-04-91
		EP-A- 0448704	02-10-91
		JP-T- 4502336	23-04-92
		US-A- 5468845	21-11-95
		US-A- 5266683	30-11-93
		US-A- 5344654	06-09-94
		US-A- 5354557	11-10-94
		CA-A- 2027259	18-04-91
WO-A-8809344	01-12-88	AT-T- 120761	15-04-95
		AU-B- 612370	11-07-91
		AU-A- 1804988	21-12-88
		AU-B- 648591	28-04-94
		AU-A- 8579991	13-02-92
		DE-D- 3853515	11-05-95
		DE-T- 3853515	17-08-95
		EP-A- 0318554	07-06-89
		EP-A- 0623679	09-11-94
		JP-T- 2500329	08-02-90
		US-A- 5482858	09-01-96
		US-A- 5476786	19-12-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09293

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8809344		US-A- 5132405	21-07-92
		US-A- 5091513	25-02-92
		US-A- 5258498	02-11-93

WO-A-9105565	02-05-91	AU-A- 6870791	16-05-91
		CA-A- 2070393	19-04-91
		EP-A- 0496833	05-08-92
		JP-T- 5501500	25-03-93

EP-A-0132021	23-01-85	AU-B- 575049	21-07-88
		AU-A- 2751384	15-11-84
		DE-A- 3485219	05-12-91
		JP-A- 60034997	22-02-85
		JP-A- 7173193	11-07-95
		US-A- 4863899	05-09-89
		US-A- 4816561	28-03-89
		US-A- 5240912	31-08-93

WO-A-9417099	04-08-94	US-A- 5420243	30-05-95
		AU-A- 6093294	15-08-94
		CA-A- 2153789	04-08-94

WO-A-9014359	29-11-90	US-A- 5061786	29-10-91
		AT-T- 118015	15-02-95
		CA-A- 2057896	26-11-90
		DE-D- 69016655	16-03-95
		DE-T- 69016655	17-08-95
		EP-A- 0473649	11-03-92
		ES-T- 2070322	01-06-95
		US-A- 5118791	02-06-92
		US-A- 5268455	07-12-93
